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ABSTRACT 
 
 
 Erythropoiesis maintains stable tissue oxygenation in the basal state, while 
accelerating red cell production in anemia, blood loss or high altitude. The principal 
regulator of erythropoiesis is the hormone erythropoietin (Epo). In response to hypoxic 
stress, Epo can increase a 1000-fold, driving erythropoietic rate by up to 10-fold. It’s 
been suggested that survival pathways activated by the Epo receptor (EpoR) underlie its 
regulation of erythropoietic rate. A number of apparently redundant EpoR survival 
pathways were identified in vitro, raising the possibility of their functional specialization 
in vivo. 
 Here I assessed the roles of three survival pathways activated by EpoR in 
erythroblasts in-vivo: the suppression of cell-surface Fas and FasL, the suppression of the 
pro-apoptotic regulator Bim, and the induction of the anti-apoptotic regulator Bcl-xL. I 
used the novel CD71/Ter119 flow-cytometric method of identifying erythroblast 
maturation stages in vivo to measure these apoptotic pathways in fetal liver and adult 
erythropoietic tissues. I found that these pathways differ markedly in their regulation of 
erythropoietic rate. 
 Using mouse genetic models, I found that apoptosis mediated by interaction 
between erythroblasts that co-express cell-surface Fas and FasL plays a key 
autoregulatory role in stabilizing the size of the erythroblast pool in the basal state. 
Further, mice mutant for Fas or FasL showed a delayed erythropoietic response to 
hypoxia or high Epo. This suggests that Fas and FasL accelerate the stress response by 
providing an apoptotic ‘cell reserve’ that can be rescued by Epo in stress.  
 
  
 
v 
I also examined the in-vivo behavior of two cell-intrinsic apoptotic regulators, 
Bcl-xL and Bim, previously unexamined in stress. The induction of Bcl-xL was rapid but 
transient, whilst the suppression of Bim was slower but persistent. My data suggest that 
Bcl-xL is a key mediator of EpoR’s anti-apoptotic signal very early in the stress response, 
before Bim and Fas are suppressed. Bcl-xL adaptation to high Epo occurs through 
inhibition of Stat5 activation, and resets it for the next acute stress. 
 My findings suggest that in vivo, Epo regulates erythropoietic rate through 
erythroblast apoptosis, and that various apoptotic regulators play distinct and unique roles 
in this process. My work provides new molecular insights into erythropoiesis that are 
relevant to cytokine biology and to clinical approaches of disease treatment.  
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CHAPTER I 
INTRODUCTION 
  
 
1. Erythropoietin-dependent feedback loop in erythropoiesis 
 Erythropoiesis is the process of hematopoietic progenitor differentiation into red 
blood cells. In mice, definitive erythropoiesis takes place in the fetal liver during 
embryogenesis, and in the bone marrow and spleen microenvironments in the adult. In 
the basal state, erythropoietic rate is low, allowing only for the continued replacement of 
senescent erythrocytes in the periphery. Insufficient pO2 supply in tissues occurs during 
blood loss, malignant disease, high growth rate in embryogenesis, and during ascents to 
high altitude. These situations lead to an increase in the erythropoietic rate, a process 
termed stress erythropoiesis (Figure 1.1A-B). The principal regulator of both basal and 
stress erythropoiesis is hormone erythropoietin (Epo), produced in the adult kidney in 
response to hypoxia. This gives rise to a negative feedback loop (Figure 1.1A), whereby 
hypoxia-induced Epo can increase the rate of erythropoiesis up to 10-fold. In turn, 
generated erythrocytes correct tissue hypoxia and lower Epo level to normal. It is not 
clear how Epo regulates basal and stress erythropoiesis in vivo (Figure 1.1C). In my 
thesis work, I used novel flow-cytometric methods and various mouse models of 
erythropoietic stress to address this important question.  
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2.   Molecular basis of serum erythropoietin increase in hypoxic stress 
Epo is essential to erythropoiesis, and Epo-/- or Epo receptor (EpoR)-/- mice are 
embryonic lethal due to failure to produce nucleated red cells 1. Epo is a 34 kDa 
glycoprotein with a high degree of sequence homology between humans and mice 2,3. It is 
produced in the fetal liver during embryogenesis, while in adulthood, the kidney 
peritubular fibroblast-like cells are the primary source of Epo 4. Epo gene transcription is 
activated by basic helix-loop-helix hypoxia-inducible transcription factors (HIF-2α and 
HIF-β) at the hypoxia-response element (HRE) sites in the 3’ enhancer of Epo 5. While 
HIF-β is constitutively expressed and localizes to the nucleus, HIF-2α stability is 
regulated post-translationally. Under normal oxygen conditions, HIF-2α is hydroxylated 
by the prolyl hydroxylase domain enzymes (PHDs), polyubiquitinated by the von Hippel-
Lindau (VHL) E3 ubiquitin ligase protein, and subsequently degraded by the proteasome. 
Low oxygen results in a reduced hydroxylation of HIF-2α, and leads to its stabilization 
and nuclear translocation to markedly induce Epo transcription 6,7. HIF-2α conditional-
knockout mice develop anemia after post-natal ablation 8. Conversely, mice with targeted 
inactivation of the VHL gene have increased Epo and over-abundance of erythrocytes 
(polycythemia) 9,10. Serum Epo increases with decreasing hematocrit (red cell fraction of 
total blood volume), reaching up to 10,000 mU/mL in severe anemia compared to basal 
levels of about 10 mU/mL 4,11. Epo induction can be detected within the first two hours of 
hypoxic stress. It peaks by 12 to 48 hours, and then tails off as corrective mechanisms are 
activated 12,13. Conversely, polycythemia suppresses endogenous Epo production to 
prevent any additional erythropoiesis until balance is restored 14. Hematopoietic 
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progenitors committed to the erythroid lineage express EpoR and become Epo-dependent 
for their survival and the subsequent differentiation.  
 
3. Acute and chronic erythropoietic stress 
 Abnormally low erythropoietic rate results in anemia, while higher-than-needed 
erythropoiesis results in erythrocytosis, sluggish blood flow and clotting. In mice, the 
bone marrow, with its limited physical space, serves as the primary site for basal 
erythropoiesis, while the spleen contains stress-responsive progenitors 15-17. Acute tissue 
hypoxia occurs when blood oxygen tension is sharply reduced. It results from blood loss, 
upon acute exposure to low atmospheric oxygen, or from acute carbon monoxide 
poisoning. Mammals have multiple and complex mechanisms to correct tissue hypoxia. 
For example, acclimatization to low oxygen at high altitude includes changes in 
ventilatory and cardiovascular function 18, plasma volume 19, blood acid-base balance, 
and systemic and cellular metabolic changes 20. Importantly, tissue hypoxia also leads to 
an increase in erythropoietic rate, which is a slower, but often more permanent corrective 
function 20. Epo and many other stress-induced factors, such as stem cell factor (SCF), 
glucocorticoids, and bone morphogenetic protein 4 (BMP4) regulate stress erythropoiesis 
in vivo 17,21-23. Of those, Epo is the principal regulator of erythropoietic rate. 
 Although Epo peaks in a matter of hours, erythropoiesis is increased for many 
days until homeostasis is re-established 24. Acute tissue hypoxia, if not corrected, 
becomes chronic hypoxic stress where the stimulus for increased erythropoietic rate 
persists. Of note, the term chronic erythropoietic stress describes the persistence of 
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erythropoietic stimulus with or without hypoxic stress (e.g. polycythemia). Chronic 
erythropoietic stress where tissue hypoxia is present often results from long-term 
physiological and pathological conditions. Pregnancy is a physiological chronic stress 
due to continued fetal demand for oxygen. Other causes include chronic obstructive 
pulmonary disease, thalassemias and sickle cell disease, and renal failure. Chronic stress 
is also present in myelodysplasia (MDS) and cancer patients with ineffective bone 
marrow erythropoiesis due to inflammatory response or chemotherapy. 
 Polycythemia results from over-active erythropoiesis in pathology, and also in 
physiological settings, such as upon a descent from high altitude 25,26. Physiological 
polycythemia resolves naturally via suppressed erythropoietic activity. In contrast, 
pathological polycythemia results from defects in hematopoietic progenitors, such as 
mutations in the EpoR or Jak2 27,28, or due to mutations in the Epo production pathway 
9,29,30. Understanding how Epo regulates the erythroid molecular pathways will allow us 
to develop new and effective treatments for anemia present in various human disorders. 
 
4. Classical stages of erythroid differentiation 
Definitive erythropoiesis is Epo-dependent and begins in the fetal liver on day 
~E11 of gestation, eventually moving to the bone marrow by birth. Starting with the 
hematopoietic stem cell (HSC) and its progeny, the common myeloid progenitor (CMP), 
cells are restricted to the megakaryocytic-erythrocytic progenitor stage (MEP) via the 
cross-antagonism between erythroid transcriptional factor GATA-1 and 
myeloid/lymphoid transcriptional factor PU.1 (Figures 1.1 and 1.2) 31,32. MEP 
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compartment contains “Burst-forming unit-erythroid” (BFU-e) progenitors and the 
“Colony-forming unit-erythroid” (CFU-e) progenitors, identifiable by colony-forming 
potential in semi-solid culture medium. BFU-e progenitor gives rise to ~500 cells in 6 to 
10 days in response to Epo and a burst promoting factor, such as interleukin-3 (IL-3) or 
SCF 33,34. In response to Epo only, CFU-e progenitor gives rise to colonies containing 8 
to 32 hemoglobinized cells after 2 to 3 days of in vitro culture 35. Starting with the CFU-
e, terminal differentiation is achieved in 3 to 4 cell cycles, with cells progressing through 
the pro-erythroblast, basophilic, polychromatic and orthochromatic erythroblast stages, as 
identified morphologically (Figure 1.2 and 1.3). Pro-erythroblasts and basophilic 
erythroblasts are large cells. They have a large nucleus and appear blue with H&E stain. 
As cells differentiate, they condense their nuclei, reduce in size, and accumulate 
hemoglobin 2,36. Orthochromatic cells are small and stain light brown. They expel their 
nuclei to become reticulocytes and are released into the bloodstream. Reticulocytes 
complete hemoglobin synthesis and mature into erythrocytes whose number and quality 
in the circulation determine tissue oxygen levels. 
 
5. Erythroblastic islands: critical niches for erythropoiesis in vivo 
 Erythroblasts possess cell-autonomous differentiation properties. However, in 
vivo, efficient erythropoiesis also relies on cell-cell interactions that occur in specialized 
developmental niches, called erythroblastic islands (Figure 1.3) 22,37. Present in the 
erythropoietic tissue, each island consists of a central macrophage surrounded by up to 30 
developing erythroblasts of various maturation status. Major functions of erythroblastic 
 
  
 
7 
island macrophages are numerous and include: iron supply for heme biosynthesis; 
phagocytosis of expelled nuclei upon differentiation; and improved erythroblast 
proliferation and survival (via cell-cell interactions through adhesion factors, or via 
secreted cytokines). These functions lead to an amplified erythroblast frequency and 
faster reticulocyte release, both essential for stress response 22. Erythroblastic islands also 
provide an opportunity for erythroblasts to interact and regulate each other (for example, 
through Fas/FasL co-expression by early erythroblasts). 
 
6.  Flow-cytometric detection of primary erythroblasts in vivo 
 The drawback of previous studies of Epo action in erythropoiesis was the use of 
leukemic erythroid cell lines, indirect detection of progenitors via colony assays, and the 
lack of reliable flow-cytometric markers for in vivo detection of erythroid cells. Our lab 
pioneered a new flow-cytometric method to study erythroblast development stages in 
vivo using two markers, CD71 and Ter119, and the cell size parameter (FSC, forward 
scatter) (Figure 1.2A). CD71 is a transferrin receptor that is highly expressed in early 
erythroblasts for iron acquisition 38,39. Ter119 is an erythroid-specific cell surface antigen 
40. This method allows us to quickly and easily identify different stages of erythroid 
development, similar to those seen by morphological examination, directly in freshly 
harvested hematopoietic tissues 41,42. In the adult, Ter119mid/CD71high cells have pro-
erythroblast morphology and are termed ProE. Total Ter119high cells further resolve into 
three subpopulations: EryA (Ter119high/CD71high/FSChigh), EryB 
(Ter119high/CD71high/FSClow), and EryC (Ter119high/CD71low/FSClow). In cytospin 
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preparations, EryA, B and C subsets morphologically correlate to the basophilic, 
polychromatic and orthochromatic stages, respectively (Figure 1.2A) 42,43. A similar 
staging method based on CD71 and Ter119 markers is applied to the fetal liver (Figure 
1.2C) 44-46. Recently, other groups have used similar flow-cytometric methods to 
visualize erythroid precursors in vivo 47,48. In my thesis work, I used our flow-cytometric 
method to test the in vivo roles of erythroid survival pathways in the mouse stress 
response.  
 
7.  Epo-responsive erythroid progenitors 
 In the basal state, the onset of Epo dependence occurs at the CFU-e stage 2,46,. 
Pro-erythroblasts (ProE) and basophilic erythroblasts (EryA) are Epo-responsive because 
they also express EpoR 49,50. Late erythroblasts are Epo-independent. Epo appears to act 
on a broader spectrum of progenitors during stress, when BFU-e and CFU-e subsets 
rapidly expand 15,51,52. Recently, stress response was shown to depend on a specialized 
spleen BFU-e progenitor 17,53,54. This self-renewing subset responds to BMP4, SCF, 
hypoxia and Epo by giving rise to stress BFU-e. In turn, stress BFU-e cells rapidly divide 
to form large colonies in vitro in response to only Epo 17. Proliferating stress BFU-e are 
characterized by their unique expression of both immature (CD34 and cKit) and mature 
(CD71 and Ter119) markers, similar to the putative human stress progenitor 
(CD34+Kit+GlyA+) isolated from patients with sickle cell anemia 55. In addition to CFU-
e, ProE and EryA cells rapidly increase in frequency and absolute number, most notably 
in the spleen during stress response (Figure 1.2B). This early increase is disproportionate 
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compared to the frequency of later erythroblasts, and is concomitant with a decrease in 
erythroblast apoptosis 42. The molecular mechanisms of how Epo regulates this cell 
expansion in vivo are not clear. 
 
8.   Epo Receptor structure and function in erythropoiesis 
 EpoR is a homodimeric type I receptor expressed at a low density on the surface 
of hematopoietic progenitors 2,56,57,58,59. EpoR is 82% homologous between humans and 
mice 2. It does not possess intrinsic kinase activity, but is pre-associated with Janus 
tyrosine kinases 2 (Jak2) required for receptor activation 60,61. Similar to EpoR-/- 
embryonic-lethal phenotype, Jak2-/- embryos die on day E12.5 due to severe anemia 62. In 
contrast, V617F mutation in the Jak2 leads to hyper-activation of signaling and 
myeloproliferative disease 27,63. Upon Epo binding, activated Jak2 phosphorylates eight 
conserved tyrosines in the cytoplasmic tail of EpoR to recruit signaling partners via their 
Src Homology 2 (SH2) domains 64,65. EpoR can activate various signaling pathways 
leading to cell proliferation, survival and differentiation. They include signal transducer 
and activator of transcription 5 (Stat5), phosphoinositide-3-kinase/AKT, phospholipase 
Cγ, Grb2/Shc, Ras, and MAPK 65,66. In addition to positive signaling that facilitates 
erythropoiesis, EpoR recruits negative regulators including CIS, SOCS1 and SOCS3, 
Shp1 and 2, and SHIP1 to prevent its over-activation 65,67. Truncations of the EpoR distal 
domain, where negative regulators of signaling are normally recruited, lead to 
polycythemia in humans and mice 28,68. Because signaling studies were performed using 
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in vitro culture, the precise in vivo stages of development at which they are activated, and 
their functional outcomes, are still not understood. 
 Interestingly, signaling pathways activated by the EpoR are common to other 
cytokine receptors 69. EpoR carries no instructive signal for erythroid differentiation 
1,66,70. Instead, EpoR is thought to play a permissive role by providing an essential 
survival signal to erythroblasts starting with the CFU-e stage, the onset of Epo-
dependence 46,71-73. Pro-erythroblasts and basophilic erythroblasts (ProE and EryA) are 
also the targets of EpoR signaling. Past the basophilic stage, EpoR expression diminishes 
and is not required to complete differentiation 2,36,49,50. 
EpoR signaling requirements are more stringent during stress where Epo can 
increase a 1000-fold. EpoR-haploinsufficient mice have normal steady-state 
erythropoiesis, but fail to achieve normal stress response 74. Similarly, mice with 
truncated EpoR lacking all tyrosines (known as EpoR-HM) respond poorly to stress 67,75. 
One important function of EpoR is activation of transcriptional factor Stat5, implicated in 
the stress response in vivo 43,76,77. Stat5-null mice die perinatally from anemia 77. In 
contrast, Stat5-deficient mice lack only the first exon of Stat5a and Stat5b, but still 
express variable levels of N-terminally truncated Stat5 that is constitutively activated 78. 
These mice are viable but suffer from embryonic anemia and a deficient stress response 
as adults 43,77. Stat5 in erythropoiesis participates in the induction of pro-survival protein 
Bcl-xL and the transferrin receptor, both important functions still unexamined during 
stress response in vivo 43,76,79,80. An additional EpoR-activated pathway, implicated in 
stress response, is the PI3K/AKT which inhibits forkhead transcriptional factors and 
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death receptor expression 81-84. To date, few studies have directly addressed how EpoR 
survival signals regulate basal and stress erythropoiesis in vivo. 
 
9.  Hypothesis: Epo regulates erythropoietic rate in vivo via progenitor 
apoptosis 
 One well-established molecular consequence of EpoR signaling in vitro is 
erythroblast survival 2,36,51,73,85-87. Therefore, EpoR has been suggested to regulate 
erythropoietic rate in vivo by activating progenitor survival pathways 73. A mechanistic 
model has been proposed where the majority of continuously generated erythroblasts 
undergo apoptosis in the basal state. Only cells least sensitive to apoptosis become 
erythrocytes. During stress, the greater the concentration of Epo, the greater the number 
of total cells rescued from cell death (Figure 1.4). This hypothesis is based on the 
observations that in vitro, CFU-e-like cells undergo apoptosis when deprived of Epo. 
Increasing Epo concentration in culture results in the increased rescue from apoptosis, 
while the cell-cycle is unaffected 36,51,73,85-87. This model contains two implicit 
requirements, untested in vivo: the strength of anti-apoptotic signal delivered by EpoR 
increases with more Epo; and that progenitors vary in sensitivity to Epo via unknown 
mechanisms. To date, multiple pathways have been implicated in erythroblast survival in 
vitro. They include pro-survival protein Bcl-xL, pro-apoptotic proteins Bim and Nix, 
death receptor Fas and its ligand, FasL, Trail-R, anamorsin, oncostatin M, Serpina-3G, 
Pim1, Trb3 and FoxO3a 42,43,88-93. However, the precise nature of the EpoR survival 
signal in vivo remains unclear. To test the hypothesis that Epo regulates erythropoietic 
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rate through erythroblast apoptosis in vivo, I focused on three survival/apoptosis 
pathways: Fas, Bim and Bcl-xL. My specific aims were to investigate their in vivo 
behavior in different erythropoietic tissues, and to compare and contrast their potentially 
unique roles in basal and stress erythropoiesis. 
 
10.  Extrinsic and intrinsic apoptotic pathways 
 Apoptosis is a programmed cell death triggered for many reasons, including 
development, growth factor withdrawal, DNA damage, and death receptor ligand binding 
94. Apoptosis is characterized by a coordinated process of cell and nuclear shrinkage, 
cleavage of intracellular proteins and DNA, and the formation of apoptotic bodies for 
phagocytosis. The proteolytic activation of cysteine-rich aspartate proteases (caspases) 
initiates apoptosis in the cell. Two main apoptotic pathways exist in the cell: the intrinsic 
pathway initiated at the mitochondria, and the extrinsic pathway activated by death 
receptors of the tumor necrosis factor superfamily (for example, Fas and Trail-R) 94. 
 Growth factor withdrawal or DNA damage initiate the intrinsic pathway. In this 
pathway, B-cell lymphoma 2 (Bcl-2) family of pro-survival and pro-apoptotic proteins 
regulate the mitochondrial permeability to cytochrome c and other proteins 95. Upon 
release from the mitochondria, these factors activate caspases in the cytosol or cleave 
DNA directly. The extrinsic pathway is activated upon death receptor ligand binding. 
This event leads to the recruitment of adaptor proteins to form death-inducing signaling 
complex (DISC), proteolytic cleavage of initiator caspases (e.g. caspase-8) and the 
activation of executioner caspases (e.g. caspase-3). The intrinsic and extrinsic apoptotic 
 
  
 
13 
pathways are linked through the caspase-8-mediated cleavage of pro-apoptotic protein 
Bid that leads to mitochondrial permeability downstream of the death receptor activation. 
My thesis work describes how Epo modulates the intrinsic and extrinsic apoptotic 
pathways in erythroblasts in vivo. 
 
11.  Pro-survival protein Bcl-xL 
 Bcl-xL is a pro-survival Bcl-2 family protein that forms heterodimers with pro-
apoptotic proteins Bax and Bak, preventing cytochrome c release from mitochondria and 
caspase activation 95. Previous work has shown that Bcl-xL is essential to prevent 
erythroblast apoptosis in vitro and in the basal state in vivo 43,76,96-99. Bcl-xL-/- mice die in 
utero of anemia 100. Bcl-xL is synergistically induced by EpoR-Stat5 signaling and 
GATA-1 transcriptional factor. It accumulates with erythroid differentiation, reaching its 
highest levels in the most mature erythroblasts 101. Most, but not all, studies suggest that 
Bcl-xL is a major mediator of the anti-apoptotic effect of Epo in erythroblasts 102. Recent 
in vitro studies using bone marrow erythroid progenitors pre-expanded in culture showed 
no clear Bcl-xL induction with Epo, while spleen, the stress reserve organ, was 
unexamined 67. In contrast, in vivo studies utilizing 5-fluorouracil-induced anemia 
showed a clear induction in the Bcl-xL protein in total bone marrow during the recovery 
103. Prior to my thesis work, it was unknown whether EpoR-Stat5-mediated Bcl-xL 
induction enhances early erythroblast survival, an essential feature of the stress response 
in vivo. 
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12.  Pro-apoptotic protein Bim 
 Pro-apoptotic BH3-only member of the Bcl-2 family, Bim, regulates lymphocyte 
homeostasis and has been implicated in erythroid apoptosis 90,104-106. Bim expression in 
hematopoiesis is regulated by FOXO transcriptional factors 107. At the protein level, Bim 
is regulated by ERK-dependent phosphorylation and degradation, as well as sequestration 
by the microtubular dynein motor complex 107-110. In response to cytokine withdrawal, 
Bim can induce apoptosis by binding and neutralizing the pro-survival Bcl-2 proteins. In 
erythropoiesis, EpoR-Jak2 signaling in cultured bone marrow erythroid progenitors 
repressed Bim transcription, whereas in erythroid cell lines, ERK repressed Bim protein 
via phosphorylation and degradation 89,90. Additional evidence suggests that GATA-1, via 
transcriptional factor LRF, suppresses Bim-mediated erythroblast apoptosis 106. Bim-
depleted erythroid cells are more resistant to apoptosis in vitro. However, Bim-/- mice 
suffer from an autoimmune syndrome making it difficult to understand the role of Bim in 
erythropoiesis in vivo 89. To date, the pattern of Bim expression in erythroblasts during 
differentiation in the basal stress and during stress is unknown, nor is it known if in vivo, 
Epo suppresses Bim to enhance erythroblast survival during stress. 
  
13.  Death receptor Fas and its ligand, FasL 
 Pro-apoptotic death receptor Fas (CD95) and its ligand, FasL have been proposed 
to regulate erythropoietic rate in vivo. Fas belongs to the tumor necrosis factor receptor 
superfamily. Upon FasL crosslinking, it activates the extrinsic and intrinsic apoptotic 
pathways. Fas and FasL are known to regulate the lymphoid compartment and non-
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lymphoid tissue homeostasis 111-116. Evidence also suggests that Fas apoptosis contributes 
to anemia in myelodysplastic syndromes and multiple myeloma 117-122. Fas and FasL 
were found to be expressed on human erythroid progenitors in vitro. These studies 
proposed FasL could negatively regulate erythroid output by inducing apoptosis in Fas-
bearing erythroblasts 92,123,124. However, mice mutant in Fas or FasL suffer from an 
autoimmune syndrome precluding the study of Fas role in erythropoiesis in vivo 125. 
 Previous publications from our lab provided the first in vivo evidence for the 
apoptotic regulation of erythropoietic rate 42,44. Spleen ProE and EryA were found to 
continually undergo high rates of cell death, an unusual finding for a healthy tissue. A 
proportion of primary spleen ProE and EryA erythroblasts were also found to co-express 
Fas and FasL, resulting in apoptosis of the Fas-bearing cells. In stress, total erythroblast 
apoptosis and Fas-positive erythroblast frequency decreased in an Epo-dose- and time-
dependent manner 42. Similarly, we found that Fas and FasL negatively regulate the rapid 
erythroblast expansion in the fetal liver 44. These correlative data suggest that in vivo, Fas 
and FasL continually mediate apoptosis locally at the erythroblastic islands, where 
progenitors interact with each other (Figure 1.3). This cell-to-cell autoregulatory 
apoptosis may help prevent wasteful fluctuations in progenitor number for a stable basal 
erythropoietic rate, which is a homeostatic function. Another possible in vivo Fas 
function is to maintain an apoptotic reserve of cells which can be immediately rescued by 
Epo from cell death during stress (Figure 1.4). In my thesis work, I tested these proposed 
Fas functions in erythropoiesis using Fas- and FasL-mutant mice bred onto an immune-
deficient background to rescue their autoimmune disease 125. 
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14.  Principal questions addressed in this thesis 
 In Chapter III, I address the role of Fas and FasL in basal and stress erythropoiesis 
in vivo, using mutant mouse models. In Chapter IV, I examine the expression patterns of 
Bcl-xL and Bim in basal and stress erythropoiesis, and the manner in which they are 
regulated by EpoR signaling. Chapter V summarizes the flow-cytometric methodologies 
developed by our laboratory. The last chapter discusses the principal results and proposes 
future directions. 
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Figure 1.1 
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Figure 1.1 Epo-mediated negative feedback loop regulates both basal and stress 
erythropoiesis to maintain normal tissue oxygen. 
(A)  To re-establish pO2 homeostasis during tissue hypoxia, kidneys increase the 
production of erythropoietin (Epo) which increases the rate of erythropoiesis. Epo levels 
increase with the degree of hypoxia, reaching a 1000-fold induction in the most severe 
hypoxic stress. 
(B)  Basal erythropoiesis in an adult occurs primarily in the bone-marrow to replace 
aging erythrocytes. Stress erythropoiesis is the increase in the rate of red cell production 
to re-establish normal tissue oxygen. In mice, spleen is an erythropoietic reserve organ 
(inset). In humans, bone-marrow is the primary site for both basal and stress 
erythropoiesis.  
(C)  The path of hematopoietic and erythroid development is illustrated. 
Hematopoietic stem cells (HSC) give rise to multiple lineages. Downstream of the HSC, 
common myeloid progenitors (CMP) cells produce macrophages and the 
megakaryocytic-erythrocytic progenitors (MEP). Erythroid differentiation proceeds from 
the burst-forming-unit erythroid (BFU-e) stage onward. Macrophages and erythroblasts 
constitute a developmental niche called erythroblastic island (described in Figure 1.3). 
Generated red cells regulate tissue pO2. My thesis work addresses the question of how 
Epo regulates erythropoietic rate. 
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Figure 1.2 
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Figure 1.2  Identification of erythroid progenitors in primary mouse tissue.  
(A)  Early erythroid progenitors (BFU-e and CFU-e), found in the MEP progenitor 
pool, are defined by their ability to form erythroid colonies in response to Epo in culture. 
Later erythroid stages (labeled with roman numerals i through iv) are traditionally 
identified based on morphological staining criteria (top). Similar erythroblast stages can 
be identified directly in hematopoietic tissue using cell surface markers CD71, Ter119, 
and forward scatter, a measure of cell size (corresponding stages are directly below 
erythroblast cytospins). EpoR expression extends to earlier compartments (yellow box 
with dashed line), but becomes essential for the formation of ProE cells from the closely-
preceding CFU-e progenitors (red arrow). ProE and EryA stages are Epo-dependent, and 
their frequency varies with the level of stress. Figure was created by me. 
(B)  Representative flow-cytometric plots of freshly-isolated splenocytes from mice 
injected with saline (basal) or a dose of Epo (stress). Animals were sacrificed two days 
post-injection. Cells were stained with CD71 and Ter119 markers. Dead cells were 
excluded using DAPI viability dye. Ter119high gate is subdivided further based on CD71 
and forward scatter (FSC). ProE (Ter119medCD71highFSChigh) and EryA 
(Ter119highCD71highFSChigh) subsets are Epo-dependent (blue) and greatly increase in 
frequency during stress. EryB (Ter119highCD71highFSClow) and EryC 
(Ter119highCD71lowFSClow) erythroid progenitors (red) arise from the EryA pool, and are 
Epo-independent 42. Modified from Figure 3.1B. 
(C)  Representative flow-cytometric plot of freshly-harvested E13.5 fetal liver stained 
with CD71 and Ter119 markers, and a viability dye. Erythroblast development in fetal 
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liver begins with the S0 subset that contains total hematopoietic progenitors [HSC 
through MEP, as shown in (A)]. S1 through S5 subsets contain fetal erythroblasts of 
increasing maturation status. Fetal liver staining method published in 46. 
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Figure 1.3 
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Figure 1.3  Erythroblastic islands: critical niches for basal and stress 
erythropoiesis in vivo.  
(I-IV)  Erythroblastic islands isolated from E15.5 fetal liver. Erythroblasts develop 
around a central macrophage (m), with most of the cells in a similar developmental stage. 
Island IV contains more mature erythroblasts. Arabic numerals indicate the likely 
developmental stage of erythroblasts (2 =most immature, 4 =most mature). Scale Bar: 
20µ. (Image used with permission from author Merav Socolovsky). 
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Figure 1.4 
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Figure 1.4 Proposed model: Epo regulates erythropoietic rate by rescuing 
progenitors from apoptosis. 
 Spleen (left), the reserve organ in mice, contains stress-responsive progenitors, 
which in the basal state undergo high rates of cell death 42. This portion of dying cells 
forms a ‘reserve’ population (black fraction) to be rescued from apoptosis when needed. 
In contrast, bone marrow (right) replaces senescent erythrocytes (RBC) during the steady 
state, but it has a lower apoptotic reserve and smaller physical space capacity for stress 
erythropoiesis. In vitro studies suggested a model where increasingly greater Epo (stress) 
leads to a graded rescue of erythroblasts from apoptosis (indicated by a decreasing 
apoptotic fraction). Spleen can increase its absolute erythroblast number because, unlike 
the bone marrow, it can physically enlarge in size (indicated by the increasing size of the 
circles). My thesis work tested the survival pathways activated by the EpoR in spleen and 
bone marrow erythroid progenitors during stress erythropoiesis in vivo. Figure was 
designed and created by me. 
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Chapter II Attributions and Copyright information 
 
MATERIALS AND METHODS 
 
All sections of this chapter were written by me. Materials and Methods discussed in this 
chapter are applicable to the subsequent Chapters III and IV. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Mice 
 Balb/C mice were purchased from Taconic, C57BL/6J strains were purchased 
from the Jackson Laboratories (Bar Harbor, ME). MyD88-/- mice were kindly provided to 
us by Dr. Egil Lien (University of Massachusetts Medical School, Worcester, MA). 
B6.MRL-Faslpr/J (Jackson Laboratories stock #000482) were crossed with B6.129.S7-
Rag1tm1Mom/J (Jackson Laboratories stock #002216) to obtain homozygous double-mutant 
lpr-Rag1-/- mice (C57BL/6J background). The homozygous double mutant gld-Rag1-/- 
mice (Balb/C background) were obtained by crossing CPt.C3-Faslgld/J (Jackson 
Laboratories, stock #002932) with C.129.S7(B6)-Rag1tm1Mom/J (Jackson Laboratories 
stock #003145). Genotyping was performed by PCR according to Jackson Laboratories 
protocols. In all experiments, lpr-Rag1-/- and gld-Rag1-/- mice were compared to their 
respective Rag1-/- controls. Mice were used at 10 to 14 weeks of age.  
 Stat5-/- mice were obtained from Dr. Lothar Hennighausen, (NIDDK, Bethesda, 
MD). β-thalassemia mice and the ts-VHL-/- mice were described previously 42. Bim-/- 
mice, B6.129S1-Bcl2l11tm1.1Ast/J (stock #004525), were purchased from Jackson 
Laboratories. EpoR-H and EpoR-HM mice were obtained from Dr. James Ihle, St. Jude 
Children’s Research Hospital, Memphis, TN 75. In all experiments, mice were matched 
for the same background strain, gender, and age. For low oxygen chamber experiments, 
Balb/C male littermates of 6 to 11 weeks of age were used. All experiments with mice 
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were conducted in accordance with an animal protocol approved by the University of 
Massachusetts Medical School IACUC committee. 
 
Erythropoietic stress 
 Recombinant human erythropoietin (Epoetin alfa, Amgen, Thousand Oaks, CA) 
was injected at the indicated doses subcutaneously in a total volume of 150 µl in sterile 
isotonic saline. Human purified Fas:Fc chimeric fusion protein (BD Biosciences, San 
Diego, CA) was injected at 100 µg per mouse, intraperitoneally. Reduced atmospheric 
oxygen treatment was conducted using the BioSpherix A-chamber (BioSpherix, Lacona, 
NY) for the indicated time periods. Hypoxia was achieved by displacing oxygen with 
nitrogen at normal atmospheric pressure. Temperature, humidity and carbon dioxide 
readings were monitored.  
 
Live cell surface-staining for flow cytometry 
 Antibody staining and flow cytometry were performed as described (Chapter V 
and 42,44). Cells from freshly isolated tissues were gently strained through 40-µm strainer 
in the presence of cold phosphate-buffered saline and 5% fetal calf serum (1xPBS/5% 
FCS) or 0.2% bovine-serum albumin (BSA).  
The following antibodies and reagents were used: PE- or FITC-rat anti-mouse 
CD71 (C2 clone), PE- or APC-rat anti-mouse Ter119, biotin-hamster anti-mouse Fas 
(Jo2 clone) or FasL (MFL3 clone) (BD Biosciences). DAPI (Roche, Indianapolis, IN) or 
7-AAD (BD Biosciences) viability dyes were used. 
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Cells were immunostained for 20-45 minutes on ice in the presence of blocking 
rabbit or mouse immunoglobulin (Jackson ImmunoResearch, West Grove, PA), 2.5 
µg/mL fluorochrome-conjugated anti-Ter119 (BD Biosciences, San Diego, CA), and 2.5 
µg/mL fluorochrome-conjugated anti-CD71 (BD Biosciences).  
Staining for Fas or FasL was done along with anti-CD71/Ter119 for 1 hour on ice 
with 5 µg/mL biotin-conjugated anti-Fas (Jo2 clone, BD Biosciences) or 5 µg/mL biotin-
conjugated anti-FasL (MFL3 clone, BD Biosciences). APC-conjugated streptavidin 
(Invitrogen, Carlsbad, CA) was used to amplify the biotin signal after washing the cells. 
Following all the staining steps, cells were washed twice and resuspended in the viability 
dye-containing buffer until analysis. Proper washing of cells is essential to specific signal 
detection. Alexa Fluor 350-Annexin V (Invitrogen) staining was performed according to 
the manufacturer’s instructions (1 hour on ice in Annexin V-specific buffer; Annexin V 
buffer was also used for subsequent washes and viability dye staining).  
 
Intracellular protein staining  
 To detect intracellular Bcl-xL and Bim, cells were first stained with LIVE/DEAD 
fixable viability stain (Invitrogen), followed by surface-labeling for Ter119 and CD71 in 
the presence of blocking IgG. Next, cells were fixed with PBS solution containing 3% 
paraformaldehyde and 2% sucrose, and frozen in 90%FBS/10%DMSO at -80°C. On day 
2, samples were thawed, washed with 1xPBS/0.2%BSA buffer, and permeabilized with 
BD Cytofix/CytopermTM Perm/Wash reagent. Cells were then stained in the Perm/Wash 
solution with anti-Ter119 (to maintain Ter119 signal in fixed cells) and with anti-Bcl-xL 
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antiserum (BD Biosciences 556361) or anti-Bim antibody (Cell Signaling, #2819), or 
isotype control. Isotype control for Bcl-xL was Normal Rabbit Serum (Jackson 
Immunoresearch). Isotype control for Bim was Rabbit IgG (Jackson Immunoresearch). 
Primary Bcl-xL or Bim staining was detected using secondary antibody (anti-Rabbit-
APC, Invitrogen A-10931). Proper washing of cells is essential to specific signal 
detection. Biological sample used for determining the isotype control’s background 
fluorescence consisted of a cell mix pooled from all mouse samples in a given experiment 
(isotype signal was similar across individual biological samples regardless of genotype or 
treatment). 
 
Phospho-Stat5 staining  
 Cells were first stained with LIVE/DEAD viability dye, then resuspended in 
phosphowash (1xPBS, 1 mM sodium orthovanadate, 1 mM β-glycerol phosphate, 1 
µg/mL microcystin), fixed in 1.6% paraformaldehyde, permeabilized in 80% acetone and 
stored at -80°C. Thawed cells were stained in 1xPBS/3% milk with AF647-conjugated 
anti-phospho-Stat5 antibody (BD Biosciences 612599) and for Ter119 and CD71 as 
described previously.  
 
Reticulocyte detection 
 Reticulocytes were detected as a DNA-negative, RNA-positive cell population in 
blood, as described 48. 1-2 µl of EDTA-preserved whole blood were stained at room 
temperature for 30 minutes in 1xPBS with RNA/DNA dye Thiazole Orange (Sigma-
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Aldrich, St. Louis, MO; used at ~1:1000 dilution of fresh 1 mg/mL stock solution in 
methanol), followed by addition of DNA dye DRAQ5 (BioStatus, Shepshed, United 
Kingdom; used at 1:2500 of 5 mM stock solution) for 5 minutes at 37°C. Cells must be 
kept in original Thiazole Orange/DRAQ5 staining solution until analysis. Data were 
collected using the 488nm and the 633nm lasers [FITC and APC (670/40 filter) channels, 
respectively] on LSRII (BD Biosciences) flow cytometer. 
For all flow cytometry experiments, stained cells were analyzed on LSRII flow 
cytometer (BD Biosciences). Cell sorting was done at the Umass Flow Cytometry Core 
Facility on a DakoCytomation MoFlo (Fort Collins, CO). 
 
Flow cytometry data analysis 
 Data were analyzed with FlowJo software (Tree Star, Ashland, OR), as described 
in more detail in Chapter V 42,46. Singlets and live cells (based on DAPI, 7-AAD, or 
LIVE/DEAD stains) were selected, and subsets were gated based on Ter119, CD71 
expression and forward scatter (FSC). Gating strategy for fetal liver and adult 
erythroblasts was performed as described in Chapter V. For Fas surface stain, Fas-
positive gate was drawn based on secondary antibody-only control, as described above. 
For Annexin V, positive gate was drawn based on the sample where Annexin V stain was 
omitted. For each subset in each biological sample, non-specific isotype control’s median 
fluorescent intensity (MFI) signal was subtracted from the MFI of Bcl-xL or Bim signal 
prior to plotting the data. 
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Peripheral blood analysis 
 Hematocrit was determined using the CritSpin Microhematocrit centrifuge kit 
(Iris Sample Processing, Westwood, MA). For Complete Blood Count (CBC), whole 
blood was collected by cardiac puncture of euthanized animal into EDTA collection tubes 
and processed on Heska Hematology Analyzer (Heska, Loveland, CO) at the Umass 
Animal Facility.  
 
CFU-e colony assay 
 Freshly isolated fetal liver, spleen and bone-marrow cells were manually counted, 
and cells were plated for tissue culture in M3231 Methocult® methylcellulose media 
(StemCell Technologies, Vancouver, Canada) supplemented with 2 U/mL rh-Epo 
(Amgen). On day 3, plates were stained with 3,3'-Diaminobenzidine (Sigma-Aldrich) and 
scored for erythroid colonies. Results are expressed as total CFU-e colonies per 106 live 
plated cells. 
 
Erythropoietin ELISA 
 Enzyme Linked Immunosorbent Assay (ELISA) for mouse Epo was performed 
according to the manufacturer’s instructions (Quantikine ELISA, R&D Systems, 
Minneapolis, MN). EnVision 2102 Multilabel Reader (Perkin Elmer, Waltham, MA) was 
used to quantify fluorescence. Data were converted into mU/mL by multiplying pg/mL 
value by 129,000 IU/mg (International Standard for fully glycosylated Epo protein 4,126). 
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Statistical analyses and data presentation 
 Statistical analysis of basal state Fas and FasL-mutant mouse data in Chapter III 
was performed using PASW (SPSS, Chicago, IL) and SAS (SAS, Cary, NC) statistical 
software. Specifically, data were log-transformed and residuals were tested for normality 
by Kolmogorov-Smirnov test (performed in PASW). Log-transformed data were then 
analyzed by general linear mixed model ANOVA with gender and genotype as fixed 
effects, and with experiment as the random effect (performed in SAS). Unadjusted p-
values (p<0.05 considered significant) were reported in Chapter III figures for each 
gender-genotype group.  
 F probability distribution test (F test) in Chapter III was performed on residuals 
derived from untransformed data: First, experiment, gender and genotype were taken into 
account for deriving the residuals (performed in PASW). Residuals were next compared 
using F test in Microsoft Excel software (Redmond, WA). Similar, or even more 
significant, p-values were obtained via F test on raw pooled data directly within 
Microsoft Excel. 
 For all other statistical tests, Microsoft Excel or GraphPad Prism software (La 
Jolla, CA) were used. For presentation in the figures, all data were plotted using 
Microsoft Excel or GraphPad Prism software, and adjusted in Adobe Photoshop and 
Illustrator Software. 
 
Quantitative real-time PCR  
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 Total RNA was prepared from freshly sorted erythroblasts using the AllPrep 
DNA/RNA Micro Kit (Qiagen) with on-column DNase treatment. Reverse-transcription 
was conducted using Superscript II (Invitrogen) with random hexamer primers. The ABI 
7300 sequence detection system, TaqMan reagents and TaqMan MGB probes (Applied 
Biosystems) were used, and several dilutions of each template were used to ensure 
detection in the linear range of the assay. A ‘no template’ and ‘no reverse-transcriptase’ 
controls were included. The threshold cycle (Ct) for housekeeping genes GAPDH or β-
actin were subtracted from the Ct for genes of interest to yield a relative expression value. 
Where indicated, the relative expression for each gene of interest in each sample was then 
normalized to its expression in the S0 fetal liver subset or saline-injected bone-marrow 
EryA adult subset (Chapter IV).  
QRT-PCR TaqMan probes used: GAPDH (Mm99999915_g1), β -actin 
(Mm02619580_g1), β -globin (Mm01611268_g1). Bcl-xL primers were 
CTGGGACACTTTTGTGGATCTCT and GAAGCGCTCCTGGCCTTT. BimEL primers 
were TCTTTTGACACAGACAGGAGC and AATCATTTGCAAACACCCTCC. BimL 
primers detected both BimEL and BimL isoforms, and were 
CTCAGTGCAATGGCTTCCATA and AATCATTTGCAAACACCCTCC. 
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CHAPTER III 
 
 
NEGATIVE AUTOREGULATION BY FAS STABILIZES ADULT 
ERYTHROPOIESIS AND ACCELERATES ITS STRESS RESPONSE 
 
 
ABSTRACT 
 Erythropoiesis maintains a stable hematocrit and tissue oxygenation in the basal 
state, while mounting a stress response that accelerates red cell production in anemia, 
blood loss or high altitude. Thus, tissue hypoxia increases secretion of the hormone 
erythropoietin (Epo), stimulating an increase in erythroid progenitors and erythropoietic 
rate. Several cell divisions must elapse, however, before Epo-responsive progenitors 
mature into red cells. This inherent delay is expected to reduce the stability of 
erythropoiesis and to slow its response to stress. Here we identify a mechanism that helps 
to offset these effects. We recently showed that splenic early erythroblasts, ‘EryA’, 
negatively regulate their own survival by co-expressing the death receptor Fas, and its 
ligand, FasL. Here we studied mice mutant for either Fas or FasL, bred onto an immune-
deficient background, in order to avoid an autoimmune syndrome associated with Fas 
deficiency. Mutant mice had a higher hematocrit, lower serum Epo, and an increased 
number of splenic erythroid progenitors, suggesting that Fas negatively regulates 
erythropoiesis at the level of the whole animal. In addition, Fas-mediated autoregulation 
stabilizes the size of the splenic early erythroblast pool, since mutant mice had a 
significantly more variable EryA pool than matched control mice. Unexpectedly, in spite 
of the loss of a negative regulator, the expansion of EryA and ProE progenitors in 
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response to high Epo in vivo, as well as the increase in erythropoietic rate in mice 
injected with Epo or placed in a hypoxic environment, lagged significantly in the mutant 
mice. This suggests that Fas-mediated autoregulation accelerates the erythropoietic 
response to stress. Therefore, Fas-mediated negative autoregulation within splenic 
erythropoietic tissue optimizes key dynamic features in the operation of the 
erythropoietic network as a whole, helping to maintain erythroid homeostasis in the basal 
state, while accelerating the stress response.  
 
INTRODUCTION 
The production of red blood cells (erythropoiesis) is continuous throughout life, 
maintaining an optimal number of circulating red cells and tissue oxygen tension (pO2). 
A decrease in tissue pO2, as may occur in anemia, bleeding, high altitude or respiratory 
disease, drives erythropoiesis up to 10-fold its basal rate. This response is regulated 
through a negative feedback loop in which decreasing tissue pO2 increases synthesis of 
the hormone Epo (Figure 3.1A) 7,24,127. Epo-mediated activation of its receptor, EpoR 56, 
on erythroid progenitors increases their number and consequently, erythropoietic rate and 
tissue pO2. During accelerated rates of erythropoiesis, Epo cooperates with additional 
factors, notably glucocorticoid hormones and stem cell factor 15,21,128,129. 
Epo controls an early cellular compartment within the ‘erythroblastic island’, the 
developmental niche on the surface of a macrophage that supports erythroid maturation 
130 (Figure 3.1A). Three to five cell divisions must elapse before cells in this early 
compartment mature into red blood cells. This inherent delay in the pO2/Epo-regulated 
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feedback loop is likely to compromise the stability and rapid stress response of the 
erythropoietic system. Additional control mechanisms may therefore exist to compensate 
for this inherent delay.  
The earliest Epo-dependent progenitor is the ‘Colony-forming Unit-erythroid’ or 
CFU-e, giving rise to colonies of at least 8 red cells within 48-72 hours in vitro 35. Its 
erythroblast progeny are classified by their morphology 131. We previously developed a 
flow-cytometric approach to identify erythroblasts directly in freshly-harvested mouse 
hematopoietic tissue, using cell surface markers CD71, Ter119 and cell size, measured by 
flow-cytometric forward scatter (FSC). We classify increasingly mature erythroid 
precursors subsets as ‘ProE’ (CD71high Ter119med), ‘EryA’ (CD71highTer119highFSChigh), 
‘EryB’ (CD71highTer119highFSClow) and ‘EryC’ (CD71lowTer119highFSClow) 42 (Figure 
3.1A-B). We found that, in addition to the well documented increase in CFU-e 52,132, the 
early erythroblast subsets ProE and EryA are responsive to EpoR signaling in vivo 42.  
Epo promotes erythroblast survival in vitro 73, suggesting this mechanism may 
underlie its regulation of erythropoietic rate. Our recent experiments in vivo 42 confirm 
this hypothesis. During basal erythropoiesis, the majority of ProE and EryA undergo 
apoptosis, particularly in spleen, the murine organ of erythropoietic reserve 133. During 
stress, high Epo decreases their apoptosis, increasing ProE and EryA number 42. The 
reasons for this apparently wasteful mechanism of erythropoietic rate regulation have not 
been addressed experimentally.  
EpoR activates several survival pathways, including Stat5-mediated induction of 
Bcl-xL 76,99,134,135, other Stat5 targets 67,90,136,137 and the EpoR-activated phosphoinositide 
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3-kinase (PI3K)-AKT pathway 81,82. The death receptor Fas, and its ligand, FasL, were 
first proposed to contribute to erythroid homeostasis based on their expression in human 
bone marrow 92. We found that, in vivo in the mouse, splenic ProE and EryA, but not 
their bone marrow counterparts, co-express Fas and FasL. During stress, high Epo 
suppresses their Fas expression, strongly correlating with their decreased apoptosis 42. 
These findings suggested the hypothesis that, in the basal state, splenic ProE and EryA 
negatively regulate their own survival through Fas and FasL-mediated inter-cellular 
interactions; and that Epo-mediated Fas suppression is a key mechanism regulating 
erythropoietic expansion during stress (Figure 3.1A) 42. 
Negative autoregulation through co-expression of Fas and FasL was previously 
implicated in terminating the clonal expansion of activated T cells 138-140. Similarly, we 
recently found that Fas and FasL co-expression in fetal liver erythroid progenitors 
terminates their initial wave of expansion at the onset of fetal erythropoiesis 44. Here we 
set out to assess the contribution of Fas and FasL to erythropoiesis in the adult. We bred 
lpr or gld mice, mutant in Fas and FasL respectively, onto the Rag1-/- immune-deficient 
background, in order to avoid an autoimmune syndrome that may impact erythropoiesis. 
Our findings in both the lpr-Rag1-/- and gld-Rag1-/- mice were similar, showing that Fas-
mediated autoregulation in spleen negatively regulates erythropoiesis at the whole animal 
level. Strikingly, these experiments also revealed that Fas-mediated autoregulation 
imparted key dynamic properties to the erythropoietic system. We found that it is 
responsible for stabilizing the basal precursor pool, enhancing their resistance to random 
perturbations. Further, it also accelerated the erythropoietic response to high Epo, an 
 
  
 
40 
unexpected effect for a negative regulator. Therefore, the dynamic properties of the Fas-
mediated autoregulation offset the dynamic deficits of the slower, pO2/Epo-regulated 
feedback. Of interest, negative autoregulatory loops, in the context of simple 
transcriptional networks, were shown to accelerate the response to a stimulus, and to 
enhance network stability 141-144. Our findings here suggest that these loops, which are 
abundant in biological systems, similarly improve the homeostasis and dynamic 
responses of lineage-specific progenitors in vivo.  
 
RESULTS 
Hypoxia and return to normoxia alter Fas expression and survival of early 
erythroblasts 
Erythropoietic stress results in suppression of Fas expression and reduced 
apoptosis in splenic ProE and EryA 42. These findings suggested the model illustrated in 
Figure 3.1A, in which Fas-mediated cell death is a result of intercellular interactions 
between Fas and FasL-co-expressing cells within the spleen early erythroblast 
compartment; these interactions are blocked by high Epo during stress (Figure 3.1B).  
Here we investigated this model further by housing mice in a hypoxic 
environment of 11% oxygen for 8 days, followed by a return to normoxia (21% oxygen). 
Hypoxia caused a sharp increase in plasma Epo (Figure 3.1C, lower left panel), 
suppressing Fas expression in EryA and enhancing their survival (Figure 3.1C, upper 
panel: example of flow-cytometric measurements of Fas expression and Annexin V 
binding; middle panels: summary of data from 2 to 9 mice per time point). Decreased 
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apoptosis and Fas expression were associated with increased spleen EryA (Figure 3.1C, 
lower right panel). A return to 21% oxygen resulted in a rapid reversal, with Epo and 
EryA declining below their starting levels, and both Fas expression and apoptosis rising 
well above their starting basal levels. These results suggest that modulation of Fas-
mediated apoptosis by Epo plays a role in both the expansion of the EryA pool in 
response to hypoxia, and in its rapid contraction with the return to normoxia. 
 
Effect of reducing Fas-mediated apoptosis with Fas:Fc in vivo 
To examine the effect of Fas on EryA survival directly, we administered MyD88-/- 
mice with the purified chimeric molecule, Fas:Fc 145, which acts as a decoy receptor, 
binding FasL on the surface of EryA and blocking its ability to activate Fas. Control 
MyD88-/- mice were injected intraperitoneally with an equal volume of saline. The 
MyD88-/- strain was used in order to avoid potential reaction to contaminating bacterial 
Lipopolysaccharide (LPS) in the Fas:Fc preparation 146. A single administration of Fas:Fc 
(100 µg) resulted in a ~20% reduction in unoccupied surface FasL in both splenic ProE 
and EryA, measured by binding of the Fas-blocking monoclonal antibody MFL3, 
directed against FasL (Figure 3.10D) 147. This procedure decreased the number of 
Annexin V+ EryA from 70% in control to 50% in Fas:Fc-injected mice by 48 hours. 
There was an associated increase in EryA, and a doubling in blood reticulocytes (Figure 
3.10). Reticulocytes, identified by their RNA content, mature within 24 hours 148; a 
doubling of reticulocytes suggests a doubling of erythropoietic rate over the most recent 
24 hours. These results support a causal relationship between Fas expression, EryA 
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survival and erythropoietic rate.  
 
The dose/response characteristics of Epo-mediated Fas suppression and EryA 
expansion  
To assess the quantitative relationship between Epo, Fas suppression and EryA 
numbers we injected mice (n=38) with varying doses of Epo, of between 1 and 300 Units 
/25 g body weight. We measured the Fas response on day 3, previously found to 
correspond to the lowest Fas expression level attained following acute Epo injection 42. 
We found that EryA frequency in Ter119+ spleen cells was inversely related to the 
fraction of EryA cells that expressed Fas (Figure 3.2A, left panel). Half maximal 
suppression of Fas expression was seen in mice injected with 10 U /25 g (Figure 3.2A, 
right panel), corresponding to a doubling of EryA frequency. Complete suppression of 
Fas expression was seen at 30U /25g, and resulted in a 6-fold increase in EryA frequency.  
 
The frequency of EryA is inversely related to their Fas expression  
The relationship between EryA frequency, and the fraction of EryA that express 
Fas, may be fitted by a model in which EryA undergo Fas-mediated negative 
autoregulation (Figure 3.2B). We considered the frequency of EryA within the 
erythroblastic island, ‘A’, to be the result of three principal factors: first, a continuous 
input from earlier progenitors, ‘ß’; second, a continuous output, proportional to A, ’αA’, 
into more differentiated progenitor subsets; and last, Fas-dependent cell death. We 
assumed that Fas-mediated cell loss would result when two EryA cells, expressing Fas 
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and FasL respectively, interact within the erythroid compartment. The probability of such 
an encounter is proportional to the product of the frequencies of Fas+ and FasL+ EryA 
cells. This product is approximately equal to A2F, where ‘F’ denote the fraction of EryA 
cells that express Fas (Figure 3.2B; the fraction of EryA that express FasL in adult spleen 
is high enough that it can be approximated to 1; see Text 3.1: ‘Regulation of the EryA 
progenitor pool by Fas’). These considerations allow the steady-state level of EryA, at 
any given level of Fas, to be found by solving a quadratic equation. The inverse 
relationship between EryA and Fas in Figure 3.2A is fitted well by a hyperbolic curve 
that represents the (positive) steady-state solutions for EryA (‘A’) in this equation, at 
different steady-state levels of Fas (‘F’) (R2=0.89, Text 3.1). This goodness of fit 
supports the model’s key assumption, that Fas-mediated cell loss is a result of negative 
autoregulation within the EryA pool, and is proportional to the square of the frequency of 
EryA within the erythroblastic island. Further, it suggests that Epo concentration, which 
sets the desired steady-state EryA pool size, does so in part by regulating the level of Fas 
expression in the EryA population (Figure 3.1A).  
 Of note, using a different modeling approach, we found a similar relationship in 
fetal liver, where Fas-mediated loss of early erythroblasts was proportional to the square 
of the frequency of early erythroblasts in the tissue 44.  
 
Generation of Fas and FasL-deficient mice on an immune-deficient background 
We made use of the lpr and gld mouse strains that carry naturally-occurring loss-
of-function mutations of Fas and FasL, respectively 125. The lpr mutation consists of an 
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insertion of an early transposable element, carrying a polyadenylation signal, in the 
second intron of the Fas gene. This causes premature termination of the transcript and a 
drastic decrease in Fas transcription, though it does not fully eliminate it. In the gld strain, 
there is a point mutation at the C-terminus of FasL that abolishes its ability to bind Fas. 
Both the lpr and gld mice develop a lymphoid proliferative autoimmune syndrome 149. In 
order to avoid this complication, we bred these mouse strains onto an immune-deficient, 
Rag1-/- background that lacks T and B cells 150. Erythroid parameters, such as basal 
hemoglobin concentration, though consistent within a given inbred strain, differ 
somewhat between mice of different genetic backgrounds, likely reflecting quantitative 
differences in the control of erythropoiesis 151. We therefore chose to generate two 
distinct genetic background strains. The gld-Rag1-/- mice were bred on the Balb/C 
background, and the lpr-Rag1-/- mice on the C57BL/6 background. As controls, we used 
age and strain-matched Rag1-/- mice, which on either the Balb/C or the C57BL/6 
backgrounds, have normal erythropoietic parameters when compared with wild-type mice 
of the same background strain. Further, the double homozygous mutant strains, gld-Rag1-
/- and lpr-Rag1-/-, showed no sign of autoimmunity, as evident from their small spleen 
size, absence of immune cells from the blood and spleen, and lack of anemia (Table 3.1).  
 
Basal Erythropoiesis in lpr-Rag1-/- and gld-Rag1-/- mice 
The chronic absence of an erythropoietic regulator may not be apparent from 
simple inspection of the hematocrit in the steady state 76. This is due to a vast 
erythropoietic reserve, coupled with the pO2/Epo negative feedback loop which 
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automatically adjusts Epo levels and erythropoietic rate so as to maintain a near- normal 
tissue pO2. Therefore, to assess how the loss of a regulator affects steady state 
erythropoiesis requires analysis at all levels of the pO2/Epo negative feedback loop, 
including Epo concentration and the erythroid progenitor and precursor pools. We first 
examined the hematocrit (the fraction of all blood volume that is attributable to red blood 
cells), blood reticulocytes and plasma Epo. lpr-Rag1-/- mice on the C57BL/6 background 
had a normal reticulocyte count and normal hematocrit (Figure 3.3A, top left panel, Table 
3.1). However, plasma Epo was significantly lower, by 35%, than in control mice 
(p=0.001; Epo= 9.0±0.8 mU/mL, mean ±SEM, in lpr-Rag1-/-, and 13.7±1.0 for Rag1-/- 
controls; Figure 3.3A, bottom left panel, and Figure 3.3B). Therefore, lpr-Rag1-/- mice 
compensate for the chronic absence of a negative regulator through the pO2/Epo negative 
feedback loop, decreasing Epo concentration so as to avoid an unnecessary increase in 
hematocrit.  
By contrast, the gld-Rag1-/- mice, on the Balb/C background, had a significantly 
elevated hematocrit (p<0.00001; hematocrit= 52.0 ±0.3% vs. 49.8 ±0.4% for gld-Rag1-/- 
vs. Rag1-/- respectively, mean ±SEM, Figure 3.3A; a similar difference was found in a 
second group of mice assayed using a Coulter counter, Table 3.1). Reticulocyte count 
was also more than double that of controls (p<0.0001; Reticulocyte count= 1.40 ±0.14% 
vs. 0.59 ±0.04% for gld-Rag1-/- vs. Rag1-/- respectively, Figure 3.3C-D), and hemoglobin 
concentration was also significantly elevated in 2 independent experiments (Table 3.1). 
As comparison, mice we housed for 3 weeks in 12% oxygen, equivalent to an altitude of 
14,000 feet, increased their hematocrit from 51.6 ±0.2 to 57.8 ±0.5%, an increase of 6%. 
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Therefore, the 2.2% increase in hematocrit in the gld-Rag1-/- mice represents 
approximately a third of the erythropoietic output in high altitude hypoxia. Unlike the 
lpr-Rag1-/-, plasma Epo in the gld-Rag1-/- mice was not significantly different to that of 
controls (Figure 3.3A), possibly because of the already low basal Epo in control Balb/C 
mice which was ∼40% lower than in control mice on the C57BL/6 background (Figure 
3.3A, lower panels, black symbols). 
Of note, responses by both gld-Rag1-/- (Balb/C background) and the lpr-Rag1-/- 
(C57BL/6 background) mice have in common a higher erythropoietic rate per unit plasma 
Epo than in matched control mice, consistent with the absence of a negative regulator of 
erythropoiesis.  
 
Increased splenic CFU-e, ProE and EryA in gld-Rag1-/- and lpr-Rag1-/- mice 
A representative flow-cytometric histogram in Figure 3.4A shows that the 
frequency of the ProE and EryA subsets within gld-Rag1-/- spleen erythropoietic tissue 
(Ter119+ cells) was increased. A similar analysis in 11 to 40 mice per strain/sex 
combination is summarized in Figures 3.4B and 3.4D. An increase in subset frequency 
does not necessarily reflect a corresponding increase in cell number, since it may also 
arise as a result of decreased cell number in other subsets. We therefore also examined 
the absolute number of cells in each of the erythroid precursor subsets, computed by 
multiplying the subset frequency data by the fraction of Ter119+ cells per spleen and the 
spleen weight, for each individual mouse (Figure 3.5A).  
These data show significant increases, ranging from 1.5- to 4-fold, depending on 
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genotype and sex, in both the frequency and absolute number of spleen CFU-e, ProE, 
EryA and EryB, in gld-Rag1-/- and lpr-Rag1-/- mice (Figures 3.4A-C and 3.5A). 
Specifically, all the splenic ProE, EryA and EryB subsets showed increased frequency 
within the Ter119high compartment in both gld-Rag1-/- and lpr-Rag1-/- mice relative to 
matched controls, with this increase reaching statistical significance in ten of the twelve 
comparisons made, namely ProE (p<0.02), EryA (p<0.002) and EryB (p<0.002) in 
female lpr-Rag1-/- mice, ProE (p<0.002), EryA (p<0.002) and EryB (p<0.02) in male lpr-
Rag1-/- mice, ProE (p<0.02), EryA (p<0.02) and EryB (p<0.02) in female gld-Rag1-/- 
mice, and EryB (p<0.02) in male gld-Rag1-/- mice. The frequency of ProE and EryA in 
male gld-Rag1-/- mice was also increased relative to controls but did not reach statistical 
significance. Similarly, the absolute number of cells in each of these erythroid subsets 
increased in both gld-Rag1-/- and lpr-Rag1-/- mice, reaching significance in nine of the 
twelve comparisons made, namely, ProE (p<0.005), EryA (p<0.0005) and EryB 
(p<0.0005) in female lpr-Rag1-/- mice, ProE (p<0.0005), EryA (p<0.0005) and EryB 
(p<0.05) in male lpr-Rag1-/- mice, and ProE (p<0.05), EryA (p<0.005) and EryB (p<0.05) 
in female gld-Rag1-/- mice. The number of ProE, EryA and EryB in male gld-Rag1-/- mice 
also increased but the differences did not reach statistical significance (Figure 3.5A). The 
number of gld-Rag1-/- mice available for analysis was smaller than that of the other 
sex/strain combinations (Figures 3.4B and 3.5A), possibly accounting for the failure of 
the change in their erythroblast subsets to reach statistical significance.  
Of note, there was no significant change in any of the equivalent subsets in bone 
marrow (Figure 3.4D) for any sex/strain combination. These results are consistent with 
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the pattern of erythroid Fas and FasL co-expression, which is largely restricted to spleen 
42. The largest increases were observed in ProE and EryA, in agreement with their higher 
Fas and FasL expression 42.  
 
Variability in basal erythropoietic rate and in the size of splenic erythroid subsets in 
gld-Rag1-/- and lpr-Rag1-/- mice 
Whilst the mean size of the ProE and EryA pools increased in gld-Rag1-/- and lpr-
Rag1-/- mouse populations, their actual size in individual mice was highly variable. Using 
an F-test we found significantly higher variance in both the frequency and absolute 
number of nearly all erythroblast subsets in the gld-Rag1-/- and lpr-Rag1-/- mice, and in 
gld-Rag1-/- reticulocytes, compared with matched Rag1-/- controls (significantly different 
variance is marked with an ‘f’; Figures 3.3D, 3.4B-C, 3.5A). The EryA frequency 
distributions (Figures 3.5B and 3.11) show the larger spread of EryA pool size in the 
mutant mice. We also found increased coefficient of variation (CV) for EryA and ProE in 
male, but less so in female, gld-Rag1-/- and lpr-Rag1-/- mice (Figures 3.5B and 3.11). The 
coefficient of variation measures variability independently of the population mean. 
Overall, CV values for all splenic erythroblast subsets and for peripheral blood 
reticulocytes in both gld-Rag1-/- and lpr-Rag1-/- male and female mice, are significantly 
increased (p=0.017, Figure 3.11B). These findings indicate that a key function of Fas-
mediated negative autoregulation is to suppress variability in the steady-state precursor 
pool and in erythropoietic rate, thus stabilizing the basal state. 
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A delayed response to Epo-driven erythropoietic stress in gld-Rag1-/- and lpr-Rag1-/- 
mice 
We took two approaches to assess the stress response of the gld-Rag1-/- and lpr-
Rag1-/- mice. First, we injected mice with a single high dose of Epo (300 U /25 g body 
weight), and followed the resulting increase in erythropoietic rate for 6 days (Figure 
3.6A-D). Initially, on days 1 and/or 2, hematocrit was higher in both gld-Rag1-/- and lpr-
Rag1-/- mice compared with controls, by 1-2%, possibly reflecting the larger basal 
erythroblast pool in these mice. However, between days 2 and 3, there was a significantly 
faster increase in hematocrit in control mice, which rose by over 4% in the space of 24 
hours, overtaking the hematocrit of gld-Rag1-/- and lpr-Rag1-/- mice (Figure 3.6A, 3.6D). 
There was no equivalent rapid increase in hematocrit in the gld-Rag1-/- and lpr-Rag1-/- 
mice. By subtracting the mean hematocrit on day 2 from the mean hematocrit on day 3, in 
5 independent comparisons between independent experiments on those days, we found 
that the rate of change in the hematocrit was significantly higher in control mice 
(p<0.005, Figure 3.6D). The slower increase in hematocrit in both gld-Rag1-/- and lpr-
Rag1-/- mice at this time was due to a slower expansion of EryA precursors, in spite of 
their larger basal EryA pools (Figure 3.6B, 3.6C). The difference in EryA expansion was 
largest on days 2 (lpr-Rag1-/- mice) and 3 (gld-Rag1-/- mice) (Figure 3.6C), corresponding 
to the time when Epo-mediated Fas suppression in wild-type mice reaches its peak 42.  
Of note, EryA expansion in control mice was a massive, 30- to 60-fold increase 
over the basal EryA pool. The shortfall in EryA on day 2 in the lpr-Rag1-/- mice was 
equivalent to 10 times the size of the basal EryA pool, or 30% of the total expansion in 
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control mice on that day (Figure 3.6B,C, p<0.05; the size of the basal EryA pool is 
marked Figure 3.6C as a black bar). A similar delay in EryA expansion was seen in gld-
Rag1-/- mice (Figure 3.6B,C). Further, injection of a much lower Epo dose (10U /25 g 
body weight) in lpr-Rag1-/- mice again resulted in delayed hematocrit and ProE responses 
(Figure 3.12). Therefore, the presence of Fas-mediated negative autoregulation 
accelerates the erythropoietic response over a wide Epo stress range.  
Analysis of changes in the ProE population showed similar results. In spite of its 
larger size in the basal state, expansion of the ProE pool in both gld-Rag1-/- and lpr-Rag1-
/- mice was slower between days 1 and 3, the differences in the absolute size of the pools 
reaching significance on days 1 (gld-Rag1-/- mice) and 3 (lpr-Rag1-/- mice) (Figure 3.7A). 
Furthermore, the rate of increase in ProE in response to Epo peaked in all mice between 
days 1 and 2, attaining a significantly lower level in gld-Rag1-/- and lpr-Rag1-/- mice 
compared with matched controls (p=0.00004, Figure 3.7B,C).  
 
A delayed erythropoietic stress response to reduced atmospheric oxygen in gld-
Rag1-/- mice 
 In a second approach, we examined the response of the gld-Rag1-/- mice to an 
acute reduction of atmospheric oxygen to 11% (Figure 3.8). The response to reduced 
atmospheric oxygen is complex since, in addition to elevating serum Epo, it stimulates 
additional cytokines as well as changes in ventilation and plasma volume that may 
indirectly alter erythropoietic responses 18,19,21. Furthermore, the actual increase in serum 
Epo in response to lower atmospheric oxygen is determined not only by the initial 
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hypoxic stimulus, but also by the ensuing erythropoietic response, which determines the 
duration of tissue hypoxia (Figure 3.1A). We chose to examine gld-Rag1-/- mice, since, 
unlike the lpr-Rag1-/- strain, their starting baseline Epo levels are very similar to those of 
their matched controls (Figure 3.3B). We found that in spite of their higher starting 
hematocrit and reticulocyte count, the increase in erythropoietic rate in gld-Rag1-/- mice 
was significantly slower, as seen by a significantly delayed increase in hematocrit (Figure 
3.8A) and a lower reticulocyte count (Figure 3.8B). There was a correspondingly slower 
increase in EryC erythroblasts (Figure 3.8D), at both 24 and 72 hours. This sluggish 
response presumably prolonged the tissue hypoxia in these mice, as reflected by their 
higher serum Epo at 72 hours (Figure 3.8C). These results clearly show a delayed stress 
response in mice lacking Fas-mediated negative autoregulation of erythroblasts.  
Unlike the response to injection of a fixed, high Epo dose (Figure 3.6), the slower 
erythropoietic response to hypoxia in the gld-Rag1-/- mice was not associated with a 
difference in the size of the ProE/ EryA pools at the early (24 hour) time point. Such a 
difference may have occurred earlier; alternatively, hypoxia may accelerate the 
maturation of EryA cells, so that reserve, Fas+ EryA cells in control mice do not 
contribute to an increase in the EryA pool but instead differentiate rapidly and contribute 
to the increase that we see in the EryC pool by 24 hours (Figure 3.8D). Indeed, it has 
been observed previously that hypoxic stress as a result of bleeding or phenylhydrazine 
stress accelerates erythroblast maturation 152-154. The larger number of EryA in gld-Rag1-
/- by 72 hours presumably reflects the higher Epo level at that time, in turn a result of the 
more prolonged stress these mice presumably experience, due to their sluggish 
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erythropoietic response to the initial hypoxic stimulus.  
 
DISCUSSION 
We investigated the role of Fas and FasL-mediated negative autoregulation in the 
early erythroblast pool. We generated gld-Rag1-/- and lpr-Rag1-/- mouse strains, deficient 
in FasL and Fas, respectively, bred onto two distinct genetic backgrounds. Both these 
strains showed similar erythropoietic deficits. They confirm the hypothesis that Fas and 
FasL are negative regulators of splenic EryA and ProE, resulting in negative regulation of 
erythropoiesis at the whole animal level. In addition, they show a striking, non-redundant 
role for Fas in stabilizing basal erythropoiesis. Surprisingly, in spite of the removal of a 
negative regulator and the consequent larger basal precursor pool, the response of the 
mutant mice to erythropoietic stress was significantly delayed. These findings reveal that 
an autoregulatory loop local to erythropoietic tissue can exert key dynamic properties on 
erythropoiesis as a whole. They also provide experimental evidence that regulation of 
erythroid precursors through apoptosis, though apparently wasteful, accelerates the 
response to erythropoietic stress.  
 
The presence of a local negative autoregulatory loop in spleen erythropoietic tissue 
Several lines of evidence suggest that EryA and ProE negatively regulate their 
own survival through their Fas and FasL-mediated interactions. First, the pattern of co-
expression of both Fas and FasL by EryA and ProE 42,44; second, the close apposition of 
cells within the erythroblastic island, making an interaction between Fas+ and FasL+ cells 
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possible 44; and last, our finding that a mathematical model in which EryA negatively 
regulate their own survival via the Fas/FasL interaction, accounts well for the 
experimental data correlating splenic EryA frequency with their Fas expression, across a 
wide range of Epo concentrations in vivo (Figure 3.2 and Text 3.1). 
  
Fas-mediated negative autoregulation decreases erythropoiesis at the whole-animal 
level 
 Both acute and chronic inhibition of Fas suggest that it negatively regulates 
erythropoiesis at the level of the whole animal. An acute decrease in erythroblast FasL by 
transient administration of the decoy receptor Fas:Fc resulted in an acute increase in 
erythropoietic rate, reducing ProE and EryA apoptosis and doubling reticulocyte number 
by 48-72 hours (Figure 3.10).  
 Chronic loss of Fas function in the gld-Rag1-/- and lpr-Rag1-/- mice is likely to 
elicit compensation through the pO2/Epo-mediated negative feedback loop, which 
automatically adjusts Epo levels and erythropoietic rate so as to maintain a near-normal 
basal hematocrit and tissue pO2. Although lpr-Rag1-/- mice had normal reticulocytes and 
hematocrit, their plasma Epo was significantly lower, by 35%, than in matched Rag1-/- 
controls, evidence of compensatory adjustment. By contrast, gld-Rag1-/- mice were 
apparently unable to significantly lower their already low plasma Epo. Consequently, 
their reticulocyte numbers in peripheral blood, a direct measure of erythropoietic rate, 
more than doubled, and there was a corresponding significant 2.2% increase in 
hematocrit. This increase is equivalent to a third of the increase in hematocrit we 
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observed in mice housed in 12% oxygen, equivalent to hypoxia at 14,000 feet.  
 While many pathways have been implicated in the regulation of erythropoietic 
rate, a specific contribution to the stress response in vivo had been determined for very 
few. Of note, mice lacking ERK1, a recently described negative regulator of splenic 
erythropoiesis, showed a similar increase in hematocrit to that seen here for the gld-Rag1-
/- mice, without a significant change in plasma Epo 155. Taken together, both the lpr-Rag1-
/- and gld-Rag1-/- strains show increased erythropoietic rate per unit plasma Epo when 
compared with matched controls, confirming that local negative regulation at the level of 
splenic erythropoietic tissue has a negative effect at the level of the whole animal.  
 There is no indication that Fas and FasL interact with alternative receptors or 
ligands. Therefore, the difference in the response of the gld-Rag1-/- and lpr-Rag1-/- mice 
at the level of the hematocrit and serum Epo is likely attributable to their different genetic 
backgrounds. The response of both these mouse strains at the level of the ProE and EryA 
precursors, the direct sites of action of Fas and FasL, was very similar.  
 
Loss of Fas function results in a specific increase of spleen ProE and EryA pools 
 We found a significant 1.5- to 4-fold increase in the number of splenic, but not 
bone marrow, ProE and EryA in both the gld-Rag1-/- and lpr-Rag1-/- mice, consistent with 
the pattern of erythroid Fas and FasL expression 42. We also identified an increase in 
CFU-e specific to spleen, suggesting that these cells are regulated by Fas, in agreement 
with their counterpart in fetal liver 44. Bone marrow progenitor subsets were either 
normal or even decreased in number, possibly as a compensatory response to their 
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increase in spleen (Figure 3.4C,D).  
The increase in spleen ProE, EryA and CFU-e is due to the absence of a spleen-
specific negative regulator, rather than erythropoietic stress, since it is not associated with 
elevated serum Epo, and since there is no associated increase of bone marrow 
progenitors. It is unlikely that the increase in ProE/EryA is a consequence of expansion in 
an earlier, Fas-regulated progenitor compartment, since there was no significant change 
in bone marrow erythroid progenitors, platelets or white cells (Table 3.1). An earlier 
report of increased CFU-S in adult lpr and gld mice 156 is complicated by the autoimmune 
syndrome in these mice, which in the present work we addressed by breeding the lpr and 
gld mutant mice onto the immune-deficient Rag1-/- background.  
The expansion in ProE and EryA precursor pools in the gld-Rag1-/- and lpr-Rag1-/- 
mice represents a substantial non-redundant negative regulatory function of Fas. 
Nevertheless, it is likely to be an underestimate of the actual number of ProE/EryA that 
are regulated by Fas in wild-type mice, as suggested by the response to stress (see 
below). Compensatory mechanisms that could ameliorate the absence of Fas or FasL 
include upregulation of alternative negative regulators such as ERK1 155, attenuation of 
alternative EpoR anti-apoptotic pathways such as Stat5-induced Bcl-xL, phosphoinositol-
3 kinase/AKT and suppression of Bim and Foxo3a 23,90,134, or a decrease in factors that 
stimulate erythropoiesis such as BMP4 53.  
 
A stabilizing function for the Fas and FasL-mediated negative autoregulatory loop  
Random variation in the number of progenitors is an inevitable consequence of 
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inherent fluctuations in biological systems 157-159, found in mice that are genetically 
identical, of similar age and housed in similar stable conditions. The pO2/Epo-mediated 
negative feedback loop (Figure 3.1A) adjusts overall mean erythropoietic rate in the face 
of such fluctuations over time, but the intrinsic delay in this loop may result in 
oscillations and limit the system’s stability. Here we found that in the absence of Fas or 
FasL, there was a significant increase in variability, reflected by both increased variance 
and increased coefficient of variation, of splenic ProE, EryA and EryB in individual 
mice, compared with control mice (Figures 3.4B and 3.5A). Bone marrow erythroid 
subsets were not affected, but there was increased variability of overall erythropoietic 
rate, as reflected by the reticulocyte counts. Therefore, Fas-mediated autoregulation in 
spleen has a stabilizing effect on erythropoiesis at the whole animal level, offsetting the 
limitations of the pO2/Epo-mediated negative feedback loop. 
The stabilizing influence of the Fas/FasL interaction is a result of its sensitivity to 
the size of the erythroblast pool. For comparison, a recently identified cell-autonomous 
negative regulator of splenic erythropoiesis in vivo, ERK1, does not appear to contribute 
to the stability of erythropoiesis 155. Fas-mediated apoptosis of ProE or EryA depends on 
the probability that two cells expressing Fas and FasL respectively, encounter each other 
within the erythropoietic niche. This probability is dependent on their frequency in tissue 
(Figure 3.2 and Text 3.1). Should their frequency be in excess, Fas-mediated loss of EryA 
would accelerate, providing an automatic correction. Conversely, a shortage of EryA 
would lower the probability of their interaction and death, allowing their number to 
increase. Both negative and positive corrections take place locally in erythropoietic 
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tissue, with little delay and without the need to engage the pO2/Epo-mediated negative 
feedback loop, avoiding potentially deleterious corrective swings in systemic tissue pO2.  
 
Fas-mediated negative autoregulation accelerates the stress response 
Unexpectedly for mice lacking a negative erythropoietic regulator, the response of 
gld-Rag1-/- and lpr-Rag1-/- mice to acute Epo administration was delayed. The splenic 
EryA pool expanded 30-fold its basal size in control mice by day 2; this massive increase 
was reduced by 30% in the gld-Rag1-/- and lpr-Rag1-/- mice, reflecting a significant 
shortfall, equivalent to 10 times the size of the basal EryA pool. This shortfall occurred in 
spite of a larger than normal basal EryA pool in the mutant mice. We found a similar 
delay in the expansion of ProE cells in the gld-Rag1-/- and lpr-Rag1-/- mice. 
To explain this phenomenon, we propose the model illustrated in Figure 3.9. 
EryA are continuously formed from earlier progenitors (=EryA input) but the majority 
dies, with only a small fraction remaining as the basal EryA pool. However, the 
apoptosis-prone EryA form a reserve population that may be rapidly recruited by high 
Epo during stress. We propose that the rapid, 30-fold expansion in EryA within 2 days of 
Epo administration corresponds to the size of the reserve EryA population. The smaller 
initial expansion in the gld-Rag1-/- and lpr-Rag1-/- mice suggests that part of the EryA 
reserve is regulated through Fas, and is missing in these mutant mice.  
These observations suggest that the high apoptotic rates of ProE and EryA in the 
basal state, in part due to Fas, provide a mechanism that accelerates the stress response. 
The rescue of ProE/EryA from apoptosis allows a faster increase in their number 
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compared with their generation by cell division from earlier progenitors. This faster 
increase accelerates erythropoietic rate and prevents a prolonged tissue hypoxia. We 
found that the response of the erythropoietic system to reduced atmospheric oxygen was 
similarly delayed in gld-Rag1-/- mice, as reflected by lower reticulocyte counts and a 
slower increase in hematocrit. In this more complex, hypoxic stimulus to the system, we 
noted that the principal difference in the erythroblast pools between gld-Rag1-/- and 
control mice appeared at the EryC stage, rather than in the earlier, ProE and EryA stages. 
We suggest that this may be due to accelerated maturation of erythroblasts, noted in the 
older literature in response to hypoxic stress 152-154.  
Of note, in ERK1-/- mice, the stress response is timely and somewhat amplified 
155. Unlike Fas-mediated autoregulation, which is exerted at the level of erythroblasts, 
ERK1 appears to suppress a much earlier, BMP-dependent BFU-e progenitor, which is 
therefore unlikely to contribute to the initial, acute phase of stress.  
 
The negative autoregulatory motif  
Negative autoregulation is a frequent motif in biological networks. Computational 
and experimental approaches in simple transcriptional networks in E.Coli suggested that 
it has two principal effects: conferring resistance to random fluctuations, and accelerating 
the response to a stimulus 141-144,160,161. To our knowledge, the functional role of negative 
autoregulation within higher-level intercellular networks had not been tested 
experimentally. Our work suggests that the negative regulatory motif may exert similar 
‘logic’ in higher-level networks, helping to maintain both stability and a fast stress 
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response of tissue progenitors.  
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Figure 3.1 
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Figure 3.1  Epo regulation of erythropoiesis through Fas-mediated apoptosis.  
(A) Epo-dependent erythroblastic island precursors CFU-e, ProE and EryA (in blue) 
co-express Fas and FasL, and mature into Epo-independent EryB, EryC and red blood 
cells (RBC, in red). ‘F’ =Fas expressing cells, shown undergoing cell death as a result of 
interaction with FasL-expressing cells within the Epo-dependent (blue) compartment 
(black flat-headed arrow). A negative feedback loop driven by tissue pO2 regulates Epo 
levels in blood, which in turn enhance erythroblast survival, by either suppressing Fas 
and FasL expression, or by non-Fas dependent pathways. HSC =hematopoietic stem 
cells.  
(B) Flow-cytometric identification of Epo-dependent ProE and EryA subsets (in blue) 
and Epo-independent EryB and EryC (in red), in adult Balb/C mouse spleen, in basal 
conditions (top panels) or 48 hours following Epo injection (300 U /mouse, lower 
panels). ProE are defined as Ter119medCD71high cells; Ter119high cells are further 
subdivided based on forward scatter (FSC) and CD71 expression into EryA (CD71high 
Ter119highFSChigh), EryB (CD71highTer119highFSClow) and EryC (CD71lowTer119high 
FSClow).  
(C) The erythropoietic response of mice to a hypoxic environment. Mice (Balb/C) 
were examined either in the basal state (‘a’, 21% atmospheric oxygen), when housed in 
11% oxygen for 8 days (assay times ‘b’ and ‘c’ at 13 hours and 3 days, respectively), and 
when placed back in normoxia (21%; assay times ‘d’ and ‘e’, at 1 and 2 days post-
hypoxia). Top panels show representative flow-cytometric histograms of Fas expression 
and Annexin V binding at the indicated assay times. Gates refer to the Fas+ and Annexin 
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V+ populations, determined with reference to staining controls in which either the anti-
Fas antibody (left panel) or Annexin V (right panel) were omitted. The fraction of cells 
positive for Fas or Annexin V at each time point is noted. Middle panel shows a summary 
of similar data, 2 to 9 mice per time point. Lower panels show corresponding serum Epo 
levels and EryA cell number in spleen (expressed as total EryA cells /gram body weight). 
*p<0.05, **p<0.002, ***p<0.0001 (two-tailed t-test, unequal variance). 
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Figure 3.2 
 
 
  
 
64 
Figure 3.2 Fas and FasL-mediated negative autoregulation of the EryA pool. 
(A) Wild-type Balb/C mice were injected with a single Epo injection subcutaneously, 
of 1, 3, 6, 10, 30, 100 or 300 U /25 g body weight. Spleen EryA were examined on day 3 
post injection. Left panel shows EryA cell frequency (of total erythroid cells) relative to 
basal frequency, plotted against the number of EryA cells that express Fas (Fas+ EryA, 
expressed as a ratio to basal levels). Data points represent individual mice. Blue =mice in 
the basal state (n=15), red =mice injected with Epo (n=38). For clarity only mice injected 
with 30 U (which maximally suppress Fas) or less are included in the left panel (for 30 U, 
6 highest data points lie at the maximal Fas suppression and maximal EryA frequency). 
Data are fitted with a curve derived from the mathematical model described in panel (B) 
and in the Text 3.1. Right panel shows the dependence of Fas+ EryA on the dose of 
injected Epo, in the same dataset as in the left panel; all mice injected with a given Epo 
dose were pooled into one data point, mean ±SEM. 
(B) Schematic of the factors that regulate the size of the EryA pool, ‘A’, measured as 
the fraction of all Ter119+ cells that are EryA. F =fraction of EryA cells that express Fas. 
ß =input into the EryA pool from earlier progenitor stages. αA =output from the EryA 
pool into later erythroid subsets (EryB). A2F =Fas-mediated cell loss. See mathematical 
model described in Text 3.1. In panel (A) of this figure, A is plotted against F, expressed 
as a ratio to the A and F values in the basal state, respectively.  
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Figure 3.3 
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Figure 3.3  Increased erythropoiesis in mice deficient in the Fas pathway. 
 Legend in (A) also applies to panels (B) and (D). lpr-Rag1-/- mice are on the 
C57BL/6 background (in blue), and are compared with control Rag1-/- mice on the 
C57BL/6 background. gld-Rag1-/- mice are on the Balb/C background (in red), and are 
compared with control Rag1-/- mice on the Balb/C background. 
(A) Hematocrit (=fraction of the blood volume that is due to red cells) and Plasma 
Epo of lpr-Rag1-/-, gld-Rag1-/- and Rag1-/- age- and strain-matched control mice. M= 
males. F= females. Box and whiskers delineate the central 50% and 90% of readings, 
respectively. Median is indicated with a horizontal line; arithmetic mean with a ‘+’. Data 
points correspond to individual mice. Between 11 and 40 mice examined per genotype. 
*p<0.05, **p<0.005, ***p<0005 (ANOVA). 
(B) Hematocrit vs. plasma Epo in the subset of mice where both values were 
measured, in the basal state, for lpr-Rag1-/- and matched Rag1-/- control mice (left panel), 
and for gld-Rag1-/- and matched Rag1-/- controls (right panel). Data are mean ±SEM of 
≥16 mice. *p≤0.001 (two-tailed t-test, unequal variance). 
(C) Flow-cytometric measurement of reticulocyte number. Top: whole blood stained 
with either DRAQ5 (detects DNA) or Thiazole Orange (TO, detects both DNA and 
RNA). Reticulocytes lack a nucleus but retain RNA. They therefore form a DRAQ5-
negative, TO-positive population. Bottom panel shows analysis in wild-type (WT) mice 
either in the basal state or following Epo injection; and in gld-Rag1-/- and control Rag1-/- 
mice.  
(D)  Reticulocytes in lpr-Rag1-/-, gld-Rag1-/- and matched Rag1-/- controls, measured 
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by flow cytometry. ***p<0.0001, two-tailed t-test, unequal variance; ff= p<0.001, F test. 
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Figure 3.4 
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Figure 3.4  Increased frequency of spleen, but not bone-marrow, erythroid 
progenitors and precursors in mice deficient in the Fas pathway. 
 The Legend in panel (B) also applies to (C) and (D).  
(A) Representative flow-cytometric analysis of spleen erythroid subsets in gld-Rag1-/- 
and matched Rag1-/- controls, showing increased frequency of ProE and EryA within 
Ter119+ cells.  
(B)  Frequency of erythroblast subsets in spleen erythropoietic tissue, measured as in 
(A), expressed as fraction of all spleen Ter119+ cells. F=female M=male. Box and 
whiskers delineate the central 50% and 95% of readings, respectively, with the median 
indicated with a horizontal line and arithmetic mean with a ‘+’. Data points are individual 
mice (11-40 mice per sex/genotype combination). Data were pooled from several 
independent experiments. 
(C) CFU-e progenitors in spleen and bone marrow (per 1x106 plated cells). Data 
pooled from two independent experiments for females, and one experiment for males, for 
each genotype.  
(D)  Frequency of erythroblast subsets in bone marrow expressed as fraction of all 
spleen Ter119+ cells.  
For all panels, *p<0.05 **p<0.02, ***p<0.002 (ANOVA, for difference in 
means). f= p <0.05 ,ff= p<0.02, fff= p<0.002 (F test, for difference in variance).  
 
 
  
 
70 
Figure 3.5  
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Figure 3.5  Loss of Fas function results in a larger and more variable basal spleen 
erythroid progenitor pool. 
(A) Spleen erythroid subsets ProE, EryA or EryB, expressed as absolute number of 
cells per gram body weight, in gld-Rag1-/-, lpr-Rag1-/- and matched Rag1-/- controls, 
shown separately for male (M) and female (F) mice. Data correspond to the same mouse 
dataset as in Figure 3.4. Box and whiskers delineate the central 50% and 90% of 
readings, respectively, with the median indicated with a horizontal line and arithmetic 
mean with a ‘+’. Data points correspond to individual mice. Between 11 and 40 mice 
were examined per genotype; data pooled from several independent experiments. 
*p<0.05, **p<0.005, ***p<0.0005 (ANOVA, for difference in means); f =p<0.05, ff 
=p<0.005, fff =p<0.0005 (F test, for difference in variance).  
(B) Frequency distribution histograms for EryA, in male and female lpr-Rag1-/- and 
matched Rag1-/- controls. The coefficient of variation for each group is shown. Purple 
line is the fitted normal distribution curve. Same dataset as in panel (A). 
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Figure 3.6 
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Figure 3.6  Delayed response to Epo-induced stress in mice deficient in the Fas 
pathway. 
(A-D) gld-Rag1-/-, lpr-Rag1-/- and matched Rag1-/- control mice were injected with Epo 
(300 U /25 g body weight) subcutaneously at t=0. The erythropoietic response was 
followed for 6 days. Data are mean ±SEM for 3 to 18 mice per time point per genotype, 
pooled from up to 3 experiments per time point. Data at t=0 are the basal state data shown 
in Figures 3.3A and 3.5A, pooled for males and females. 
(A) Hematocrit measurements. 
(B) Spleen EryA (cells per gram body weight) in the same mouse set as in the top 
panel. Data points are individual mice, with the mean ±SEM for each day marked as a 
horizontal line.  
(C) The difference in mean EryA number (shown in panel B) between the mutant gld-
Rag1-/- or lpr-Rag1-/- and their matched Rag1-/- controls, for each day. The size of the 
corresponding control (Rag1-/-) EryA pool is marked with a black bar. 
(D) The rate of change in hematocrit between days 2 and 3 following Epo injection. 
The same dataset as in panel (A), showing the differences in hematocrit measured in 
multiple independent experiments on days 2 and 3. Altogether 5 independent 
comparisons are shown. 
For all panels, *p<0.05, **p<0.005, ***p<0.0005 (t-test, unequal variance). 
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Figure 3.7 
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Figure 3.7 Delayed response to Epo-induced stress in mice deficient in the Fas 
pathway. 
(A-C) Analysis of the ProE response to Epo injection. The same experiment and dataset 
as in Figure 3.6. 
(A) Spleen ProE (cells per gram body weight). Data points are individual mice, with 
the mean ±SEM for each day marked as a horizontal line. Data pooled from 1 to 3 
experiments with 3 to 18 mice per genotype. 
(B) The rate of change in spleen ProE between days 1 and 2 post-Epo injection in the 
mutant gld-Rag1-/- (indicated in red) or lpr-Rag1-/- (blue) and their matched Rag1-/- 
controls. Dataset as in panel (A). Each point represents the mean difference in ProE 
between independent experiments done on days 2 and 3, in 5 independent comparisons.  
(C) The rate of change in spleen ProE throughout the first 3 days of response to Epo, 
computed as in panel B. The rate of change between days 0 and 1, days 1 and 2, and days 
2 and 3, were plotted on days 0.5, 1.5 and 2.5, respectively. Data points represent pooled 
mutant (lpr/gld) or control differences (mean ±SEM).  
For all panels, *p<0.05, **p<0.005, ***p<0.0005 (t-test, unequal variance). 
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Figure 3.8 
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Figure 3.8  Delayed response to hypoxia-induced stress in mice deficient in the 
Fas pathway. 
(A-D) gld-Rag1-/- or control mice were transferred to a hypoxia chamber with ambient 
11% oxygen for 1 or 3 days. Data are mean ±SEM for 4 to 9 age- and gender-matched 
mice per time point per genotype. Data at t=0 are the basal state data shown in Figures 
3.3A and 3.5A, pooled for males and females. 
(A)  Hematocrit measurements, performed via CritSpin microcentrifugation. 
(B)  Reticulocyte measurements, performed flow-cytometrically, as in Figure 3.3C. 
(C)  Plasma Epo, measured by ELISA. 
(D)  Spleen erythroid subsets ProE, EryA, EryB and EryC, expressed as absolute 
number of cells per gram body weight in gld-Rag1-/- and matched Rag1-/- controls.  
For all panels, *p<0.05, **p<0.005, ***p<0.0005 (t-test, unequal variance). 
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Figure 3.9 
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Figure 3.9  Absence of a Fas-regulated EryA reserve delays the response to stress. 
EryA cells are continuously formed from earlier precursors (‘input’). In the basal 
state, when Epo concentrations are low, only a small fraction of these cells survive, 
forming the ‘basal EryA pool’ (in purple). The remaining EryA undergo apoptosis, either 
through Fas (‘Fas-regulated reserve’, green) or alternative mechanisms (‘Alternative 
reserve’, blue). Together, the EryA reserve pools are 30- to 60-fold the size of the basal 
pool (see Figure 3.6). During the initial response to stress, high Epo levels rescue the 
EryA reserve pools from apoptosis, resulting in an immediate increase in the size of the 
surviving EryA pool and an increase in erythropoietic rate (solid colors indicate surviving 
cells, dashed lines indicate cells that underwent apoptosis). 
We suggest that lpr and gld mice partially compensate for the absence of the Fas-
regulated reserve by generating fewer EryA cells (a smaller input). In this way, the 
absence of Fas-mediated apoptosis does not excessively increase the basal EryA pool 
(which does increase 1.5- to 4-fold, see Figure 3.5; this increase is much smaller than the 
stress-induced increase and is not shown). During stress, the absence of the Fas-regulated 
reserve in lpr and gld mice reduces the number of EryA that may be immediately 
recruited into the surviving EryA pool and consequently delays the stress response.  
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Figure 3.10 
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Figure 3.10, associated with Figure 3.1. Inhibition of Fas with Fas:Fc decreases 
EryA death and increases erythropoietic rate.  
 MyD88-/- mice (C57BL/6 background) were each injected intraperitoneally with 
100 µg of human purified Fas:Fc chimeric protein (BD Biosciences), or with an equal 
volume of saline (200 µl). 
(A) Flow-cytometric histogram of Annexin V binding of spleen EryA cells, showing 
decreased apoptosis 48 hours following injection of Fas:Fc.  
(B) Summary of Annexin V binding in two independent experiments, at 48 hours and 
at 72 hours post-injection. Data points correspond to individual mice.  
(C) Summary of reticulocyte count (red blood cells younger than 24 hr, identifiable 
by their cytoplasmic RNA, which is absent in older red cells) in the same 
mice/experiments as in panel (B). Fas:Fc caused an increase in reticulocytes, reflecting 
increased erythropoietic rate. 
(D) Summary of FasL-positive frequency in spleen ProE and EryA 24 hours post-
Fas:Fc. Fas:Fc treatment blocked immunodetection of FasL on the cell surface. 
 
 
  
 
82 
Figure 3.11 
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Figure 3.11, associated with Figure 3.5. Increased variance in lpr/gld erythroid 
progenitor subsets. 
(A) Frequency distribution histograms for EryA, in male and female gld-Rag1-/- and 
matched Rag1-/- controls. The coefficient of variation for each group is shown. Purple 
line is the corresponding normal distribution curve. Same dataset as in Figure 3.5. A 
similar analysis for the lpr-Rag1-/- mice is shown in Figure 3.5B. 
(B) Coefficient of variation (CV) for subsets ProE, EryA-C and reticulocytes in male 
or female lpr-Rag1-/- or and gld-Rag1-/- mice and corresponding Rag1-/- controls. The 
difference in CV between control and lpr/gld is significant at p=0.017 (paired t-test, 
treating the CV as a standard statistical variable). 
 
 
  
 
84 
Figure 3.12 
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Figure 3.12, associated with Figure 3.6  Delayed response to Epo injection in lpr-
Rag1-/- mice.  
 Female mice were injected with 10 U of Epo subcutaneously. Hematocrit, ProE 
and EryA progenitors were measured on day 3 post injection. *p<0.05 (two-tailed t-test, 
unequal variance). Basal hematocrit values are for lpr-Rag1-/- females. 
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Table 3.1 
 
 
 
 
 
 
 
Table 3.1, associated with Figure 3.3.  
 Complete blood counts (CBC) for the indicated mouse strains. n =number of mice 
used for each strain in each experiment. HCT =hematocrit. HGB =hemoglobin. RBC 
=red blood cells. MCV =mean corpuscular volume. WBC =white blood cells. PLT 
=platelets. All data are mean ±SEM. t-test (unequal variance) p-values are indicated. 
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Text 3.1  Regulation of the EryA progenitor pool by Fas. 
 The data in Figure 3.2A (left panel) can be fitted by a model in which Fas acts as 
a negative autoregulator of the EryA pool (Figure 3.2B).  
Let the number of EryA cells within the erythroblastic island be ‘A’. ‘A’ is expressed 
relative to the basal frequency of EryA within the erythroblastic island, (measured 
experimentally as the fraction of Ter119+ cells that are ‘EryA’ in the basal state).  
‘A’ is the result of three principal factors (Figure 3.2B):  
• a continuous input from earlier progenitors, β;  
• a continuous output, αA, into more differentiated progenitor subsets;  
• Fas-dependent loss through cell death.  
 
The probability of Fas-mediated cell death is proportional to the probability of a Fas-
positive EryA cell encountering an EryA cell that expresses FasL, at sufficiently close 
quarters to result in activation of the Fas receptor. If the fraction of EryA cells that 
expresses Fas is denoted by ‘F’, then the frequency of Fas-positive EryA cells in the 
erythroblastic island is ‘AF’; similarly, if the frequency of FasL expression amongst 
EryA is ‘L’, the frequency of FasL-positive EryA cells in the island is ‘AL’. The 
probability of this encounter is therefore proportional to AF *AL = A2FL . However, 
since nearly all EryA cells express FasL, and since the change in FasL expression in 
response to Epo is relatively small, we can substitute L ≈1. The probability of Fas-
mediated cell death is therefore proportional to ‘A2F’, a term that varies with the square 
of the frequency of EryA in the erythroblastic island, for any given level of Fas.  
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This model allows us to predict how the frequency of EryA changes with Fas 
expression in response to Epo. Thus, change in EryA pool over time, 
dA
dt , is given by: 
 
dA
dt = β − kA
2F −αA  (1) 
where ‘k’ is a proportionality constant. When a new steady state is attained between days 
2 and 3 following an Epo injection (Liu et al), there is no net change in ‘A’, making   
 
dA
dt = 0 . Therefore, equation (1) becomes:  
 β − kA2F −αA = 0  (2) 
For a given constant value of β, α and F, the corresponding value of ‘A’ may be found by 
solving equation (2) as a simple quadratic equation: 
 A = α ± α
2 + 4kFβ
−2kF  (3) 
 
Epo levels change with erythropoietic stress, suppressing F. We assume that the input β 
and the output coefficient, α, remain relatively constant in spite of changes in the level of 
Epo. The inverse relationship between EryA (‘A’, expressed relative to the basal 
frequency of EryA within Ter119+ cells) and the number of Fas+ EryA (‘F’, expressed 
relative to the frequency of Fas+ cells within EryA cells) in Figure 3.2A is fitted well by a 
hyperbolic curve that represents the (positive) solutions for ‘A’ in equation (3), for 
different steady-state levels of Fas (‘F’) (R2=0.89). 
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The initial fitted constants were β=1.3, α=0, k=0.5. R2=0.88. 
The zero value fitted by the ‘solver’ software for α reflects its low actual value relative to 
β, with the result that the curve fitting for equation (3) is relatively insensitive to small 
changes in α around zero. To find the actual value for α:  
As F→ 0, then, from equation (2),   
 A = β
α
 (4) 
 
Experimentally, we know that under these circumstances, ‘A’ is in the order of 30- to 60-
fold the basal EryA pool (This increase is the measured expansion of EryA. Figure 3.4A 
and main text). From equation (4), and from the value for β obtained by the curve fitting, 
this gives a value for α between 0.02 and 0.04. Substituting these values in the equation 
describing the curve in Figure 3.2A does not substantially alter the curve and its fitness to 
the data (R2 remains 0.89).  
 
 
  
 
90 
Chapter IV Attributions and Copyright information 
The material in this chapter has been submitted for publication in Blood Journal in a 
modified format. This chapter represents original work by the authors. 
 
Contrasting Dynamic Responses in vivo of the Bcl-xL and Bim Erythropoietic 
Survival Pathways 
Miroslav Koulnis1#, Ermelinda Porpiglia1#, Alberto Porpiglia1, Ying Liu1, Kelly 
Hallstrom1 and Merav Socolovsky1 
1Department of Pediatrics and Department of Cancer Biology, University of  
Massachusetts Medical School, Worcester MA USA. 
# authors contributed equally 
 
Specific Authorship Contributions:  
 MK performed experiments presented in Figure 4.1A-E, Figure 4.2D, Figure 4.3B 
and part of 4.3C, Figure 4.4A-I, part of Figure 4.5A, Figure 4.5B and C, Figure 4.6C-E, 
Figure 4.8A and C-E, Figure 4.9, Figure 4.11, and Figure 4.12. He also designed and 
drew models shown in Figure 4.7. MK, with guidance from MS, also analyzed the 
majority of data [with the exception of Figure 4.2A-C and E, Figure 4.3A, Figure 4.5A 
(left panels), Figure 4.6A-B and F, Figure 4.8B, and Figure 4.10]. MK created and 
adjusted all figures for publication, and wrote part of the manuscript. 
 EP performed experiments, analyzed the results, and presented data for Figure 
4.6A, B and F. 
 
  
 
91 
 AP, together with MK, performed experiments and analyzed part of the results in 
Figures 4.1A-E, Figure 4.3B-C, Figure 4.4G-I, Figure 4.5A and C, Figure 4.8A, D and E. 
 YL performed experiments presented in Figure 4.2A-C and E, Figure 4.3A and 
part of 4.3C, Figure 4.5A, and Figure 4.10. 
 KH performed experiments presented in Figure 4.8B, and helped MK perform 
experiments in Figure 4.8C. 
 MS designed research, analyzed and interpreted data and wrote the manuscript. 
 
 
Disclosure of Conflicts of Interest: 
 
None of the authors have any conflicts of interest to declare. 
  
 
  
 
92 
CHAPTER IV 
CONTRASTING DYNAMIC RESPONSES IN VIVO OF THE BCL-XL AND BIM 
ERYTHROPOIETIC SURVIVAL PATHWAYS 
 
ABSTRACT   
 Survival signaling by the erythropoietin (Epo) receptor (EpoR) is essential for 
erythropoiesis and for its acceleration in hypoxic stress. A number of apparently 
redundant EpoR survival pathways were identified in vitro, raising the possibility of their 
functional specialization in vivo. Here we used mouse models of acute and chronic stress, 
including a hypoxic environment and β-thalassemia, to identify two markedly different 
response dynamics for two early erythroblast survival pathways in vivo. Induction of the 
anti-apoptotic protein Bcl-xL is rapid but transient, whilst suppression of the pro-
apoptotic protein Bim is slower but persistent. Similar to sensory adaptation, however, 
the Bcl-xL pathway ‘resets’, allowing it to respond afresh to acute stress superimposed on 
a chronic stress stimulus. Using ‘knock-in’ mouse models expressing mutant EpoRs, we 
found that adaptation in the Bcl-xL response is due to adaptation of its upstream regulator 
Stat5, both requiring the EpoR distal cytoplasmic domain. We conclude that survival 
pathways show previously unsuspected functional specialization for the acute and chronic 
phases of the stress response. Bcl-xL induction provides a ’stop-gap’ in acute stress, until 
slower but permanent pathways are activated. Further, pathological elevation of Bcl-xL 
may be the result of impaired adaptation, with implications for myeloproliferative disease 
mechanisms.  
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INTRODUCTION  
 Hypoxic stress accelerates the production of red cells by up to ten-fold 162. 
Erythropoietin (Epo) is essential for both basal and stress erythropoiesis. Epo exerts its 
effect by activating its receptor, EpoR, on the surface of erythroid progenitors 163. 
Colony-forming unit-erythroid (CFU-e) progenitors and their immediate proerythroblast 
and basophilic erythroblast progeny are Epo-dependent 2. Until recently, the rarity of 
these cells within hematopoietic tissue confined their biochemical study to in-vitro 
culture systems, where they were found to undergo apoptosis when deprived of Epo 73. It 
was therefore suggested that Epo regulates erythropoietic rate through the number of 
erythroid progenitors it rescues from apoptosis 73.  
 Recently, we 42 and others 47,164 made use of cell-surface markers to identify 
maturation-specific erythroblast subsets directly within freshly isolated mouse 
hematopoietic tissue 42, including the Epo-responsive ProE (proerythroblasts, 
CD71highTer119medium ) and EryA (early basophilic erythroblasts, CD71highTer119 high 
FSChigh). This approach confirmed the central role of apoptosis in the erythropoietic 
stress response, showing that a substantial fraction of the early erythroblast compartment, 
particularly splenic ProE and EryA, undergo apoptosis in vivo in the normal basal state. 
Stress-induced high Epo levels suppress apoptosis and consequently promote early 
erythroblast expansion and an increase in erythropoietic rate 42. 
Although a number of EpoR-activated survival pathways have been identified 
67,76,81,90,136, relevance to erythropoiesis in vivo was documented for only a few, largely 
through gene ‘knockout’ studies revealing abnormal basal or stress erythropoiesis 
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43,76,84,155,165. Importantly, it is unknown how multiple survival pathways integrate in vivo 
to provide a coherent erythropoietic stress response, and whether the large number of 
survival pathways represents redundancy or functional specialization. The study of these 
pathways in vivo, now made possible with the advent of flow-cytometric techniques 
(Chapter V) 42,47,164, may assist in answering this question.  
 We recently investigated the role of the death receptor Fas, and its ligand, FasL, 
which are co-expressed by early erythroblasts and suppressed by EpoR signaling in vivo 
42,44 (Chapter III). We found that, in addition to regulating cell survival, this pathway 
stabilizes basal erythropoiesis and accelerates its response to stress (Chapter III). 
Therefore, anti-apoptotic pathways may have system-level functions that are not 
immediately apparent from their anti-apoptotic effects in culture. Here we set out to 
investigate two apoptotic regulators of the Bcl-2 protein family that are targeted by EpoR 
signaling, the anti-apoptotic protein Bcl-xL, and the pro-apoptotic Bim protein. Bcl-xL 
induction is a major survival pathway in erythroblasts 96,97, where it is regulated by 
EpoR-activated Stat5 76,78 synergistically with GATA1 101. Bcl-xL-/- mice die in utero of 
anemia, and Bcl-xL-/- ES cells do not contribute to erythropoiesis in chimeric mice 166. In 
a Stat5-deficient mouse 167, reduced Bcl-xL in early erythroblasts results in ineffective 
erythropoiesis and anemia 43. Severe ineffective erythropoiesis in adult erythroblasts 
conditionally-deleted for Bcl-xL 165 is corrected if mice are also deleted for the pro-
apoptotic proteins Bax and Bak 88, suggesting that the requirement for Bcl-xL in 
erythropoiesis is due to its anti-apoptotic effect.  
 In spite of the clear role for Bcl-xL in basal erythropoiesis, it is not known 
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whether erythroblast Bcl-xL levels increase further during stress, contributing to enhanced 
erythroblast survival. Elevated levels of erythroblast Bcl-xL have been implicated in 
Polycythemia Vera 168,169, suggesting that Bcl-xL-mediated enhanced erythroblast 
survival has the potential to increase erythropoiesis above the basal rate 169. It is not, 
however, known if this happens physiologically. 
We contrasted Bcl-xL with Bim, a BH3-only pro-apoptotic Bcl-2 family protein 
170. Bim downregulation is a key component of survival signaling by cytokines and 
oncoproteins such as Bcr-Abl or Jak2V617F in hematopoietic progenitors 171,172. EpoR 
survival signaling in vitro was recently shown to be in part due to decreased Bim mRNA 
89,90 and to ERK-mediated phosphorylation and degradation of the Bim protein 89. 
Further, Bim-/- mice have normal red cell numbers but these arise from a smaller pool of 
progenitors with enhanced survival 89. Like Bcl-xL, in addition to EpoR signaling, Bim 
suppression is also mediated by GATA-1, via its transcriptional target LRF 106. LRF-/- 
mice, which die in utero secondary to severe erythroblast apoptosis and anemia, were 
partly rescued by Bim deletion 106. In spite of the clear role of Bim suppression in 
erythroblast survival, it is not known whether this pathway participates in the stress 
response.  
Here we used intracellular multiparameter flow cytometry to measure Bcl-xL and 
Bim in stage-specific erythroblasts directly in erythropoietic tissue of fetal and adult mice 
as they are undergoing differentiation and responding to stress in vivo. We found a 
similar, highly dynamic activation of the Bim and Bcl-xL survival pathways in the fetus 
that was dependent on both developmental day and erythroblast differentiation stage. 
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These pathways diverge, however, in the adult, where their contrasting dynamic 
responses suggest a clear segregation of function during the acute and chronic phases of 
the stress response.  
 
RESULTS  
Erythroid developmental delay in Stat5-/- embryos 
The definitive erythropoietic lineage generates enucleated red cells and first begins in the 
murine fetal liver on embryonic day 11.5 (E11.5). Using cell surface markers CD71 and 
Ter119, we divided fresh fetal liver into a developmental sequence of increasingly mature 
subsets S0 to S5 46 (Figure 4.1A). Most S0 cells (≥70%) are erythroid progenitors at the 
colony-forming unit stage (CFU-e), just preceding the onset of Epo/EpoR dependence 
that takes place at the transition from S0 to S1 46. Subsets S1 to S5 contain increasingly 
mature Epo-dependent CFU-e, proerythroblasts and erythroblasts 46. Between E11.5 and 
E14.5, fetal liver cell number increases 1000-fold, and the majority shift in maturational 
stage from earlier erythroid progenitors and precursors (S0/S1/S2) at E11-E12, to late 
erythroblasts at E13-E14 44 (Figure 4.1A). We previously showed that these dynamic 
changes are associated with an apoptosis rate that is dependent on both differentiation 
stage and developmental day 44. Apoptosis is seen principally in CFU-e and early 
erythroblasts (S1-S2), where it is highest on E11.5, decreasing to a low value on E12-
E12.5 and rising again on E13-E14 44.  
 Given this dynamic picture, we set out to characterize the developmental and 
maturation-stage-specific expression of Bcl-xL and Bim in wild-type and in Stat5-/- mice 
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(Figure 4.1). The Stat5-/- mice 77 are anemic in utero leading to perinatal death, a similar 
but more severe phenotype to that of the hypomorphic Stat5 mouse in which only the first 
Stat5 exon is deleted 76,167. We first analyzed the CD71/Ter119 profiles on sequential 
developmental days and found that erythroblast maturation in the Stat5-/- embryos was 
delayed, as seen by their delayed progression from the S1 to S3 (Figure 4.1A,B). 
Specifically, on E12.5, the S1 subset contained only 10% of wild-type fetal liver cells, 
but 35% of the Stat5-/- fetal liver cells (p<0.005); by contrast, the more mature S3 subset 
contained ≥60% of wild-type, but only 20% Stat5-/- fetal liver (p=0.005). This pattern was 
not simply due to delayed expression of the cell surface markers Ter119 or CD71, as 
evident from cell size analysis of the S1 and S3 subsets using the flow-cytometric 
forward scatter parameter, which was unaltered for cells in each respective subset.   
 
Bcl-xL and Bim expression in fetal liver is differentiation-stage and embryonic-day 
dependent  
 We assessed Bcl-xL and Bim protein expression using intracellular flow 
cytometry (Figure 4.1C,D), employing an anti-Bcl-xL antibody that we previously 
verified for its specificity 43, and an anti-Bim antibody whose specificity we verified 
using Bim-/- splenocytes (Figure 4.8A). We found that, consistent with previous findings 
in vitro 78,97, Bcl-xL is expressed at very low levels in the early S0-S2 compartment and 
increases with erythroblast differentiation (Figure 4.1C,D, upper panels). However, in 
addition, Bcl-xL expression was highly dependent on developmental day, with high levels 
in the early S0-S2 subsets of E11.5 embryos, decreasing rapidly in the same subsets with 
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embryonic age (Figure 4.1D, upper panel).  
Expression of the anti-apoptotic Bim protein is also dependent on both 
differentiation stage and embryonic day. We found a highly significant increase in both 
the long (BimL) and extra-long (BimEL) transcripts (Figure 4.8B, p<0.0001) and in the 
Bim protein (Figure 4.1D, lower panel, p<0.0001) with the transition from S0 to S1, a 
transition that marks the onset of erythroid progenitor dependence on EpoR 46. This 
raised the possibility that induction of the pro-apoptotic Bim protein at the S0/S1 
transition may be the cause of EpoR dependence. However, we found no significant 
differences in Epo dependence or in the sensitivity of Bim-/- fetal liver erythroid 
progenitors to Epo using a CFU-e assay in vitro (Figure 4.8C). 
Bim protein expression peaks in S1 and is gradually suppressed with erythroid 
differentiation, reaching its lowest values in mature erythroblasts (Figure 4.1D, lower 
panel). Similar to Bcl-xL, Bim expression was also a function of developmental day. For 
a given maturation subset, Bim expression is lowest on E11.5, peaking on E12.5, and 
decreasing in older embryos (Figure 4.1D). The changing fetal liver Bcl-xL and Bim 
during embryonic days E11.5-E12.5 match our previous findings of large changes in 
apoptosis, cell number and Fas expression at this time 44.  
 
Bim and Bcl-xL expression in fetal liver are regulated by Stat5 
The rapidly changing expression of Bim and Bcl-xL during E11.5-E12.5 (Figure 
4.1D), and the developmental delay in the Stat5-/- fetal liver (Figure 4.1A,B), together 
impede our ability to assess the role of Stat5 in regulating Bim and Bcl-xL expression at 
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this time. However, the CD71/Ter119 profiles and Bim and Bcl-xL expression begin to 
stabilize at E13.5, and the Stat5-/- fetal liver profile approaches that of wild-type embryos 
(Figure 4.1D, Figure 4.1A,B). We therefore compared Bim and Bcl-xL expression in 
Stat5-/- fetal liver and wild-type littermates on E13.5-E14.5 (Figure 4.1E, Figure 4.8D,E).  
Bcl-xL expression in the Stat5-/- fetal liver was 1.5- to 2-fold lower in the early 
erythroblast subsets S1 (p=0.01), S2 (p=0.03) and S3 (p=0.002). Bim levels in Stat5-/- 
fetal liver were 30% and 40% higher, respectively, in the S3 and S4/5 subsets (p<0.01), 
suggesting Stat5 regulates its expression. For comparison, we also assessed expression of 
the erythroblast apoptotic regulators Fas and FasL in the Stat5-/- fetal liver. We found no 
significant difference in Fas expression between Stat5-/- embryos and wild-type 
littermates (Figure 4.9).   
 
Bcl-xL is rapidly induced in adult early erythroblasts in response to a single Epo 
injection  
We examined Bcl-xL expression in response to a single dose of Epo, the principal 
mediator of the stress response. A single subcutaneous injection (300 U /25 g) results in a 
rapid increase in serum Epo, peaking by 6 hours, persisting for 24 hours and declining to 
baseline by 36 hours (Figure 4.2A). We measured Bcl-xL expression by intracellular flow 
cytometry, in each of the adult flow-cytometric erythroblast subsets ProE, EryA, EryB 
and EryC 42 (Chapter V and Figure 4.2B), in freshly explanted bone-marrow and spleen 
at the indicated time points (Figure 4.2C-E). In control, saline-injected mice, Bcl-xL 
expression increases 6-fold with differentiation from ProE to EryC in both bone-marrow 
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and spleen, a pattern similar to that of fresh fetal liver (representative histograms in 
Figure 4.2C; summary of several experiments in Figure 4.2E). Injected Epo caused a 
further induction of Bcl-xL expression in all erythroblast subsets (Figure 4.2C,E). 
Proportionally, this increase was largest and most rapid in the earliest subsets, where 
basal Bcl-xL levels are lowest, and where it peaked 5-fold its basal level within 16 hours 
of Epo injection in splenic ProE (p=0.0006) and 3-fold by 18 hours in splenic EryA 
(p=0.0009) (Figure 4.2C,E).  
To assess the sensitivity of the Bcl-xL pathway to injected Epo, we carried out a 
dose/response curve in vivo, injecting mice with the indicated Epo dose and examining 
peak Bcl-xL expression at 18 hours in splenic EryA (Figure 4.2D). This analysis shows 
that half the maximal response is obtained with the injection of 3 U /25 g, estimated to 
result in a serum concentration of 0.3 U/mL, approximately a ~10-fold increase above 
basal serum Epo. This response is more sensitive than that of the Fas-suppression 
pathway, where we found a half-maximal response with an injection of 10 U /25 g 
(Chapter III).  
Induction of the Bcl-xL protein is associated with an increase in the Bcl-xL mRNA 
that follows a similar time course (Figure 4.3A).  
 
Expression pattern of Bim in basal and stress adult erythropoiesis 
 We used intracellular flow cytometry in adult spleen and bone-marrow, freshly 
explanted at the indicated time points following either saline or Epo injection (300 U /25 
g), to examine Bim expression. Bim is expressed at its highest levels in the early, ProE 
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subset, declining gradually in subsequent differentiation subsets and reaching a quarter of 
its ProE level in EryC (Figure 4.3B). In response to an Epo injection Bim levels 
decreased further in all subsets (Figure 4.3B,C), with the largest decline in the early 
bone-marrow and spleen ProE progenitors, where they fell ~2-fold (p<0.0001).  
Importantly, the time course of Bim suppression in response to Epo injection was 
much slower, and more prolonged, than the Bcl-xL response. Maximal Bim suppression 
was reached at 72 hours post injection in most subsets, a time when the Bcl-xL induction 
had already peaked and returned to baseline (Figure 4.3C).  
 
The erythroblast response to reduced atmospheric oxygen 
 The modulation of erythroblast Bim and Bcl-xL levels by an Epo injection in vivo 
suggested that these pathways are likely to play a role in the physiological stress 
response. To test this, we placed mice in a reduced oxygen environment in which 
atmospheric partial oxygen pressure was reduced to 11% for up to 5 days (Figure 4.4). 
Epo levels in blood plasma rose rapidly in the first 24 hours, from a basal level of 12 
mU/mL, to a peak of 29 mU/mL (p=0.001). This high Epo level was sustained until day 
3. On days 4 and 5 Epo began to decline to a new, lower plateau of 18 mU/mL (Figure 
4.4A).  
 The hematocrit response was rapid, rising from 51.5% to 56% in the first 24 
hours, and reaching a sustained plateau of 57% (Figure 4.4B). The rapid initial increase 
in hematocrit is likely in part to be the result of plasma volume adjustment in response to 
hypoxia 19,173.  
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 We examined the response of individual flow-cytometric erythroblast subsets in 
freshly explanted tissue at the indicated time points (Figure 4.4C-I). The results shown 
are from 23 pooled experiments, with at least 6 mice per time point. To evaluate the 
various responses in relation to the plasma Epo levels, the Epo response in Figure 4.4A is 
replicated as a gray line in subsequent panels (Figure 4.4E-I). 
 The absolute numbers of spleen ProE and EryA erythroblasts increased over the 
initial 3 days, reaching new plateaus that were 4- and 3-fold higher than basal values, 
respectively (Figure 4.4C,D). This increase in cell number was associated with a marked 
and significant reduction in apoptosis, with the number of Annexin V+ cells declining 
from 55% to 32% (p=0.002) and 42% to 30% (p=0.001) in the ProE and EryA subsets, 
respectively (Figure 4.4E). 
 
The response of erythroblast Bim, Fas and Bcl-xL to reduced atmospheric oxygen 
 Given the clear changes in ProE and EryA apoptosis, we investigated their 
expression of the apoptotic regulators Fas, Bim and Bcl-xL. We previously showed that 
cell surface Fas on spleen ProE and EryA decreases in response to a number of acute and 
chronic erythropoietic stress conditions. Maximal Fas suppression is reached within 24 to 
48 hours and is maintained for the duration of the stress stimulus (Figure 4.4F) (Chapter 
III) 42.  
 The Bcl-xL response was rapid and transient, its expression peaking by 18 hours 
in both ProE and EryA, and then rapidly dipping below baseline by 24 hours, in spite of 
the persisting high Epo levels (Figure 4.4G). The response of Bim, by contrast, was 
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slower, reaching maximal suppression at 48 hours, with low levels maintained for the 
duration of high Epo levels (Figure 4.4H,I).  
 We examined the possibility that the transient increase in Bcl-xL may be due to 
the relatively modest increase in plasma Epo generated by the hypoxic environment. We 
injected mice with Epo (300 U /25 g) daily for 3 consecutive days, which generates 
increasingly high plasma Epo equivalent to that of maximal stress conditions 162 (Figure 
4.2A). We measured the Bcl-xL response 18 hours following each injection (Figure 4.10). 
The amplitude of the Bcl-xL response was larger in response to this higher Epo dose than 
in the response to the hypoxic environment, as expected from the Epo dose/Bcl-xL 
response curve (Figure 4.2D). However, the response to the second and third Epo 
injections was smaller or absent (Figure 4.10), suggesting that the transience of the Bcl-
xL response is unrelated to Epo dose. 
 
Response of the Bim and Bcl-xL pathways to chronic erythropoietic stress   
We went on to assess the Bim and Bcl-xL response to chronic erythropoietic 
stress. The Bcl-xL expression profiles in the ProE/EryA-C subsets in either spleen or 
bone-marrow was unaltered by 3 distinct erythropoietic stress conditions: pregnancy at 
mid-gestation, chronic anemia due to β-thalassemia 174, and chronic erythrocytosis due to 
tissue-specific deletion of the von Hippel-Lindau gene that results in elevated Epo (ts-
VHL-/-) 9 (Figure 4.5A). Plasma Epo is elevated to 30 mU/mL and 220 mU/mL in the ts-
VHL-/- and β-thalassemia mice, respectively (Figure 4.11), a concentration range in 
which Bcl-xL induction was seen in acute stress (Figure 4.4). Further, we have previously 
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shown that cell surface Fas and FasL are downregulated in the same chronic stress 
models 42. 
Unlike Bcl-xL, Bim expression in the β-thalassemia mice was suppressed in all 
erythroblast subsets (Figure 4.5B), to levels similar to those seen in response to an acute 
Epo injection (Figure 4.3B). 
 
The Bcl-xL response to an ‘acute on chronic’ stress stimulus 
  The transience of the Bcl-xL response to stress is reminiscent of sensory systems 
that undergo adaptation, such as neutrophil chemotaxis or sensory neural adapting 
systems. These systems respond to a change in the stimulus, rather than to absolute 
stimulus levels 175. We therefore asked whether the desensitization of the Bcl-xL pathway 
to chronic stress was permanent, or whether an acute change in the level of stress, 
superimposed on a chronic stress stimulus, would re-stimulate Bcl-xL induction.  
 We injected β-thalassemia mice with a single Epo dose of 300 U /25 g, and 
examined their Bcl-xL response at 18 hours post injection. We found a clear induction in 
Bcl-xL in all erythroblast subsets in the β-thalassemia mice, closely resembling that of 
control mice in the bone-marrow, and only a little short of the wild-type response in the 
spleen (Figure 4.5C). This experiment suggests that while the Bcl-xL response 
desensitizes to chronic stress, it rapidly responds to new changes in stress superimposed 
on the chronic stress levels.  
 
Stat5 activation in vivo undergoes adaptation 
 
  
 
105 
 We asked whether adaptation in the Bcl-xL stress response is due to adaptation in 
Stat5, its upstream regulator. We first examined the time course of Stat5 activation in 
vivo following Epo injection (300 U /25 g), using intracellular flow cytometry in freshly 
explanted spleen and bone-marrow at the indicated time points post-injection (Figure 
4.6A). The number of ProE and EryA containing active, phosphorylated Stat5 (p-Stat5) 
increased rapidly following injection, peaking by 30 minutes, but declining rapidly to a 
lower level by 6 hours (Figure 4.6A). Of note, plasma Epo peaked at 6 hours (Figure 
4.2A), suggesting the decline in p-Stat5 is intrinsic to the p-Stat5 response and is not due 
to declining Epo.  
 Signal adaptation may be due to negative feedback 176,177. p-Stat5-mediated 
transcriptional activation of SOCS family proteins results in their feedback inhibition of 
the Jak2 and Stat5 response 178. This negative regulation in part depends on SOCS protein 
binding to phosphotyrosines on the activated EpoR cytoplasmic domain 163. To 
investigate the possibility that Stat5-mediated negative feedback is responsible for 
adaptation in the p-Stat5 response, we investigated two ‘knock-in’ mouse models, 
expressing the EpoR mutants EpoR-H and EpoR-HM 75, both lacking the negative 
regulatory distal portion of the EpoR cytoplasmic domain containing 7 of its 8 
phosphotyrosines, including SOCS family docking sites 163. In EpoR-HM, the remaining 
Y343, a Stat5 docking site, is mutated to phenylalanine 75. The EpoR-H mouse has a 
mildly elevated basal hematocrit. By contrast, the EpoR-HM mouse has only a mild 
anemia in the basal state but a deficient stress response 75.  
 We tested the response of freshly harvested fetal liver early erythroblasts derived 
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from EpoR-H, EpoR-HM and wild-type embryos to continuous stimulation with Epo for 
up to 6 hours in vitro. The time course of response of wild-type erythroblasts was similar 
to that of adult erythroblasts in vivo (Figure 4.6A,B). The peak p-Stat5 response to Epo 
stimulation in EpoR-HM erythroblasts was 15% of the response in wild-type or EpoR-H 
mice, in agreement with previous results 179. In EpoR-H erythroblasts, peak p-Stat5 was 
similar to that of the wild-type response, though baseline p-Stat5 was higher. In both 
EpoR-HM and EpoR-H, duration of the initial p-Stat5 peak was prolonged substantially 
(Figure 4.6B). These findings suggested that the distal EpoR cytoplasmic domain, likely 
through binding to Stat5-induced SOCS family proteins, is responsible for curtailing the 
p-Stat5 response. 
 
The Bcl-xL and Bim stress responses in EpoR-H and EpoR-HM mice 
 The finding that the p-Stat5 signal undergoes adaptation (Figure 4.6A,B) suggests 
it may be responsible for the adaptation in the Bcl-xL response. To test this, we asked 
whether failure of p-Stat5 adaptation in the EpoR-H mice (Figure 4.6B) would prevent 
adaptation of the Bcl-xL response.   
 We therefore injected EpoR-H mice with Epo (300 U /25 g) and examined the 
resulting induction in Bcl-xL. The peak Bcl-xL response was closely similar to that of 
matched wild-type control mice (Figures 4.6C and 4.12A). There was little increase in 
Bcl-xL in EpoR-HM mice, consistent with p-Stat5 as the principal regulator of the Bcl-xL 
stress response (Figures 4.6C and 4.12A). Importantly, there was a failure of adaptation 
of the Bcl-xL response in EpoR-H mice. Bcl-xL levels remained elevated well above their 
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initial baseline at 36 and 48 hours post-injection in spleen ProE, and at 36 hours in EryA 
and EryB (p<0.005, Figure 4.6D), even though Bcl-xL levels in wild-type mice (Figure 
4.6D) and serum Epo (Figure 4.2A) had returned to baseline. This strongly suggests that 
adaptation in the Bcl-xL response requires the EpoR distal cytoplasmic domain and is 
most likely a result of adaptation in the p-Stat5 response, also dependent on this domain 
(Figure 4.6B).  
 Bim expression was suppressed in EpoR-HM mice in response to a single Epo 
injection (300 U /25 g). However, suppression was less efficient than in wild-type mice, 
by a small but statistically significant amount (Figures 4.6E, 4.12B, p=0.03 and p=0.001 
in ProE and EryA, respectively). These results suggest that, in addition to Stat5, other 
pathways, likely ERK, regulate the EpoR-mediated Bim suppression 89.  
 
The p-Stat5 response to an ‘acute on chronic’ stress stimulus 
 Although Bcl-xL expression is not elevated in chronic stress, it is induced in 
response to an acute stimulus superimposed on the chronic stress stimulus (Figure 4.5C). 
Given the proposed role of Stat5 activation in Bcl-xL induction, we similarly examined 
the p-Stat5 response to chronic and ‘acute on chronic’ stress stimuli. We found no 
increase in the level of p-Stat5 activation in ProE freshly isolated from β-thalassemic 
mice (Figure 4.6F, upper panel), in spite of the chronically elevated plasma Epo in these 
mice (Figure 4.11). A single injection of Epo (300 U /25 g) however, resulted in a rapid 
increase in p-Stat5 activation in both β-thalassemic mice and in matched control mice 
(Figure 4.6F, lower panels). Therefore, both the p-Stat5 and Bcl-xL responses ‘reset’ 
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during chronic stress, allowing them to respond afresh to an acute change in stress.  
 
DISCUSSION 
We examined Bim suppression and Bcl-xL induction, two EpoR-activated 
erythroblast survival pathways in fetal and adult basal and stress erythropoiesis. Their 
analysis in vivo revealed previously unsuspected functional specialization of EpoR- 
pathways to either the chronic or acute phases of the stress response. Bcl-xL induction 
behaves like a classical sensory adapting pathway, being insensitive to the prevailing 
level of stress, and instead responding only to changes in stress level. Adaptation allows 
Bcl-xL to provide a stop-gap at the onset of stress that rapidly rescues early erythroblasts 
from apoptosis, until slower but persistent stress pathways, such as Bim or Fas 
suppression, are activated. Mechanistically, we suggest that adaptation in the Bcl-xL 
response is the result of adaptation in the response of p-Stat5, its upstream regulator.  
 
Regulation of Bim and Bcl-xL expression in early vs. late erythroblasts  
We delineated the expression pattern of both Bim and Bcl-xL proteins throughout 
erythroid maturation in adult and fetal hematopoietic tissue in vivo. The basal pattern 
observed in the absence of stress is one of low Bcl-xL and high Bim in early erythroblasts, 
gradually inverting with differentiation so that in mature erythroblasts Bim levels are 
low, and Bcl-xL levels are high (Figure 4.7A). These results are consistent with the 
previously reported increase in Bcl-xL transcript and protein with erythroid differentiation 
in vitro 78,97, and with the increase in Bcl-xL and decrease in the pro-apoptotic Bid and 
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Bax transcript with the transition from early to late erythroblasts in murine bone-marrow 
164. Together with our previous findings of high Fas and FasL co-expression in early, but 
not late, erythroblasts 23,42,44, a strong pattern emerges of apoptosis-prone early 
erythroblasts, containing high levels of pro-apoptotic regulators and only low levels of 
anti-apoptotic proteins, gradually transitioning into apoptosis-resistant late erythroblasts 
in which anti-apoptotic proteins predominate. This underlying pattern explains why high 
levels of apoptosis are seen in early erythroblasts but not in late erythroblasts during 
normal fetal and basal adult erythropoiesis in vivo 23,42,44 (Chapter III; Figures 4.1D, 4.2E 
and 4.3B), and was recently suggested as being responsible for the sensitivity of early 
erythroblasts to irradiation 164.  
Bcl-xL expression is regulated by both GATA-1 and by EpoR-activated Stat5 101. 
Similarly, Bim suppression is regulated by both EpoR-activated ERK 89 and by GATA-1-
induced LRF 106. Here we find that in addition, Bim is regulated by EpoR-activated Stat5, 
as suggested by higher Bim levels in the Stat5-/- fetal liver and to a lesser extent in the 
adult EpoR-HM mouse (Figures 4.1E, 4.6E and 4.12B). Lower Bcl-xL in the S1-S3 
subsets of the Stat5-/- fetal liver, and in EpoR-HM mice in the basal state, support older 
reports of the role of Stat5 in the induction of erythroid Bcl-xL 43,76,78. The role of Stat5 is 
especially notable, however, in the Bcl-xL stress response, which is absent in the EpoR-
HM mice (Figure 4.6C).  
Based on their expression patterns, we propose that EpoR and GATA-1 -mediated 
regulation of Bim and Bcl-xL are largely segregated into the early and late erythroblast 
compartments, respectively (Figure 4.7A). Specifically, the underlying, largely stress-
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insensitive gradual increase in Bcl-xL and gradual suppression of Bim with 
differentiation, is likely to be mediated by GATA-1. Superimposed on this pattern are 
Epo-mediated, stress-dependent adjustments that accelerate Bcl-xL induction and Bim 
suppression in early erythroblasts (Figures 4.2, 4.3 and 4.7A). Thus, only the apoptosis-
prone CFU-e, proerythroblasts and early basophilic erythroblasts (=’early erythroblast 
compartment’) are dependent on EpoR signaling for survival in the basal state. Further, 
during hypoxic stress, it is principally the early erythroblast compartment that is Epo-
responsive, undergoing expansion as a result of a rapid drop in apoptosis 23,42,44 (Chapter 
III and Figure 4.4E). The susceptibility of the early erythroblast compartment to 
apoptosis is precisely the characteristic that gives plasticity to the erythropoietic system, 
allowing the level of EpoR signaling to determine erythropoietic rate. 
We previously showed that Epo-mediated suppression of early erythroblast 
apoptosis during stress is strongly correlated with suppression of early erythroblast Fas. 
Using Fas and FasL-mutant mice, we recently found that the Fas suppression pathway 
accounts for ~30% of the early erythroblast expansion in stress (Chapter III). Bim 
suppression and Bcl-xL induction are therefore likely to cooperate with Fas suppression, 
and potentially with as yet uncharacterized other anti-apoptotic pathways, in achieving 
the full expansion of the early erythroblast compartment during stress.  
In late erythroblasts, Bim, Bcl-xL and Fas expression are relatively unaffected by 
EpoR-stress signaling. Consistent with this, in Stat5-/- embryos and in EpoR-HM mice, 
where EpoR-Stat5 signaling is deficient, Bcl-xL levels are only modestly lower in late 
erythroblasts; the underlying pattern, likely GATA-1-mediated, of a gradual increase in 
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Bcl-xL and decline in Bim, is preserved.  
Importantly, our results show that Stat5-regulated Bcl-xL expression in vivo varies 
with differentiation stage, with embryonic day, and with the phase of the stress response. 
These factors should therefore be considered in the interpretation of Bcl-xL measurements 
in vivo and in models of this system in vitro.  
 
Adaptation allows functional specialization of the Bcl-xL response to the acute phase 
of stress 
 The acute and chronic phases of the stress response differ in their requirements. 
At the onset of stress the speed of the response is paramount, a property that is 
unimportant during the chronic, maintenance phase. Here we find that the Bcl-xL 
response is significantly faster than Bim or Fas suppression. In addition, the Bcl-xL 
response undergoes rapid adaptation, which makes it insensitive to the prevailing 
absolute level of stress. Like other classical sensory adapting mechanisms, though, it is 
re-activated as soon as a new change in stress takes place. In this way, the dynamic range 
of the Bcl-xL response is extended, allowing a rapid response to changes in stress 
irrespective of the baseline stress levels. Our new data on the Bcl-xL pathway show that 
distinct molecular mechanisms regulate the acute and chronic phases of stress. The EpoR 
is therefore capable of generating at least two broad types of signal: persistent, giving rise 
to persistent suppression of Bim and Fas, and a rapidly adapting signal, responsible for 
the adaptation of the Bcl-xL response (Figure 4.7B).  
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Mechanism of adaptation in the Bcl-xL response 
We identified adaptation in the p-Stat5 response in erythroblasts in vivo and 
suggest this to be the mechanism of adaptation in the Bcl-xL response. Both p-Stat5 and 
Bcl-xL respond similarly to an ‘acute on chronic’ stress stimulus, a response typical of 
other biological adapting systems like sensory adaptation or neutrophil chemotaxis. 
Adaptation of both p-Stat5 and Bcl-xL depends on the distal domain of the EpoR, a 
previously documented negative regulatory domain that contains docking sites for the 
Stat5-induced SOCS family of negative regulators 163 (Figure 4.7C). Negative feedback is 
a well-documented mechanism of adaptation in sensory systems 176,177. Stat5 
transcriptionally activates SOCS inhibitors that feed back to limit Jak2 and Stat5 
activation 178. Though well-documented, the precise effect of this pathway on the p-Stat5 
signal was not previously investigated. Here we found that in EpoR-H mice that lack this 
feedback inhibition, peak p-Stat5 signal intensity is not higher than in wild-type. 
However, the duration of the peak is prolonged (Figure 4.6D). Therefore, p-Stat5-
mediated negative feedback is likely responsible for the adaptation of both the p-Stat5 
and Bcl-xL responses. 
 
Implications for myeloproliferative disease mechanisms 
 The rapid adaptation of the Bcl-xL response to stress raises the possibility that 
prolonged periods in which Bcl-xL is elevated may be harmful. Indeed, persistently 
elevated levels of Bcl-xL are characteristic of Polycythemia Vera and other 
myeloproliferative syndromes 168,169,180. High Bcl-xL was suggested as a cause of Epo-
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independent erythroid differentiation in Polycythemia Vera and of the apoptosis 
resistance of other myeloproliferative syndromes and neoplasms 168,180,181. Our results, 
supported by recent reports of SOCS protein inactivation in myeloproliferative disease 
182,183, suggest that impairment of p-Stat5 and Bcl-xL adaptation may contribute to their 
prolonged activation. Together these results point to the importance of adaptation in the 
Bcl-xL response as a homeostatic and tumor-suppressive mechanism. 
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Figure 4.1 
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Figure 4.1 Delayed maturation and altered Bcl-xL and Bim expression in Stat5-/- 
fetal liver. 
(A) Representative CD71/Ter119 profiles of Stat5-/- fetal livers and wild-type 
littermates freshly isolated on consecutive embryonic developmental days (E11.5 to 
E14.5). S0 to S4/5 are increasingly differentiated erythroid progenitors and precursors 
subsets 46. Dead cells were excluded using LIVE/DEAD viability dye. E11.5 S3 cells are 
yolk sac-derived, primitive lineage erythroid cells. 
(B) Summary statistics for analysis performed as in ‘A’, on 5 to 21 embryos per data 
point (mean ±SEM). Pooled from 3 independent experiments with multiple litters. Stars 
indicate statistically significant difference between wild-type and Stat5-/- subsets with the 
following p values: For S1, E12.5 *p=0.002, E13.5 *p=0.00001. E14.5 *p=0.014. For S3, 
E12.5 *p=0.005, E13.5 *p=0.00004. E14.5 *p=0.010 (two-tailed t-test, unequal 
variance). 
(C) Intracellular flow cytometry for Bcl-xL and Bim proteins, in the indicated fetal 
liver subsets. Representative histograms are shown. Freshly isolated wild-type E14.5 fetal 
liver cells were stained with CD71, Ter119 and the LIVE/DEAD viability dye as in ‘A’. 
Cells were then fixed, permeabilized and stained intracellularly with: an anti-Bcl-xL 
antibody or non-specific Rabbit Serum; an anti-Bim antibody or Rabbit IgG isotype 
control.  
(D) Bcl-xL and Bim protein expression profiles, measured as in panel ‘C’, in fresh 
wild-type fetal liver cells at the indicated embryonic days, in each of the indicated 
differentiation subsets S0 to S4/5. Expression is measured as median fluorescence 
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intensity (MFI), from which non-specific background fluorescence, defined as the MFI of 
the corresponding subset when binding an isotype control antibody/non-specific serum, 
was subtracted. Data points are mean ±SEM.  
For Bcl-xL: n=5 to 14 wild-type embryos per data point, pooled from 3 
independent experiments with multiple litters. Statistical significance values: S1, E11.5 
vs. E14.5, *p<0.05 (two-tailed t-test, unequal variance). E14.5 S2 vs. S3, and E14.5 S3 
vs. S4-5, *p<0.0002 (paired t-test).  
For Bim: n=6 wild-type Balb/C embryos per data point. Statistical significance 
values: E13.5 S0 vs. E13.5 S1, *p<0.0001; E12.5 S1 vs. E12.5 S3, *p<0.0001; E11.5 S1 
vs. E12.5 S1, *p<0.0001 (two-tailed t-test, unequal variance). Similar developmental 
pattern was observed in C57BL/6 and Balb/C backgrounds.  
(E) Lower Bcl-xL and higher Bim protein expression in E14.5 Stat5-/- embryos 
compared with wild-type littermate controls, at the indicated differentiation subset. 
For Bcl-xL: n=11 to 21 embryos per genotype, with each symbol type representing 
median expression for one litter. Means ±SEM for the population are indicated. Statistical 
significance values: S2, *p=0.03. S3, *p=0.002 (paired t-test).  
For Bim: data points are individual embryos. Mean ±SEM for the population is 
shown. Statistical significance values: S3 and S4-5, *p<0.01, two-tailed t-test, unequal 
variance. See also Figure 4.8D,E. 
MK performed all experiments for this figure with help from AP. 
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Figure 4.2 
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Figure 4.2 Bcl-xL induction in adult early erythroblasts in response to Epo 
injection. 
(A) Time course of plasma Epo, assayed by ELISA, following a subcutaneous 
injection of 300 U /25 g. Two mice (identified as either circles or triangles) were assayed 
per time point.  
(B) Gating strategy for freshly explanted ProE, EryA, EryB and EryC spleen 
erythroid subsets 42. Live cells were selected, and subsets gated based on Ter119, CD71 
expression and forward scatter (FSC). 
(C) Representative flow-cytometric histograms of intracellular Bcl-xL protein in the 
indicated spleen erythroblast subsets. Anti-Bcl-xL antiserum was used to stain 
erythroblasts from a saline-injected mouse (blue histograms), or an Epo-injected mouse 
(300 U /25 g, red histograms) in freshly explanted spleen at 18 hours post injection. An 
isotype control antibody was used to measure the non-specific binding in each subset 
(grey histograms). 
(D) Epo dose/ Bcl-xL response in vivo in spleen EryA. Wild-type Balb/C mice were 
injected subcutaneously with either saline (=basal, blue circle) or a single, increasing 
dose of Epo (1, 3, 10, 20, 30, or 300 U /25 g, red circles). Bcl-xL was measured by flow 
cytometry as in panel ‘C’ at 18 hours post-injection, with the non-specific fluorescence 
reading subtracted for each subset. Data from two independent experiments were pooled 
and normalized. Data points were fitted with a Hill curve. Each data point represents 
mean ±SEM of n=3 to 4 mice. 
(E) Bcl-xL expression measured as in panel ‘C’ in freshly explanted spleen, in each 
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erythroblast subset at each of the indicated time points following a single Epo injection 
(300 U /25 g). Each data point for Epo-injected mice is mean ±SEM of n=4 mice for 
t=16, 18, 24, 48 hours; and mean of 2 mice for t=12 hours. Blue curves are mean ±SEM 
of n=14 saline-injected mice pooled from all time points. The same blue curves are 
reproduced for comparison with Epo-injected mice at each time point). Statistical 
significance values: ProE at t=16h, in bone-marrow *p=0.005, in spleen *p=0.0006. 
EryA in spleen, *p=0.0009 at 16h, *p=0.0009 at 18h. EryA in bone-marrow, *p=0.013 at 
16h, *p=0.015 at 18h. The induction of Bcl-xL in splenic EryA was significantly higher 
than in bone-marrow EryA (*p=0.021). Two-tailed t-test with unequal variance used for 
all comparisons. 
 MK performed experiments for part (D) and analyzed the data. YL performed the 
rest of experiments presented in this figure. 
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Figure 4.3 
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Figure 4.3 Transient Bcl-xL induction contrasts with slower Bim suppression in 
response to Epo injection. 
(A) Time course of Bcl-xL mRNA expression following a single Epo injection (300 U 
/25 g), in freshly isolated and sorted spleen and bone-marrow EryA. Quantitative real-
time PCR, data points are mean ±SEM of 3 independent experiments. Data are expressed 
relative to the β-actin mRNA and normalized to the value in bone-marrow EryA in 
saline-injected mice.  
(B) Bim protein expression in adult erythroid differentiation subsets 3 days following 
a single injection of either Epo (red, 300 U /25 g) or saline (black). Bim was measured by 
flow cytometry in freshly explanted tissue, as illustrated in Figure 4.8A. Data are mean 
±SEM of n=21 mice for saline injection, and n=10 mice for Epo injection. *p<0.000005 
(two-tailed t-test, unequal variance) for differences between Epo-injected and saline-
injected mice. 
(C) Time course of Bcl-xL upregulation (red symbols, plotted on the left, red-
numbered y-axis) and Bim suppression (black symbols, plotted on the right-numbered y-
axis) in spleen (circles) and bone-marrow (BM, triangles) in response to a single Epo 
injection (300 U /25 g) on day 0. Includes a subset of the data plotted in panel ‘B’ (for 
Bim) and Figure 4.2E (for Bcl-xL). For Bim, 5 experiments were normalized together. 
Bim data are mean ±SEM of n=21 mice for day 0, and n=3 to 10 mice for days 1 to 5. 
Bim ProE curves (black lines) for spleen and bone-marrow were hand-drawn. Statistical 
analysis was performed by comparing Bim readings on day 0 with readings on the 
following days. Where indicated, spleen ProE: *p<0.005. Spleen EryA: *p<0.025. BM 
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ProE: *p<0.02; BM EryA: *p<0.01. For all statistical tests, two-tailed t-test with unequal 
variance was used. 
 YL performed experiments for part (A) and Bcl-xL experiments for part (C). MK 
performed all the Bim experiments with help from AP, and analyzed data presented in 
this figure. 
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Figure 4.4 
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Figure 4.4 A reduced oxygen environment elicits a rapid, transient Bcl-xL 
induction and a slow, persistent Bim suppression. 
(A – I) Mice were placed in a low oxygen chamber (11%) on day 0, for the numbers of 
days indicated. 
(A) Endogenous plasma Epo, assayed by ELISA. Data are mean ±SEM. Difference 
relative to day 0 (n=27 mice) were significant at the following levels: day 1 (n=6), 
*p=0.001; day 3 (n=6), *p=0.006; day 4 (n=12), *p<0.0001; day 5 (n=3), *p=0.0000005. 
This Epo time course is drawn as a grey line in panels E to I. 
(B) Daily hematocrit (HCT) measurements on blood collected immediately post-
euthanasia. Data are mean ±SEM of n≥6 mice per time point. Differences from day 0 are 
significant at the following levels: 12h, *p=0.019; 18h to day 5, *p<0.0002. 
(C-D) Absolute number of spleen ProE and EryA per gram body weight. Data pooled 
from 23 independent experiments. Each data point is mean ±SEM of n≥6 mice. 
Differences from day 0 (n=82 mice) are significant at the following levels: Spleen ProE 
day 1, *p=0.005; day 2, *p=0.047; days 3 to 5, *p≤0.005. Spleen EryA day 2, *p=0.034; 
days 3 to 5, *p≤0.001. 
(E) Annexin V binding in spleen ProE (blue) and EryA (black). Data points are mean 
±SEM of 33 mice for day 0 and 3 to 7 mice for subsequent days, pooled from 2 to 5 
independent experiments per day. Differences from day 0 are significant at the following 
values: Spleen ProE days 3 to 5, *p≤0.002. Spleen EryA day 1, *p=0.001; day 3, 
*p=0.03; day 4, *p=0.02; day 5, *p=0.001.  
(F) Fas-positive cell frequency in spleen ProE (blue) and EryA (black), measured by 
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flow cytometry in freshly explanted tissue. Data are mean ±SEM of n=26 mice, pooled 
from 4 experiments (day 0) or n=3 mice for subsequent days. Differences from day 0 are 
significant at the following values: Spleen ProE day 1, *p=0.024; day 3, *p<0.00001; day 
5, *p=0.001. Spleen EryA day 5, *p=0.04.  
(G) Bcl-xL protein expression in spleen ProE and EryA measured by flow cytometry 
in freshly explanted tissue. Data pooled from three independent experiments. Each data 
point is mean ±SEM of n≥3 mice. Differences from day 0 (n=17) are significant at the 
following levels: Spleen ProE 18h (n=3), *p<0.001; 24h (n=7), *p=0.019; day 2 (n=5), 
*p<0.0005. Spleen EryA 12h, *p=0.046; 18h, *p<0.0001; day 2, *p=0.02 
(H-I) Bim protein expression in spleen (H) and bone-marrow (I) ProE and EryA, 
measured by flow cytometry in freshly explanted tissue. Data are mean ±SEM of n≥3 
mice pooled from two experiments. Differences from day 0 are significant at the 
following levels: Spleen ProE day 1, p=0.014; days 3-5, p<0.002. Spleen EryA day 0.5, 
p=0.0014; day 2, p=0.038; days 3-5, p<0.03. Bone-marrow ProE day 2, p=0.007; day 3, 
p<0.00001; day 4, p<0.001; day 5, p=0.04. Bone-marrow EryA day 1, p=0.002; day 2, 
p=0.0001; day 3, p=0.05. 
For all statistical tests, two-tailed t-test with unequal variance was used.  
MK performed all the experiments presented in this figure with help from AP, and 
analyzed all of the data. 
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Figure 4.5 
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Figure 4.5 The Bcl-xL response to chronic stress and to ‘acute on chronic’ stress.  
(A) Bcl-xL expression in each of the three indicated mouse models of erythropoietic 
stress (red symbols) and matched controls (blue symbols), measured in freshly explanted 
tissue. Each data point is mean ±SEM of 2 to 4 mice. There were no statistically 
significant differences between chronic stress and control mice. 
(B) Representative experiment showing Bim expression in β-thalassemia mice in 
spleen (top) and bone-marrow (bottom). Two wild-type (black symbols) and one β-
thalassemia mouse (red symbols) are shown.  
(C) The Bcl-xL response to an ‘acute on chronic’ stimulus. Bcl-xL expression in 
spleen and bone-marrow erythroblasts in β-thalassemia mice and matched controls, 18 
hours following a single injection of either Epo (300 U /25 g, red symbols) or saline (blue 
symbols). Data points are mean ±SEM of n=3 to 4 mice. Representative of 4 independent 
experiments. Statistically significant differences in Bcl-xL between Epo and saline 
injections in each mouse model were seen in wild-type spleen ProE, *p=0.025; EryA, 
*p=0.0009; EryB, *p=0.01; EryC, *p=0.006; β-thalassemia spleen EryA, *p=0.0004; 
EryB, *p=0.004; EryC, *p=0.03; Wild-type BM EryA, EryB and EryC, *p≤0.0005; β-
thalassemia BM EryA and EryB, *p<0.0005; EryC, *p=0.025. The increase in spleen 
EryA Bcl-xL was significantly higher (p=0.023) in wild-type spleen than in wild-type β-
thalassemia mice. For all statistical tests, two-tailed t-test with unequal variance was 
used. 
 MK performed β-thalassemia experiment in part (A), and all of experiments in 
parts (B) and (C), with help from AP [part (C)]. YL performed the rest of experiments 
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shown in part (A). MK analyzed all the data in part (A) for β-thalassemia, and in parts 
(B) and (C).  
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Figure 4.6 
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Figure 4.6 Adaptation in the Bcl-xL and p-Stat5 responses is dependent on the 
EpoR C-terminal cytoplasmic domain.  
(A) The p-Stat5 response in spleen ProE and EryA in vivo, measured in freshly 
explanted spleen at the indicated time points following a single Epo injection (300 U /25 
g). Data are pooled from four independent experiments. Each time point is the mean ± 
SEM of data from 2 to 4 mice. 
(B) The p-Stat5 time course in response to Epo stimulation for the indicated periods. 
Freshly harvested fetal liver cells from EpoR-HM, EpoR-H and matched wild-type 
embryos at E13.5 were stimulated in vitro with 2 U/mL Epo. p-Stat5 in S1 cells is shown, 
expressed as median fluorescence intensity above background (isotype-control antibody). 
Representative of 3 similar experiments. 
(C) The Bcl-xL response in EpoR-H and EpoR-HM mice. Bcl-xL was measured 18 
hours following a single injection of either Epo or saline, in freshly explanted spleen 
ProE and EryA of EpoR-H, EpoR-HM or wild-type controls. Data are mean ±SEM of 
n=3 to 5 mice per bar. Significant Bcl-xL increase from basal levels in spleen ProE and 
EryA was seen in Epo vs. saline injected wild-type (black) and EpoR-H (red) mice (stars 
without brackets: WT ProE *p=0.003; EpoR-H ProE *p=0.012; WT EryA *p=0.00004; 
EpoR-H EryA *p=0.0001), but not in EpoR-HM mice. Bcl-xL was reduced in basal state 
EpoR-HM spleen EryA (red star with red bracket, *p=0.027) compared with wild-type 
basal control. Bcl-xL induction in wild-type spleen EryA was significantly above that of 
EpoR-HM EryA (black stars with brackets, *p=0.007, two-tailed t-test with unequal 
variance). 
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(D) Time course of the Bcl-xL response in EpoR-H mice and in matched wild-type 
controls, following a single Epo injection (300 U /25 g). Measurements were made in 
freshly explanted spleen at the indicated time points. Bcl-xL is significantly higher in 
EpoR-H at 36 and 48 hours (p<0.005, paired t-test on all subsets).  
(E) Bim protein in spleen ProE and EryA of wild-type and EpoR-HM mice on day 3 
following a single Epo injection (300 U /25 g). Data are mean ±SEM of n=4 to 5 mice 
per bar. There was no significant difference in basal Bim between EpoR-HM and wild-
type control mice. Bim was significantly suppressed following Epo injection (*p<0.001). 
Bim was suppressed by a significantly smaller extent in EpoR-HM ProE and EryA 
subsets (stars with brackets, *p=0.03 and *p=0.001, respectively, two-tailed t-test with 
unequal variance).  
(F) The p-Stat5 histograms in vivo at peak response (30 minutes) following a single 
injection of either Epo (300 U /25 g) or saline, in either β-thalassemia mice or in matched 
wild-type controls, measured in freshly explanted spleen ProE. The p-Stat5+ gate was 
drawn based on the non-erythroid population in spleen (grey histograms).  
 EP developed and performed experiments, and analyzed the data shown in parts 
(A), (B) and (F). MK performed all of the experiments and data analysis in parts (C-E). 
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Figure 4.7 
 
  
 
133 
Figure 4.7 Regulation of Bcl-xL and Bim expression in erythropoiesis. 
(A) Model depicting expression of Bcl-xL and Bim in the late and early erythroblast 
compartments, in basal erythropoiesis (solid lines) and during stress (fading shaded area). 
GATA-1 induces Bcl-xL and suppresses Bim with differentiation, with maximal 
responses achieved in late erythroblasts. During stress, EpoR signaling operates 
principally in the early erythroblast compartment, accelerating both Bim suppression and 
Bcl-xL induction. Model does not quantitatively depict the actual data. 
(B) Contrasting dynamic stress responses of the Bcl-xL, Bim and Fas pathways, both 
driven by the EpoR in the early erythroblast compartment. A sudden increase in stress 
drives a rapid, but transient adapting Bcl-xL response. This response is re-activated with a 
further change in the stress level, but is insensitive to the absolute level of stress. Bim and 
Fas suppression in response to stress is slower but persistent and reflects the level of 
stress.  
(C) Mechanism of adaptation in the Bcl-xL response. EpoR-HM activation of both p-
Stat5 and the Bcl-xL is drastically attenuated, due to the absence of Stat5 phosphotyrosine 
docking sites on the EpoR-HM mutant receptor, in support of the role of p-Stat5 in the 
EpoR and stress-induced Bcl-xL induction. In wild-type mice, the EpoR distal 
cytoplasmic domain binds p-Stat5-activated negative regulators of Jak2 and Stat5 such as 
SOCS3, SOCS2 and CIS, limiting the duration of both the p-Stat5 and the Bcl-xL 
responses. In EpoR-H mice, absence of the distal EpoR domain results in a prolonged 
response and loss of adaptation.  
 MK designed and created all parts of this figure. 
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Figure 4.8 
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Figure 4.8 Bim and Bcl-xL in fetal liver erythropoiesis. 
(A) Bim protein measurement by intracellular flow cytometry. Freshly explanted 
spleen cells from wild-type (blue) and Bim-/- (red) mice were stained with the 
LIVE/DEAD viability dye, fixed, permeabilized, and stained with an anti-Bim antibody 
(Cell Signaling, #2819) or isotype control IgG, as described in materials and methods. 
Dead cells were excluded from analysis. Highly similar data were obtained when gating 
on erythroid subsets in spleens of wild-type and Bim-/- mice. 
(B) Quantitative real-time PCR for the Bim isoforms BimEL and BimL in sorted S0 
and S1 subsets from freshly harvested wild-type fetal liver. Data were expressed as a 
ratio to β-actin mRNA in each sample and normalized to the levels measured in S0 cells. 
Differences between S0 and S1 are statistically significant, BimEL+L, *p=0.0003; BimL, 
*p=0.0000004 (two-tailed t-test, unequal variance). 
(C) CFU-e assay performed on wild-type and Bim-/- fetal livers. CFU-e colonies per 
whole fetal liver are shown for each genotype. Data are mean ±SEM of 6 individual fetal 
livers per genotype from the same E13.5 litter. Grey bars are a pool containing one Bim 
wild-type embryo and five Bim+/- embryos. No significant (NS) difference in CFU-e 
numbers between the genotypes was observed (p>0.05, two-tailed t-test, unequal 
variance). Similar results were obtained when data were expressed as CFU-e colonies per 
1x106 plated cells. Representative of two similar experiments. 
(D) Lower Bcl-xL expression in Stat5-/- embryos compared with wild-type littermate 
controls, at the indicated embryonic day and differentiation subset. n=11 to 21 embryos 
per genotype, with each symbol type representing median expression for one litter. 
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Means ±SEM for the population are indicated. Statistical significance values: E13.5 S1, 
*p=0.012 (paired t-test).  
(E) Higher Bim protein expression in Stat5-/- embryos compared with wild-type 
littermate controls: data points are individual embryos. Mean ±SEM for the population is 
shown. Statistical significance values: E13.5 S3 and S4-5, *p<0.01, two-tailed t-test, 
unequal variance.  
 MK performed experiments, analyzed and presented the data shown in parts (A) 
and (C-E). KH helped MK perform experiments in part (C), and also performed 
experiments for part (B). 
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Figure 4.9 
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Figure 4.9 Fas expression in E14.5 fetal liver erythroblasts. 
 Cell-surface Fas was measured on freshly explanted fetal livers from wild-type or 
Stat5 heterozygous embryos (n=6) and from Stat5-/- embryos (n=3). No significant 
differences were detected between the genotypes (two-tailed t-test, unequal variance). 
 MK performed experiment and analyzed the data presented in this figure. 
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Figure 4.10 
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Figure 4.10 The Bcl-xL response to repeated Epo injections.  
 Bcl-xL expression in spleen EryA following consecutive Epo injections. Wild-
type mice were injected at time points 0, 24 and 48 hours with either Epo (300 U /25 g, 
indicated with arrowheads) or with saline. Bcl-xL expression was assayed by flow 
cytometry in 2 mice for each treatment, 18 hours following each injection.  
YL performed this experiment and analyzed the data.
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Figure 4.11 
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Figure 4.11 Plasma Epo measurements in mice with β-thalassemia and in ts-VHL-
/- mice.  
 For each mouse model, two independent ELISAs, each with similar results, were 
pooled together. Individual mouse data as well as mean ±SEM are shown. Epo increase 
in β-thalassemia was significant at p=0.002 (two-tailed t-test, unequal variance).  
 MK performed all of the experiments and data analysis presented in this figure. 
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Figure 4.12 
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Figure 4.12 The Bcl-xL and Bim Epo responses in the EpoR-H and EpoR-HM 
mice. 
Experiment and same mouse dataset as in Figure 4.6C and 4.6E.  
(A) Bcl-xL expression in spleen (left) and bone-marrow (right) in erythroid subsets, 18 
hours post-Epo or saline injection in wild-type, EpoR-H, and EpoR-HM mice. 
Experiment and same mouse dataset as in Figure 4.6C.  
 Left panel: Black stars without brackets indicate significant Bcl-xL induction in 
spleen EryB and EryC subsets in Epo treated mice (*p<0.005). No significant Bcl-xL 
induction was observed in EpoR-HM spleens (light blue vs. dark blue bars). EpoR-HM 
mice failed to increase Bcl-xL to the level of EpoR-H or wild-type mice (black stars with 
brackets, *p<0.02). Basal Bcl-xL levels in EpoR-HM EryB and EryC were also lower 
than in basal wild-type mice (red stars with red brackets, *p<0.05). 
 Right panel: Bcl-xL induction in the bone-marrow erythroid subsets was observed 
for all three genotypes. Stars indicate significant differences. Wild-type Epo response vs. 
control: ProE, EryA and EryB, *p<0.0002. EpoR-H Epo response vs. control: ProE, EryA 
and EryB, *p<0.0001; EryC, *p=0.025. EpoR-HM Epo response vs. control: ProE, 
*p=0.003; EryA, EryB and EryC, *p<0.05. Magnitude of Bcl-xL induction in EpoR-HM 
subsets was lower compared with wild-type induction (black stars with brackets, 
*p<0.006). Basal Bcl-xL levels in EpoR-HM bone-marrow subsets were lower than in 
basal wild-type mice (red stars with red brackets, *p<0.02).  
(B)  Bim expression in spleen (left) and bone-marrow (right) in erythroid subsets, 3 
days following Epo or saline injection in wild-type, EpoR-H, and EpoR-HM mice. 
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Experiment and same mouse dataset as in Figure 4.6E. Data are mean ±SEM of n=4 to 5 
mice per bar.  
 In both wild-type and EpoR-HM spleen EryB and EryC subsets, Bim was 
significantly suppressed below their respective basal levels with Epo (black stars, no 
brackets, *p<0.001). Similar findings were observed in the bone-marrow subsets (wild-
type subsets: *p<0.0005; EpoR-HM subsets: *p<0.03). Magnitude of Bim suppression in 
EpoR-HM mice was lower than in the wild-type mice (black stars with brackets, 
*p<0.005). Some differences in basal Bim levels were observed between wild-type and 
EpoR-HM mice (gray bars vs. light blue bars, not indicated in plots: spleen EryB, p=NS; 
spleen EryC, *p=0.02; BM ProE, *p=0.004; BM EryA, *p=0.01; BM EryB, p=NS; BM 
EryC, *p=0.03).  
For all statistical tests, two-tailed t-test with unequal variance was used. 
 MK performed all of the experiments and data analysis presented in this figure. 
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CHAPTER V 
IDENTIFICATION AND ANALYSIS OF MOUSE ERYTHROID PROGENITORS 
USING THE CD71/TER119 FLOW-CYTOMETRIC ASSAY 
 
 
SHORT ABSTRACT  
 A flow-cytometric method for identification and molecular analysis of 
differentiation-stage-specific murine erythroid progenitors and precursors, directly in 
freshly-harvested mouse bone marrow, spleen or fetal liver. The assay relies on cell-
surface markers CD71, Ter119, and cell size. 
 
INTRODUCTION  
The study of erythropoiesis aims to understand how red cells are formed from 
earlier hematopoietic and erythroid progenitors. Specifically, the rate of red cell 
formation is regulated by the hormone erythropoietin (Epo), whose synthesis is triggered 
by tissue hypoxia. A threat to adequate tissue oxygenation results in a rapid increase in 
Epo, driving an increase in erythropoietic rate, a process known as the erythropoietic 
stress response. The resulting increase in the number of circulating red cells improves 
tissue oxygen delivery. An efficient erythropoietic stress response is therefore critical to 
the survival and recovery from physiological and pathological conditions such as high 
altitude, anemia, hemorrhage, chemotherapy or stem cell transplantation.  
 The mouse is a key model for the study of erythropoiesis and its stress response. 
Mouse definitive (adult-type) erythropoiesis takes place in the fetal liver between 
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embryonic days E11.5 and E15.5, in the neonatal spleen, and in adult spleen and bone 
marrow. Classical methods of identifying erythroid progenitors in tissue rely on the 
ability of these cells to give rise to red cell colonies when plated in Epo-containing semi-
solid media. Their erythroid precursor progeny are identified based on morphological 
criteria. Neither of these classical methods allow access to large numbers of 
differentiation-stage-specific erythroid cells for molecular study. Here we present a flow-
cytometric method of identifying and studying differentiation-stage-specific erythroid 
progenitors and precursors, directly in the context of freshly isolated mouse tissue (Figure 
5.1). The assay relies on the cell-surface markers Ter119, CD71, and on the flow-
cytometric ‘forward-scatter’ parameter, which is a function of cell size. The 
CD71/Ter119 assay can be used to study erythroid progenitors during their response to 
erythropoietic stress in vivo, for example, in anemic mice or mice housed in low oxygen 
conditions. It may also be used to study erythroid progenitors directly in the tissues of 
genetically modified adult mice or embryos, in order to assess the specific role of the 
modified molecular pathway in erythropoiesis.  
 
PROTOCOL 
1 Harvesting of tissues: 
1.1 Prepare tubes containing 2 to 5 mL cold staining buffer (phosphate-buffered 
saline (PBS) with added 0.2% BSA and 5mM glucose). Keep tubes on ice prior to 
tissue harvest. 
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1.2 Cull mice according to appropriate approved protocol (e.g. CO2 inhalation 
followed by cervical dislocation). 
1.3 Draw blood by cardiac puncture into EDTA or heparin blood-collection tubes for 
later analysis (e.g. hematocrit, reticulocyte count or CBC analysis). 
1.4 Harvest the spleen and bones, placing tissues from each mouse in a separate tube, 
prepared in step 1. Easy access to spleen is from the left side. For the bone 
marrow, harvest one or both femurs. Keep tubes with harvested tissue on ice. 
1.5 If desired, weigh the spleen. Mice undergoing an erythropoietic stress response 
are likely to show a significant increase in spleen weight. 
 
2 Preparation of spleen cells: 
2.1 Using a pre-moistened 3 mL syringe plunger, gently push the spleen, or part of 
the spleen (ideally, 0.1 gram or less, equivalent to approximately 108 cells) 
through a 40 µm sterile cell strainer (Fisherbrand catalog number 22363547 or 
other) placed on top of a 50 mL conical tube. Keep the tube on ice during this 
procedure. Wash the cells through the strainer with a total of 2 mL staining buffer.  
2.2 Gently pipette the strained cell suspension to break up any small clumps. If 
necessary, re-strain the cells. 
2.3 Wash the cells twice by centrifugation and resuspend in cold buffer. For 
centrifugation, spin for 3’ to 5’ at approximately 1400 RPM at 4°C. 
2.4 Count the cells using a hemocytometer. Typical yields are 1-2 x 108 cells/spleen. 
For flow cytometry analysis, aliquote 1 to 2 x 106 cells per sample, either into 
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FACS staining tubes (BD Falcon polystyrene round-bottom tubes, 352008) or U-
bottom 96 well plate (BD Falcon 353910). Sample staining volume is 200 µl, to a 
final cell concentration 0.5 to 1 x 107 cells/mL or 1-2 x 106 cells/ 200 µl sample. 
 
3 Preparation of bone marrow cells: 
3.1 Prepare 1 or 3 ml syringes with an attached 26G needle, pre-filled with cold 
staining buffer.   
3.2 Remove muscles attached to the femur so as to visualize the bone clearly.  
3.3 Using sharp surgical scissors, snip off both ends of the femur, as close as possible 
to the ends of the bone. This should reveal a small hole at each cut end, leading 
into the bone-marrow cavity, which runs through the length of the femur. 
3.4 Using the pre-filled syringe in step 1, insert the needle through one of these holes, 
and gently flush the marrow out through the hole at the other end into a tube. 
3.5 Dissociate the flushed cells by gentle pipetting, and strain through a 40 µm 
strainer as for the spleen above (see section 2.1). 
3.6 Wash cells twice by centrifugation in cold staining buffer. 
3.7 Count the cells and resuspend as in section 2.4. Typical yields are approximately 
 107 cells per femur.  
 
4  Preparation of fetal liver cells: 
4.1 To prepare timed-pregnant female mice, set up mice for mating in the evening; 
examine for vaginal plugs before 10 am the following day; the day on which the 
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vaginal plug is detected is considered day 0.5. Veterinary staff may be able to 
assist investigators who are unfamiliar with this technique to identify pregnant 
females. 
4.2 Timed-pregnant female mice are culled on days E11.5 to 14.5 of pregnancy. The 
uterine horns are removed into a Petri-dish containing ice-cold culture medium or 
staining buffer. 
4.3 Embryos are removed from each uterus and the fetal liver is dissected. A 
dissecting microscope is required for E12.5 embryos or younger.  
4.4 Livers may be dissociated mechanically by pipetting in buffer, and are processed 
either individually in 96-well plates, or pooled together, depending on 
experimental requirements.  
4.5 A fetal liver at E13.5 has ∼107 cells. Cells are washed twice in staining buffer and 
resuspended at 1-2 x 106 cells/ 200 µl sample for flow-cytometric analysis.  
 
5 Antibody staining for flow cytometry: 
5.1 Prepare a primary antibody staining pre-mix to be used for all samples, except for 
control samples, containing the following:  
• ChromePure Rabbit IgG (Jackson, 015-000-003), to a final concentration of 
200 µg/mL. Check the stock concentration on the bottle (it can vary). This is 
used to block Fc receptors in mouse cells; alternative species that may be used 
for this are mouse IgG or rat IgG. Species choice is determined by the 
potential presence in the staining protocol of secondary antibodies directed 
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against primary rat/mouse/rabbit antibodies, in which case those species 
cannot be used as blocking antibodies. Alternatively, 5% rabbit serum may 
also be used in place of purified IgG. A further alternative is the use of 
monoclonal antibodies or Fab fragments directed at the mouse Fc receptors. 
The basic protocol below does not include any secondary antibodies and so 
IgG of any of the three species may be used. 
• CD71-FITC, diluted 1:200 (stock 0.5 mg/mL, BD-Biosciences, 553266) 
• Ter119-PE, diluted 1:200 (stock 0.2 mg/mL, BD-Biosciences, 553673) 
• Any additional antibodies directed at surface epitopes of interest, e.g. 
antibodies directed at Fas or FasL (final concentration 5 µg/mL) (see 42,44). 
Mix the antibody solution gently by inverting the tube 2-3 times. 
5.2 Add 200 µl of the pre-mix to each cell sample and gently resuspend the cells. 
5.3 Prepare control cell samples as follows: 
• ‘Unstained’: these cells are left in staining buffer and provide the background 
autofluorescence of the cells. 
• ‘Single color’ controls: one such control is required for each antibody/color 
used in the protocol. The cells in these controls are stained either with a 
directly conjugated primary antibody, or with both a primary antibody and a 
conjugated secondary antibody. These controls are used to correct for spectral 
overlap between channels. 
• ‘Fluorescence minus one’ (FMO) controls: one such control is required for 
each antibody/color in the protocol: cells are stained with all the 
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colors/antibodies in the protocol except for the color/antibody for which this is 
the FMO control. The FMO control for a particular channel provides the true 
background for that channel. It may include non-specific antibody of the same 
isotype, and conjugated with the same fluorescence mark as the test antibody 
(isotype control). 
5.4 Incubate samples and relevant controls in the primary antibody stain on ice for 
45’ to 1 hour in the dark (put aluminum foil cover on ice-bucket).  
5.5 At the end of incubation, wash the cells by adding 3 mL of staining buffer to each 
sample tube and spin for 3’ to 5’ at approximately 1400 RPM at 4°C. If using 96 
well plates, wash the cells three times in a volume of 200 µl. 
5.6 If relevant, apply secondary antibody stain. Apply and wash as for the first 
antibody stain. 
5.7 If relevant, a stain with Annexin V (apoptosis marker) is applied at the end of 
incubation, using a Hepes buffer as in the manufacturer’s instructions. This stain 
is applied for 15 minutes at room-temperature, or for 1 hour on ice. 
5.8 Cells are resuspended for flow cytometry analysis in staining solution containing 
a cell-impermeable DNA dye, to exclude dead cells. Several DNA dyes are 
available, including Propidium Iodide, 7-amino-actinomycin D (7AAD), or DAPI. 
The choice from amongst these depends on the available flow-cytometer 
channels, given the channels taken up for specific antibody staining, and channels 
available on the flow-cytometer. 7AAD is obtained from BD-Biosciences 
(559925) and used according to the manufacturer’s instructions. For DAPI 
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staining, make a stock of 1 mg/mL in dimethylformamide (DMF) from powder 
(Roche, 236276), keep at -20°C, and dilute 1:10,000 to 1:15,000 in staining 
buffer.   
 
6 Flow-cytometric sorting: 
6.1 Cells are labeled with CD71, Ter119, and a viability dye as described for flow-
cytometric analysis (section 5). Cell concentration during labeling may be 
increased to 5 x 107/mL.  
6.2 Antibody labeling for lineage-positive non-erythroid cells may be added with the 
primary antibody stain, if required, as follows:  
Mix an equal volume of each of the following antibodies to make the lineage 
master mix:   
FITC Rat Anti-Mouse CD41 MWReg30, BD Pharmingen  553848 
FITC Rat Anti-Mouse CD45R/B220 RA3-6B2, BD Pharmingen  553087 
FITC Hamster Anti-Mouse CD3e 145-2C11, BD Pharmingen  553061 
FITC Rat Anti-Mouse CD11b/Mac-1 M1/70, BD Pharmingen  557396 
FITC Rat Anti-Mouse Ly-6G and Ly-6C (Gr-1) RB6-8C5, BD Pharmingen  
553126  
Use the master mix at 1:80 (This is equivalent to 1:400 dilution of each individual 
antibody stocks, which are all 0.5 mg/mL). 
6.3 Use low-pressure sorting conditions and wide nozzles. For the Aria (BD 
Biosciences) we use 100 µ nozzle, 20 psi pressure. 
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6.4 Collection buffer: PBS with added 20% Fetal Bovine Serum.  
6.5 To check the purities of the sorted populations, re-run a small aliquot from each 
sample in a buffer that contains a viability dye (7AAD or similar). 
 
REPRESENTATIVE RESULTS  
 CD71/Ter119 staining of adult bone marrow or spleen identifies a developmental 
sequence of four subsets, labeled ProE, EryA, EryB and EryC (Figure 5.2) 42. 
Morphologically, these correspond to increasingly mature erythroblasts. Figure 5.2 
illustrates the gating sequence at the data analysis stage, which discards very small event 
(including nuclei, red cells), aggregated cells and dead cells.   
 Expression of cell-surface proteins may be measured simultaneously for each of 
these subsets, by adding the relevant antibodies at the same time as Ter119 and CD71 
staining. Figure 5.2 shows an example of cell-surface expression of the death receptor 
Fas 42. This measurement was carried out in mice injected with Epo, or in control mice 
injected with saline. It is apparent that Epo suppresses Fas expression in the EryA 
population in vivo 42.  
 Expression of intracellular proteins or cell cycle status may also be measured for 
cells in each subset. Figure 5.3 illustrates representative cell cycle analysis of freshly 
harvested bone-marrow cells. These measurements require, in addition to cell-surface 
staining with CD71 and Ter119, the fixation and permeabilization of cells for 
intracellular labeling (see Discussion section).  
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 In fetal liver, non-erythroid cells are first excluded by gating on ‘Lin-‘ cells that 
are negative for CD41, Mac-1, Gr-1, B220 and CD3 (Figure 5.4). The remaining cells are 
sub-divided into 6 subsets, S0 to S5. The precise pattern of cells in fetal liver is 
dependent on embryonic age (see Discussion section). A representative cell cycle 
analysis of the S3 subset in E13.5 fetal liver is shown (Figure 5.5).  
 
DISCUSSION 
 The flow-cytometric methodology allows simultaneous investigation of any 
cellular function that may be detected with a fluorescence-conjugated specific antibody 
or ligand, including cell-surface markers, protein expression, cell survival, cell signaling 
using phospho-specific antibodies 184, and cell cycle status. These measurements may be 
made in each of a number of differentiation-stage specific subsets, in the context of 
freshly isolated erythropoietic tissue. This method therefore allows assessment of 
functional and molecular changes at different levels of the erythropoietic system, in 
response to a wide range of erythropoietic stimuli or as a result of genetic mutations.  
 No antibody is without cross-reactivity, and cross-reactivity may be tissue- 
specific. It is therefore important to verify, even for previously tested antibodies, their 
specificity in the context of erythropoietic tissue, using either a null or a knock-down cell 
model.  
 Cells from specific erythroid subsets may be sorted for RNA or transcriptome 
analysis. Sort experiments should use low sorting pressures and wide nozzles, in order to 
minimize the shear stress on the cells. We recommend checking cell purity and viability 
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following each sorting experiment. Of note, in the case of multiparameter flow 
cytometry, the true background for each color is its ‘FMO’ control (see 5.3), which 
includes, in addition to autofluorescence, the background due to spectral overlap from all 
other colors. At the analysis stage, a subset-specific ‘FMO’ control needs to be used. 
 
Differentiation stage of erythroblasts within the flow-cytometrically defined subsets  
 The flow-cytometric ProE/EryA/EryB/EryC subsets are defined in terms of cell-
surface marker expression and forward scatter. While it is likely that each of these 
subsets corresponds to approximately the same morphological erythroblast differentiation 
stage in a wide variety of mouse models, we recommend verifying this when examining a 
new mouse model. Cells from each of the flow-cytometrically-defined subsets should be 
sorted and cytospin preparations examined for morphological staging of erythroblasts.  
 Although the CD71/Ter119 subsets each contain erythroblasts of similar 
differentiation stage, there remains a degree of heterogeneity within each subset. In the 
first application of the CD71/Ter119 method, we divided Ter119+ cells into regions I to 
IV based on their CD71 expression. The precise borders between these regions were 
determined arbitrarily 43. We subsequently added cell size information to the analysis, in 
the form of the forward scatter parameter. This allowed us to divide Ter119high cells into 
subsets by following natural population contours 42 (Figure 5.2). This approach resulted 
in populations of more uniform maturation and in more reproducible results, and has been 
recently adapted by other investigators 155,185,186. The EryA subset may be subdivided 
further where desired 186. One group suggested the use of CD44 in place of CD71 47. 
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Although CD44 is less useful in resolving early erythroblast stages, it may resolve later 
erythroblast subsets with more precision. Both markers may therefore be used, or 
alternatively, their choice may depend on the specific subsets of interest.  
 An alternative strategy employs multispectral imaging using the ImageStream 
technology (Amnis Corporation, Seattle, WA) 48. It allows the simultaneous and rapid 
acquisition of both morphological and flow-cytometric data on many thousands of cells. 
It is likely to become the ‘gold standard’ with respect to molecular analysis of stage-
specific erythroblasts, since the morphological criteria by which differentiation stage is 
defined may be measured directly. However, at the present time this technology is less 
widely available than conventional flow cytometry, and suffers from two drawbacks: it 
does not allow cell sorting; and it is limited to a smaller number of flow-cytometric 
parameters.  
 
Intracellular antigens 
 Detection of intracellular proteins or BrdU requires cell fixation and 
permeabilization. The precise fixation and permeabilization procedure depends on the 
intracellular antigen in question. We use the LIVE/DEAD Fixable Dead Cell Stain 
(Molecular Probes) during the fixation procedure, to distinguish viable from dead cells. 
Of note, permeabilization with detergents usually impacts the Ter119 signal, which is 
partially detergent soluble. We overcome this difficulty by using gentle detergents (such 
as the saponin-based ‘perm/wash’ buffer from BD Biosciences). We also stain for Ter119 
both prior to, and following, the fixation & permeabilization procedure, in order to 
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optimize the Ter119 signal. Alternatively, it is possible to sort viable cells from each of 
the CD71/ Ter119 subsets first, and carry out fixation and permeabilization separately on 
purified cells from each subset (e.g. see the cell cycle analysis in fetal liver) 46. 
 
Fetal liver CD71/Ter119 subsets 
 The CD71/Ter119 staining pattern in fetal liver is dependent on embryonic age 44 
(Figure 5.4). We subdivide fetal liver cells into 6 subsets, S0 to S5 46. At the onset of 
definitive erythropoiesis in fetal liver on embryonic day 11 (E11), cells are concentrated 
in subsets S0 and S1 and are largely erythroid colony-forming cells (CFU-e). With 
embryonic development, CFU-e cells differentiate into proerythroblasts and maturing 
erythroblasts, and gradually populate subsets S2 to S5 (Figure 5.4).  
 Subsets S1 to S5 are composed almost entirely of erythroid cells of the definitive 
lineage. These subsets are absent in the EpoR-/- fetal liver. A small number of Ter119+ 
cells in fetal liver correspond to the primitive (yolk sac) erythroid lineage. These cells are 
apparent in EpoR-/- fetal liver, where no definitive lineage erythroblasts arise, but by 
E13.5 form less than 1% of Ter119+ cells in wild-type fetal liver 46.   
 The S0 subset is heterogeneous. At E13.5, 70% of S0 cells are erythroid cells at 
the CFU-e stage, just prior to the onset of EpoR dependence 46. The remainder are earlier 
progenitors as well as cells of other hematopoietic lineages, principally megakaryocytes 
and macrophages; these cells may be sorted or gated out 46 (Figure 5.4).   
 
Interpretation of changes in the frequency of erythroid subsets 
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 Changes in the frequency of erythroid subsets should be interpreted with care. A 
change in frequency of cells in any given subset may be due to their altered apoptotic 
rate, altered transit time through that subset, or alternatively may be due to changes in the 
number of cells in other subsets. A common cause for increased frequency of early 
erythroblast subsets ProE and EryA is erythropoietic stress of multiple etiologies 42. 
Similar findings have been noted in the 1960’s by inspecting erythroblast morphologies 
during the stress response 154. The precise reason for the increase in the relative frequency 
of earlier precursors during stress is not clear, but in part may be due to the improved 
survival of these precursors during stress 42.  
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Figure 5.1 
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Figure 5.1  Experimental strategy to study erythropoiesis using flow cytometry. 
(A) The mouse is a key model for the study of erythropoiesis and its stress response. 
Mouse erythropoiesis occurs in the spleen, bone marrow, and in the fetal liver (middle). 
In these tissues, hematopoietic stem cells (HSC) are restricted to the erythroid lineage 
(blue and red stages), which in turn gives rise to red blood cells. Proper number of red 
cells maintains tissue oxygen (green) normal and negatively regulates Epo. Not enough 
red cells leads to tissue hypoxia. In turn, high Epo (green) increases erythropoiesis to 
correct the deficit. 
(B) To study erythroid cells, we first isolate total cells from hematopoietic tissues 
(e.g. fetal liver). 
(C) Freshly-isolated cells are labeled with fluorescent markers directed against 
erythroid, or any additional membrane or intracellular, antigens. Fluorescence data of the 
labeled sample are collected using flow-cytometer. Cells can be physically sorted using a 
cell sorter into separate tubes. 
(D) Sample data are then analyzed using FlowJo analysis for erythroid markers, 
apoptosis and cell cycle. Representative analysis of fetal liver is shown in the middle 
panel. Sorted populations can be cytospun onto microscope slides (cytospins shown), 
analyzed for their protein and mRNA content, or cultured for further analysis. 
 This figure was designed and created by MK [with the exception of FlowJo panel 
in the middle of part (D)]. 
  
 
  
 
163 
Figure 5.2 
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Figure 5.2 The CD71/Ter119 erythroid subsets in mouse spleen. 
(A) Gating strategy: Spleen cells were processed and labeled with antibodies directed 
at CD71 and Ter119. This figure shows the analysis strategy following the data 
acquisition step. Dot-plot I shows all acquired events. The diagonal gate represents events 
that are likely to be single cells/events, excluding doublets or larger aggregates. Cells in 
this gate are further analyzed in dot-plot II. Here, very small events, likely nuclei or 
debris, are excluded. The gated cells are shown in dot-plot III, where DAPI-positive cells, 
that are likely membrane-permeable apoptotic cells, are excluded from further analysis. 
Dot-plot IV shows the resulting population of viable spleen cells. The ProE gate contains 
CD71highTer119intermediate cells. Ter119high cells are further analyzed in dot-plot V. Here 
CD71high cells are subdivided into less mature, large ‘EryA’ erythroblasts 
(CD71highTer119highFSChigh) and smaller, more mature ‘EryB’ erythroblasts 
(CD71highTer119highFSClow). The most mature erythroblast subset is EryC 
(CD71lowTer119highFSClow). Dot-plot VI shows cell-surface Fas expression, specifically 
in the EryA subset, in mice in the basal state (injected with saline), and mice injected 
with a single dose of Epo. Staining with Fas was carried out simultaneously with the 
CD71/Ter119 staining. 
(B) Cytospin preparations of cells sorted from each of the indicated subsets. Cells 
were stained with Giemsa and with Diaminobenzidine, the latter generates a brown stain 
with hemoglobin. (Cytospin data were originally published in 42). 
 MK performed the experiment and data analysis for part (A). 
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Figure 5.3 
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Figure 5.3 Cell cycle analysis of CD71highTer119high erythroblasts in mouse bone 
marrow. 
 Mice were injected intraperitoneally with BrdU, and spleen and bone marrow 
were harvested 30 to 60 minutes later. Bone marrow cells were fixed and permeabilized, 
and in addition to being stained for CD71 and Ter119, were stained for BrdU 
incorporation into their replicating DNA with a monoclonal antibody directed at BrdU 
(fixation, permeabilization and BrdU-staining protocol was according to manufacturer’s 
instruction). BrdU-positive cells are in S-phase of the cycle. Interphase cells are BrdU-
negative and may be resolved into G1 or G2/M phases using the DNA dye 7AAD.  
 RP/JS/EP performed the experiment shown in this figure. 
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Figure 5.4 
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Figure 5.4 CD71/Ter119 erythroid subsets in mouse fetal liver. 
(A) Gating strategy: Fetal liver cells were labeled for CD71, Ter119, and a cocktail of 
FITC-labeled antibodies directed at non-erythroid lineage markers (‘Lin’). Viable cells 
(7AAD-negative) were analyzed for Lin expression, and the Lin- cells were further sub-
divided into the S0 to S5 erythroid subsets. Younger, E13 fetal liver is composed of less 
mature erythroblasts, shown by the near absence of cells in the mature S4/S5 subsets. 
(B) Cytospin preparations of cells sorted from each of the indicated subsets. Cells 
were stained with Giemsa and with Diaminobenzidine, the latter generates a brown stain 
with hemoglobin. (Cytospin data were originally published in 46). 
 RP and JS performed the experiments shown in this figure. 
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Figure 5.5 
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Figure 5.5 Cell cycle analysis of fetal liver erythroid subsets. 
 Pregnant mice were injected with BrdU, and fetal livers were harvested 30 to 60 
minutes later, fixed, permeabilized and stained with antibodies against CD71, Ter119 and 
BrdU. Cell cycle status of S3 cells is shown. 
 RP/JS/EP performed the experiment shown in this figure. 
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Table 5.1 Specific reagents and equipment: 
 
Name of the reagent Company Catalogue 
number 
40 mm sterile cell strainer  Fisherbrand 22363547 
Polystyrene round-bottom tubes for FACS 
staining  
BD Falcon 352008 
U-bottom 96 well plate  BD Falcon 353910 
ChromePure Rabbit IgG Jackson 
ImmunoResearch 
015-000-003 
CD71-FITC (stock 0.5 mg/mL) BD-Biosciences 553266 
Ter119-PE (stock 0.2 mg/mL)  BD-Biosciences 553673 
7AAD  BD-Biosciences 559925 
DAPI powder  Roche 236276 
FITC Rat Anti-Mouse CD41 MWReg30 BD Pharmingen  553848 
FITC Rat Anti-Mouse CD45R/B220 RA3-
6B2 
BD Pharmingen  553087 
FITC Rat Anti-Mouse CD411b/Mac-1 
M1/70 
BD Pharmingen  557396 
FITC Rat Anti-Mouse Ly-6G and Ly-6C 
(Gr-1) RB6-8C5 
BD Pharmingen  553126 
FITC Hamster Anti-Mouse CD3e 145-
2C11  
BD Pharmingen  553061 
APC BrdU Flow kit BD Pharmingen 557892 
Annexin V-biotin BD Pharmingen 556418 
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Chapter VI Attributions and Copyright information 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
All sections of this chapter were written by me. 
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CHAPTER VI 
DISCUSSION AND FUTURE DIRECTIONS 
 
6.1  Relevance of my thesis work  
 Erythropoiesis is essential to life, and is characterized by a number of remarkable 
properties. Its key regulator, Epo, spans a large concentration range, upregulating 
erythropoietic rate as high as 10-fold to precisely match physiological need. Another 
property is its rapid response to stress where a large number of cells are quickly 
generated. Yet another essential property is the ability of erythropoiesis to maintain a 
stable red cell output with minimal deviations for very long periods of time. Even though 
these are clearly observable characteristics, the molecular mechanisms that create them 
remain ‘hidden’ from view. For example, the precise nature of the EpoR survival signal 
in erythroblasts is still unclear. Many pathways have been implicated based on studies in 
vitro, but few have been tested in vivo. 
 There are many important reasons to describe these mechanisms in more detail, 
and to discover new ones. From a clinical perspective, erythropoietic stress occurs in 
many human diseases. For example, Polycythemia Vera arises due to Jak2 mutations 27. 
Anemia results from multiple causes, including ineffective erythropoiesis in 
myelodysplasia, where erythroblasts overexpress Fas and FasL 121. Other causes of 
anemia include chronic disease, kidney disease and diabetes, cancer and chemotherapy, 
nutritional deficiencies and various autoimmune anemia syndromes; anemia is also 
associated with some infectious diseases, notably parvovirus, which specifically destroys 
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red cell progenitors. Other causes include the hemoglobinopathies and other genetic 
causes of anemia. To treat these complex disorders, we must fully understand how in 
vivo, EpoR signaling regulates various cellular functions. From a basic science 
perspective, erythropoiesis contains many of the elements fundamental to other studied 
cellular systems; it has a known cytokine and its receptor, progenitors expressing the 
receptor, and final output (red cells) which negatively regulate the cytokine. Knowing 
how these components act together to create a coherent response to hypoxia may be 
relevant to our understanding of analogous responses in other cytokine-dependent 
systems, such as granulopoiesis, thrombopoiesis, or the generation of neutrophils and 
lymphoid cells 187. 
 
6.2 Innovative approach to study erythropoiesis in vivo 
 My thesis work tested the hypothesis that Epo regulates erythropoietic rate 
through progenitor survival. This hypothesis was based on studies in which several 
apoptotic regulators, including Fas/FasL, Bcl-xL and Bim, were identified downstream of 
EpoR signaling in vitro 89,96,124. How Epo regulates erythropoietic rate through these 
apoptotic pathways cannot be re-created in vitro with great certainty, and must therefore 
be tested using in vivo technology.   
 Previous in vivo approaches to address this question utilized mouse genetic 
models coupled with erythropoietic stress 52,188. Most often, stress was induced by 
bleeding the animal, or by treating it with phenylhydrazine, a highly toxic compound to 
hematopoietic environment, in order to induce acute hemolytic anemia. To understand 
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the response to stress, previous in vivo studies examined ‘peripheral’ parameters. These 
classical methods included: determining the hematocrit, hemoglobin and reticulocyte 
count in peripheral blood; determining serum Epo; determining the radioactive iron 
uptake by the hematopoietic tissue as a reflection of erythropoietic rate; examining 
hematopoietic tissues histologically for a qualitative assessment of erythropoiesis 16. Yet, 
erythroid progenitors could not be isolated for a direct biochemical analysis. To bypass 
this problem, various erythroid culture methods have been developed 189,78. The in vitro 
culture is useful for studying erythroblast biochemistry without complications inherent to 
the in vivo models. However, progenitors are often grown in the absence of a supporting 
microenvironment and with altered cytokine levels. These conditions lead to potentially 
altered expression of cell-surface markers and transcriptional factors, and to the changes 
in the timing and nature of erythroid differentiation, all of which do not directly reflect 
the in vivo process. 
 To address these many issues, our laboratory developed a novel flow-cytometric 
approach (Chapter V) making my in vivo studies possible. I used this approach to identify 
maturation-specific erythroblast subsets that form a developmental sequence directly in 
the murine hematopoietic tissue. I was able to directly measure how erythroblasts at 
specific developmental stages change in frequency with time and stress level directly in 
vivo. Flow cytometry also quantitatively measures various cellular parameters (e.g. cell-
cycle, apoptosis, cell-surface- and phospho- proteins) on a single-cell level. From this 
‘biochemical’ perspective, I addressed how EpoR signaling regulates Fas/FasL, Bcl-xL 
and Bim apoptotic proteins in specific erythroid subsets in vivo. From an ‘organism-
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level’ perspective, I used flow-cytometric and classical measurement methods in various 
genetic models of erythropoietic stress to determine where, when and how in the stress 
response each of the three apoptotic pathways plays a role. 
 
6.3  Novel findings  
 First, my analysis of erythropoiesis in vivo provides evidence in support of the 
hypothesis that erythroblast apoptosis determines erythropoietic rate. Second, my work 
describes an important new concept in the field of erythropoiesis, that survival pathways 
each have unique, specialized properties and functions in the erythropoietic response. 
Many of these properties could not have been predicted from the survival response of 
single cells in vitro. 
 In my work with Fas- and FasL-mutant mice (Chapter III), I found that Fas/FasL 
play an important autoregulatory role at the local tissue level, where they minimize 
random fluctuations in erythroblast frequency, stabilizing the size of the erythroblast pool 
in the steady state. In mice mutant for Fas or FasL, basal erythropoiesis was increased 
and, importantly, was more variable. Furthermore, the erythropoietic stress response to 
high Epo or low oxygen in mutant mice lagged significantly behind that of control mice. 
In keeping with the hypothesis originally described in Chapter I, Figure 1.4, these data 
suggest that Fas/FasL in wild-type spleen provide an apoptotic ‘reserve’ of cells. 
Although apparently wasteful in the basal state, this reserve allows mice to quickly rescue 
cells from apoptosis and recruit them to increase erythropoietic rate during stress. 
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 I also compared and contrasted the in vivo behavior of two cell-intrinsic apoptotic 
regulators, Bcl-xL and Bim (Chapter IV), previously unexamined in the stress response. I 
found Bcl-xL responded only to acute, but not chronic, stress. My data suggest that Bcl-xL 
is a key mediator of EpoR’s anti-apoptotic signal very early in the stress response in ProE 
and EryA cells, before Bim and Fas are suppressed. Bcl-xL adaptation to high Epo occurs 
at the level of Stat5 activation, and resets it for the next acute stress. 
 In addition, I ‘resurrected’ an old model of erythropoietic stress, the low 
atmospheric oxygen treatment (Figure 3.1C in Chapter III and Figure 4.4 in Chapter IV). 
This stress model provided me with a unique opportunity to test my hypothesis in a more 
physiological, albeit more complex, setting. In the process of testing this model, I found 
increased erythroblast apoptosis when mice were transferred back from hypoxia to a 
normal oxygen environment (Figure 3.1C). Therefore, regulation of apoptotic rates is 
important in both increasing and decreasing erythropoietic rate. Together, my overall 
findings suggest that in vivo, Epo regulates erythropoietic rate by modulating erythroblast 
apoptosis, and that various apoptotic regulators play distinct and unique roles in this 
process. 
 
6.4  Interpretations and future directions 
  
 Erythropoiesis is a complex and dynamic process; my thesis work addressed only 
some of its aspects. Future experiments derived from this work will provide new and 
exciting discoveries relevant to the field of erythropoiesis and other areas of molecular 
biology. 
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New flow-cytometric identification of BFU-e and CFU-e progenitors. 
 It is currently unknown whether EpoR regulates the survival of earlier erythroid 
subsets, the BFU-e and the CFU-e, in adult mice. Unlike in the fetal liver, where CFU-e 
activity was identified in both the S0 and S1 populations based only on CD71 and Ter119 
markers 46, we cannot easily identify BFU-e and CFU-e progenitors in the adult, where 
they are very rare. Previous studies used negative exclusion criteria to define CFU-e in 
the bone marrow as CD71highcKit+Ter119low (and Endoglin+) 190,191. A similar approach 
was used to define stress BFU-e as CD71medcKit+Ter119low (population I) and CFU-e as 
CD71hicKit+Ter119med (population II) 54. Overall, CD71, Ter119 and cKit may not 
provide the most precise method of staging erythroid progenitors in the adult. Therefore, 
new markers are needed to improve the specific identification of BFU-e and CFU-e 
subsets in the fetal liver as well as in adult basal and stress erythropoiesis. Based on in 
vitro methods, EpoR is thought to be induced between the BFU-e and CFU-e stages, with 
CFU-e expressing maximal levels 2. Currently, there are no reliable antibodies for flow-
cytometric use against the murine EpoR. The overall cell-surface expression of this 
receptor is very low, even in the CFU-e subset. In the future, a reliable EpoR antibody 
may allow us to better resolve early erythroid subsets and to determine EpoR expression 
in other cell lineages and tumors. 
 
Transit time through erythroid differentiation stages in basal state and in stress. 
 My work focused on understanding how erythroblasts within a given subset, as 
defined by two cell surface markers and cell size, during stress differ in their survival 
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properties from cells in the equivalent subset in the basal state in vivo. It takes roughly 3 
to 4 days for CFU-e progenitors to reach the late EryC stage. Thus, a given erythroid 
subset on day 3 of the Epo response likely does not contain the same cohort of cells 
found there at time-point 0. Furthermore, the rate at which cells transition from one 
subset to the next may be altered during stress response. Literature suggests that acute 
stress accelerates erythroid maturation, with bigger cells appearing in the blood early on. 
It was previously suggested that in response to stress, there is a ‘skipped’ cell division 
that allows polychromatic cells to become reticulocytes that are larger and contain more 
hemoglobin 153,154. Therefore, apart from effects upon erythroblast survival, these data 
point to additional Epo roles in cell cycle and differentiation. 
 The continuous input of progenitors from earlier differentiation stages may affect 
our measurements of apoptotic regulators in early erythroblasts. Thus, future experiments 
should determine the transition time of progenitors from one subset to the next in the 
basal state and during stress. To do this, an in vivo labeling system will need to be 
developed and tested (in vivo cell labeling with BrdU/CFSE, adoptive transfer of labeled 
progenitors or progenitors expressing Bcl-xL-GFP fusion protein, inducible transgenic 
mouse models). 
  
How does the continuous input from earlier erythroid compartments into the ProE pool 
affect our interpretation of observed Bcl-xL adaptation to high Epo? 
 Our data show that Epo is still high when ProE and EryA suddenly become 
refractory in their Bcl-xL response to Epo stimulation between 18 and 24 hours (Chapter 
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IV, Figures 4.2, 4.4 and 4.10). Reduction of Bcl-xL signal between 18 and 24 hours in the 
ProE population could result from: (a) a switch from positive to negative regulation of 
Stat5 signaling directly in those cells and the subsequent degradation of Bcl-xL protein, or 
(b) an input of cells with low Bcl-xL from an earlier subset of possibly an altered lineage.  
 Our results with EpoR-H mice (where Stat5 and Bcl-xL persist high for longer, as 
shown in Figure 4.6), and our laboratory’s preliminary data with SOCS3 knock-down in 
cultured fetal liver erythroid progenitors, both show persistent Stat5 activation when the 
negative regulation of EpoR signaling is disrupted. These data support our model 
according to which, Epo-sensitive progenitors themselves become refractory to Epo 
stimulation. However, we cannot exclude the possibility that some CFU-e, also refractory 
to Epo stimulation, may transition into the ProE subset by 24 hours. To address if the 
refractory period in the Bcl-xL response occurs in the same progenitors in vivo, labeled 
cells will be examined throughout the differentiation after multiple Epo injections. If the 
refractory period occurs in the same, labeled cells, a second Epo injection at 18 to 24 
hours should not induce, or maintain, Bcl-xL mRNA or protein in these cells (as in Figure 
4.10). 
 The short time-frame of Bcl-xL response (Figure 4.3) makes it unlikely that the 
input of very early, low-frequency progenitors (BMP4R/stress BFU-e 17) with low Bcl-xL 
is responsible for the Bcl-xL reduction in the ProE and EryA. To address whether these 
very early progenitors play a role in the Bcl-xL adaptation mechanism, flexed-tail mutant 
mouse defective in BMP4R progenitors that give rise to stress BFU-e 53, could be utilized. 
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If Bcl-xL adaptation in ProE and EryA in Epo-injected mutant mice is preserved, then 
progenitors prior to the CFU-e stage are likely not involved. 
 
At which differentiation stage does the suppression of Fas and Bim begin? 
 During stress, Epo persists above basal level for at least 36 hours (Figure 4.2A). 
In contrast to Bcl-xL upregulation, Fas and Bim suppression takes longer to be achieved 
(Figures 4.3 and 4.4) 42. Cell labeling experiments are necessary to address whether Fas 
and Bim suppression begins in very early CFU-e progenitors or only in the ProE and 
EryA subsets. 
 Alternatively, Epo indirectly participates in the generation of ‘stress BFU-e’ 
17,53,54 that lower Fas and Bim developmentally (via GATA-1), or via activation of other 
receptors (e.g. cKit or Glucocorticoid Receptor). To test this, flexed-tail mutant mice can 
be injected with Epo to see if Fas and Bim suppression on day 3 is absent due to the 
defect in very early, stress-responsive progenitors. Furthermore, if stress BFU-e can be 
purified, their Fas and Bim response to Epo in culture, or in vivo via adoptive mouse 
transfer, may also be studied. 
 
How does EpoR signaling lead to Fas down-regulation?  
 The mechanism of Fas/FasL down-regulation by Epo in EpoR-expressing cells 
remains unstudied. Therefore, future experiments could determine whether Epo 
suppresses Fas by decreasing Fas mRNA stability, or by suppressing its transcription. 
This could be done by sorting and culturing erythroblasts (ProE/EryA or S1-2) with or 
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without transcriptional inhibitors and monitoring Fas mRNA by quantitative real-time 
PCR. EpoR activates multiple signaling pathways including Stat5, Stat1, PI3K/AKT and 
MAPK. While Stat5 does not appear to suppress Fas (Figure 4.9), Stat1 192 and 
PI3K/AKT 83,193,194, but not ERK 155, pathways may regulate Fas transcription. These 
regulators could also be tested in vitro by depletion with shRNA, or by retroviral 
transduction of erythroblasts with dominant-negative and constitutively-active mutant 
molecules. Micro-RNAs may also regulate the expression of Fas and FasL, and could be 
tested. 
 Fas and FasL can exist in two main forms, membrane-bound and soluble: sFas 
results from alternative splicing 195, while sFasL results from cleavage of membrane 
bound FasL by metalloproteases 196. Therefore, future experiments, using metalloprotease 
inhibitors in spleen EryA cultures or in vivo, could address whether metalloproteases (e.g. 
MMP-8 and ADAM10) function as Fas or FasL sheddases and whether sheddase action 
is required for erythroblast Fas and FasL down-regulation. Alternative splice variants of 
Fas will be detected by quantitative real-time PCR, while soluble Fas or FasL will be 
monitored by an ELISA method. 
 
The role of Bim in stress erythropoiesis in vivo. 
 My work established that Bim expression declines with erythroid differentiation, 
and is further suppressed by erythropoietic stress. However, Bim-/- fetal livers contained 
normal CFU-e numbers (Figure 4.8C), which suggests that Bim is not the only pro-
apoptotic factor in early erythroblasts. Furthermore, the magnitude of Bim suppression 
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was not as high as for Fas suppression or Bcl-xL upregulation (Figure 4.3C). It has not 
been determined whether Bim-/- mice have an enhanced response to erythropoietic stress. 
Adult Bim-/- mice appear to suffer from an autoimmune disorder complicating the study 
of their erythropoietic stress response 89. To bypass this issue, experimental strategy 
similar to Fas-mutant mice (Chapter III) could be used: Bim-/- mice could be bred onto 
Rag1-/- background to prevent an autoimmune syndrome, and their basal and stress 
erythropoiesis could be examined. Multiple apoptotic regulators could also be examined 
to ensure that the phenotype is not masked by compensatory upregulation of apoptosis 
via other pathways. For example, Trail-R2 receptor, expressed on human erythroid cells 
197, could be one such molecule that needs to be tested in mouse erythroblasts. 
Furthermore, Bim-/-Rag1-/- mice can be crossed with Fas-mutant mice, providing a new 
model where two negative regulators of erythropoiesis are removed. 
  
Significance 
 Much work remains to be done in order to fully understand how EpoR regulates 
erythropoietic rate, as well as how these findings may be relevant to studying other 
systems and diseases. For example, my work on the adapting nature of Stat5-Bcl-xL 
response downstream of EpoR in vivo has potential implications for myeloproliferative 
diseases. Elevated levels of Bcl-xL were found in Polycythemia Vera and other 
myeloproliferative syndromes, where they are thought to contribute to cytokine 
independence of progenitors. Mutations in Jak2 are an established cause of persistent 
Stat5 activation and elevation of Bcl-xL. Our work suggests that failure of the 
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mechanisms of adaptation of the Stat5 and Bcl-xL response may also contribute to these 
syndromes 27,169,182,183. 
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